{"100-1.\n41\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u9ad4\u91cd\u65bc2\u661f\u671f\u4e0b\u964d4\u516c\u65a4\u4f86\u8a3a\uff0c\u4e3b\u8a342010\u5e746\u6708\u7a81\u767c\u773c\u5167\u982d\u75db\u53ca\u8996\u529b\u6a21\u7cca\uff0c\u53f3\u773c\u8996\u529b\u75311.0\u964d\u70ba0.6\uff0c\u773c\u79d1\u8a3a\u65b7\u70ba\u9752\u5149\u773c\uff0c\u7d93\u9ede\u773c\u85e5\u5f8c\u8996\u529b\u6539\u5584\u70ba0.8 (2010\u5e749\u6708) 2010\u5e7410\u6708\u6ce8\u610f\u5230\u9ad4\u91cd\u4e0b\u964d\u3001\u7121\u529b\uff0c\u5bb6\u91ab\u79d1\u62bd\u8840\u767c\u73feTSH 0.02 \u03bcU/ml \u8a3a\u65b7\u70ba\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\uff0c\u4e88\u4ee5\u670d\u7528carbimazole 10 mg b.i.d \uff0c\u4f46\u75c5\u60c5\u6709\u60e1\u5316\u4e4b\u73fe\u8c61\u56e0\u6b64\u4f86\u8a3a\u3002\u9ad4\u6aa2\u5305\u542b\u8996\u91ceconfrontation test \uff0c\u4e26\u672a\u6709\u7279\u5225\u7570\u5e38\uff0c\u62bd\u8840CBC\u53caBCS \u542b\u96fb\u89e3\u8cea\u3001HbA1C\u7686\u6b63\u5e38\uff0cfree T4 0.67 ng/dl\u3001hsTSH 0.025\u03bcU/ml \uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u5c0d\u6b64\u75c5\u4eba\u6700\u6709\u5e6b\u52a9\uff1a\nA. \u505a\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\nB. \u6e2cTSH receptor antibody\nC. \u6e2c\u773c\u58d3\u53caOrbit\u8d85\u97f3\u6ce2\nD. \u6e2c\u5b9apituitary hormone\nE. \u6e1b\u5c11carbimazole\u5291\u91cf\n": "(D)", "100-2.\n37\u6b72\u5973\u6027\u4e3b\u8a34\u9032\u884c\u6027\u547c\u5438\u56f0\u96e3\u3001\u5026\u6020\u3001\u4fbf\u79d8\u4f46\u7121\u767c\u71d2\uff0c\u8eab\u9ad4\u6aa2\u67e5\u81c9\u90e8\u6d6e\u816b\u3001\u8ca7\u8840\uff0cBP 126/94 mmHg\u3001PR 104/min\uff0c\u80f8\u90e8X\u5149\u5982\u5716\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. \u80a5\u80d6\u4f75\u4ee3\u8b1d\u75c7\u5019\u7fa4\nB. \u9ecf\u6db2\u6c34\u816b\u6027\u5fc3\u81df\u75c5\u8b8a\nC. \u7d50\u6838\u6027\u5fc3\u5305\u819c\u708e\nD. \u5145\u8840\u6027\u5fc3\u8870\u7aed\nE. \u9ad8\u8840\u58d3\u5fc3\u81df\u75c5\n": "(B)", "100-3.\n30\u6b72\u7537\u6027\u56e0\u65e9\u4e0a\u8d77\u5e8a\u722c\u4e0d\u8d77\u4f86\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u6700\u8fd11\u500b\u6708\u4f86\u98df\u617e\u5927\u589e\u4f46\u9ad4\u91cd\u537b\u4e0b\u964d4\u516c\u65a4\uff0c\u6015\u71b1\u6d41\u6c57\u3002\u6628\u591c\u56e0\u6176\u529f\u5bb4\u5927\u5403\u5927\u559d\u4f46\u4e26\u7121\u8179\u7009\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u610f\u8b58\u6e05\u695aBP 106/60 mmHg \u3001PR 110/min\uff0cregular\uff0c\u7532\u72c0\u817a\u7b2c1\u5ea6\u816b\u5927\uff0c\u96d9\u624b\u8f15\u5faetremor\uff0cDTR\u2193\uff0c\u808c\u529b\u5448\u4e0b\u80a22/5\u3001\u4e0a\u80a23/5\uff0c\u6025\u8a3a\u62bd\u8840CBC\u6b63\u5e38\uff0cNa 142 mM\u3001K 1.4 mM\u3001Ca 2.18 mM\u3001CK 756 U/L\uff0c\u4ee5\u4e0b\u5c0d\u6b64\u75be\u75c5\u7684\u6558\u8ff0\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. \u70ba\u5148\u5929\u6027\u907a\u50b3\u75be\u75c5\nB. \u70bathyrotoxic periodic paralysis\nC. \u75c5\u4eba\u9ad4\u5167K+\u7f3a\u4e4f\u88dc\u5145KCl\u5373\u53ef\nD. \u7537\u3001\u5973\u767c\u751f\u6bd4\u4f8b\u4e00\u6a23\nE. \u70ba\u81ea\u9ad4\u514d\u75ab\u6297\u9ad4\u5c0d\u6297Na/K Channel\u6240\u81f4\n": "(B)", "100-4.\n23\u6b72\u7537\u6027\u5175\u5f79\u9ad4\u6aa2\u767c\u73fe\u6027\u5668\u767c\u80b2\u4e0d\u826f\uff0cMRI\u5982\u5716\uff0c\u6700\u53ef\u80fd\u7684\u8a3a\u65b7\u662f\uff1a\nA. Pseudohermaphroditism\nB. Klinefelter syndrome\nC. Noonan syndrome\nD. Prader-Willi syndrome\nE. Kallmann syndrome\n": "(E)", "100-5.\n55\u6b72\u7537\u602715\u5e74\u4f86\u4e00\u76f4\u6709\u9ad8\u8840\u58d3\uff0c\u76ee\u524d\u4ee5Losartan 50mg qd\u3001Amlodipine 5 mg qd\u63a7\u5236\uff0c\u4f46\u5e38\u6709\u982d\u75db\u3001\u5931\u7720\u3001\u6613\u6d41\u6c57\u3001\u7126\u616e\u3001\u5fc3\u60b8\u3001\u624b\u6296\uff0c\u6700\u8fd12\u5e74\u958b\u59cb\u670d\u7528\u4e2d\u85e5\u3002\u65bc2010\u5e741\u6708\u7a81\u767c\u80f8\u75db\u3001\u5192\u51b7\u6c57\u56e0\u6b64\u9001\u5230\u6025\u8a3a\uff0c\u6b64\u6642\u8840\u58d3205/121 mmHg\uff0cTrandate\u6ce8\u5c04\u5f8c\u8840\u58d3\u6539\u5584\u800c\u4f4f\u9662\u6aa2\u67e5\uff0c\u4f4f\u9662\u6642\u8840\u58d3\u53c8\u4e0a\u5347\u81f3180/110 mmHg\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u4e0d\u6070\u7576\uff1f\nA. \u6aa2\u67e5plasma metanephrine\u53caurine catecholamine\nB. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nC. \u52a0\u4e0a\u03b2-blocker\nD. \u52a0\u4e0a\u03b1-blocker\nE. PET FDG\u6aa2\u67e5\n": "(C)", "100-6.\n\u8a3a\u65b7\u7522\u5f8c\u5a66\u5973\u5e0c\u7f55\u6c0f\u75c7\uff08Sheehan's Syndrome\uff09\u6700\u53ef\u9760\u4e4b\u6307\u6a19\u70ba\uff1a\nA. hypoprolactinemia\nB. hypothyrotropinemia\nC. hypocorticotropinemia\nD. hyposomatotropinemia\nE. hypogonadotropinemia\n": "(A)", "100-7.\n30\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u53f3\u9838\u90e8\u6709\u4e00\u7d05\u816b\u786c\u584a\u4f86\u5c31\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u53f3\u9838\u816b\u584a\u53ef\u96a8\u541e\u56a5\u79fb\u52d5\uff0c\u6709\u5c40\u90e8\u767c\u71b1\u3001\u58d3\u75db\u4e14\u76ae\u819a\u8b8a\u7d05\uff0c\u6b64\u5916\u7121\u7279\u5225\u767c\u73fe\uff0c\u75c5\u4eba\u4e00\u5411\u5065\u5eb7\uff0c\u5c0d\u65bc\u6b64\u75c5\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba:\nA. Subacute thyroiditis\uff0c\u53ef\u4ee5Steroid\u6cbb\u7642\nB. Thyroid cancer\uff0c\u5fc5\u9808\u7532\u72c0\u817a\u5168\u5207\u9664\nC. Residual thyroglossal duct\u5f15\u767c\u767c\u708e\nD. Sepsis, hematogenous spread\nE. \u6ce8\u5c04\u6297\u751f\u7d20\u6cbb\u7642\u5373\u53ef\n": "(C)", "100-8.\n32\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u5230\u6025\u8a3a\u3002\u75c5\u4eba\u4e3b\u8a343\u500b\u6708\u4f86\u5e38\u8179\u7009 (1\u59294\u223c5\u6b21)\uff0c\u6700\u8fd1\u4f75\u6709\u8179\u75db\u53ca\u610f\u8b58\u4e0d\u6e05\u3002\u904e\u53bb\u75c5\u53f2\u6709Hepatitis C\uff0c\u5b50\u5bae\u808c\u7624\u8853\u5f8c\uff0c\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\u53caKetamine \u6feb\u7528\uff0c\u9ad4\u6aa2\u767c\u73fe\u547c\u5438\u6025\u4fc3\u3001\u5fc3\u8df3144/min\u3001\u8840\u58d380/60 mm Hg\uff0c\u5916\u9662WBC 38000/\u03bcL\uff0c\u7532\u72c0\u817a\u7b2c2\u5ea6\u816b\u5927\uff0c\u8179\u90e8\u8edf\u4e14\u7121\u58d3\u75db\uff0c\u6025\u8a3a\u62bd\u8840Hb 10.4 g/dl\u3001WBC 77000/\u03bcl\u3001shift to the left\uff0cPT 35.3 sec\u3001aPTT 60.4 sec\u3001GOT 55 IU/L\u3001GPT 24 IU/L\u3001T-Bilirubin 5.03 mg/dl\u3001ALP 320 IU/L\u3001Na 140 mM/L\u3001K 4.1 mM/L\u3001BUN 25 mg/dl\u3001Cr 1.79 mg/dl\u3001AC glucose 40\rmg/dl\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u4f9dKetamine \u4e2d\u6bd2\u8655\u7f6e\r2.\u4f9dhepatitis C \u5fa9\u767c\u8655\u7f6e\r3.\u4f9d\u7532\u72c0\u817a\u5371\u75c7\u8655\u7f6e\r4.\u4f9d\u6557\u8840\u75c7\u8655\u7f6e\r5.\u4f9d\u814e\u4e0a\u817a\u5371\u75c7\u8655\u7f6e\nA. 1+2+3+4\nB. 2+3+4+5\nC. 3+4+5\nD. 4+5+1\nE. 1+3+5\n": "(C)", "100-9.\n61\u6b72\u7537\u6027\u56e0\u9ad4\u6aa2PET\u767c\u73fe\u53f3\u814e\u4e0a\u817a\u816b\u7624\u4f86\u8a3a\u3002\u75c5\u4eba\u9664\u4e86\u8840\u58d3\u9ad8\u5728\u670d\u7528Carvedilol 25 mg qd\u3001Lercanidipine 10mg qd\u3001Valsartan 60mg qd\u53caIndapamide 1.5 mg qd\u5916\uff0c\u4e26\u7121\u4e0d\u9069\u3002\u8eab\u9ad4\u6aa2\u67e5\u9664BP 150/100 mmHg\uff0c\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5Na 139 mM/L\u3001K 3.1 mM/L\u3001Ca 2.39 mM/L\u3001P 3.1 mg/dl\u3001plasma aldosterone 35 ng/dl\u3001plasma renin activity 0.36 ng/ml/hr\u3002saline infusion test\uff0caldosterone\u70ba28.5 ng/dl\uff0cAdrenal CT\u986f\u793a\u5169\u5074\u7686\u67091~2\u516c\u5206\u7d50\u7bc0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u9069\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u70baprimary aldosteronism\r2.\u70baadrenal incidentaloma\u53ea\u9808\u89c0\u5bdf\r3.\u9808\u958b\u5200\u6cbb\u7642\r4.\u9808\u88dc\u5145K+\r5.\u4ee5spironolactone\u6cbb\u7642\u70ba\u4e3b\nA. 1+3\nB. 2+4\nC. 4+5\nD. 1+5\nE. 1+3+4\n": "(D)", "100-10.\n70\u6b72\u5973\u60272007\u5e742\u6708\u9ad4\u6aa2\u9996\u5ea6\u767c\u73feCEA 15.8 ng/ml\u53canodular goiter\u56e0\u7532\u72c0\u817a\u529f\u80fd\u6b63\u5e38\u4e5f\u5c31\u4e0d\u4ecb\u610f\u30022007\u5e749\u6708CEA\u70ba 23.4 ng/ml\uff0c2008\u5e744\u6708\u66f4\u4e0a\u5347\u70ba28.3 ng/ml\uff0c\u5927\u8178\u93e1 \u53ca\u4e73\u623f\u8d85\u97f3\u6ce2\u6aa2\u67e5\u90fd\u7121\u7279\u5225\u767c\u73fe\u3002\u8eab\u9ad4\u6aa2\u67e5BP 105/70 mmHg\u3001PR 86/min\uff0c\u7532\u72c0\u817a\u54482\u5ea6\u816b\u5927\u53ca\u591a\u7d50\u7bc0\uff0c\u5176\u4ed6\u4e26\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\uff0cCBC\u6b63\u5e38\u3001BUN 12 mg/dl\u3001Cr 1.3 mg/dl\u3001Na 138 mM/L\u3001K 4.5 mM/L\u3001Ca 2.2 mM/L\u3001free T4 0.99 ng/dl\u3001hsTSH 2.87  \u03bcU/ml\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u6070\u7576\uff1a(\u61c9\u9078\u51fa\u5168\u90e8\u7b54\u6848)\r1.\u4ee5PETFDG\u5075\u6e2c\u816b\u7624\r2.\u505a\u7532\u72c0\u817a\u7d30\u91dd\u7a7f\u523a\r3.\u505a\u80f8\u81f3\u8179\u90e8CT\r4.CEA\u4e0a\u5347\u7121\u7279\u5225\u610f\u7fa9\r5.\u6aa2\u67e5serum calcitonin\nA. 1+2+3\nB. 2+3\nC. 4\nD. 3+5\nE. 5+1+2\n": "(E)", "100-1.\nThiazolidinediones \u767c\u5c55\u81f3\u4eca\u8207\u5176\u6709\u95dc\u4e4b\u53ef\u80fd\u4e0d\u826f\u53cd\u61c9\u6709\u4e0b\u5217\u6578\u9805\uff0c\u9664\u4e86\nA. \u9020\u6210\u5fc3\u8870\u7aed\u6a5f\u7387\u589e\u52a0\nB. \u9020\u6210\u809d\u6bd2\u6027\u6a5f\u7387\u589e\u52a0\nC. \u9020\u6210\u9aa8\u9b06\u6a5f\u7387\u589e\u52a0\nD. \u9020\u6210\u814e\u8870\u7aed\u6a5f\u7387\u589e\u52a0\nE. \u9020\u6210\u8180\u80f1\u764c\u6a5f\u7387\u589e\u52a0\n": "(D)", "100-2.\n\u9577\u671f\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u8840\u7cd6\u63a7\u5236\u4e0d\u4f73\u6642\uff0c\u4ee5\u54ea\u4e00\u7a2e\u80f0\u5cf6\u7d20\u88fd\u5291\u88dc\u5145\u57fa\u790e\u80f0\u5cf6\u7d20\u4e4b\u4e0d\u8db3\u8f03\u5408\u4e4e\u751f\u7406\u72c0\u614b\nA. Regular insulin\nB. Glargine insulin\nC. NPH insulin\nD. Insulin aspart\nE. Lispro insulin\n": "(B)", "100-3.\n55\u6b72\u7537\u6027\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u5df2\u670910\u5e74\uff0c\u6700\u8fd11\u6b21\u62bd\u8840\u6aa2\u67e5\u986f\u793a\uff1aAC 148 mg/dl\u3001 PC 240 mg/dl\u3001 HbA1C 8.0 %\u3001 BUN 30 mg/dl\u3001 Cr 2.0 mg/dl\u3001 Urinalysis protein (+) \uff0c\u76ee\u524d\u4f7f\u7528\u4e4b\u85e5\u7269\u6709 Metformin 500 mg tid\u3001 Glibenclamide 5 mg tid\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u4e0d\u6070\u7576\uff1a\nA. \u5c07 Glibenclamide \u6539\u70ba Gliquidone\nB. \u52a0\u5165Sitagliptin 50 mg qd\nC. \u589e\u52a0 Metformin\u5291\u91cf\u81f31000 mg bid\nD. \u52a0\u5165pioglitazone 15 mg qd\nE. \u589e\u52a0\u6ce8\u5c04basal insulin\n": "(C)", "100-4.\n29\u6b72\u7537\u6027\u56e0\u6700\u8fd1\u5bb6\u4eba\u767c\u73fe\u65e9\u4e0a\u5f88\u96e3\u53eb\u9192\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u5e38\u6709\u60e1\u5922\u4e26\u5192\u6c57\uff0c\u8d77\u5e8a\u89ba\u5f97\u5f88\u865b\u5f31\u3002\u75c5\u4eba\u6709\u7761\u524d\u5c0f\u914c\u4e4b\u7fd2\u6163\u3002\u62bd\u8840\u65e9\u98ef\u524d\u8840\u7cd6\u70ba40 mg/dl\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u6070\u7576\nA. \u809d\u3001\u814e\u529f\u80fd\u70ba\u5fc5\u8981\u6aa2\u67e5\nB. \u7532\u72c0\u817a\u53ca\u814e\u4e0a\u817a\u529f\u80fd\u6aa2\u67e5\u70ba\u5fc5\u8981\nC. \u9577\u6642\u9593(\u53ef\u905472\u5c0f\u6642)\u7a7a\u8179\u8840\u7cd6\u503c\u70ba\u5fc5\u8981\u6aa2\u67e5\nD. Whipple triad \u9451\u5225\u5ea6\u9ad8\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u8a3a\u65b7\u7387\u9ad8\n": "(E)", "100-5.\nIncretin \u7d93\u7531\u4e0b\u5217\u76f4\u63a5\u6a5f\u8f49\u6539\u5584\u8840\u7cd6\u63a7\u5236\uff0c\u9664\u4e86\nA. \u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\nB. \u6291\u5236\u5347\u7cd6\u7d20\u5206\u6ccc\nC. \u6291\u5236\u80c3\u6392\u7a7a\nD. \u6291\u5236\u98df\u617e\nE. \u6539\u5584\u80f0\u5cf6\u7d20\u6297\u6027\n": "(E)", "100-6.\n\u4e0b\u5217\u6709\u95dc\u80f0\u5cf6\u7d20\u4e4b\u5206\u6ccc\u4f55\u8005\u4e0d\u6b63\u78ba\nA. \u8461\u8404\u7cd6\u70ba\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e3b\u8981\u8abf\u7bc0\u8005\nB. \u8461\u8404\u7cd6\u6fc3\u5ea6\u9ad8\u65bc70 mg/dl\u4ee5\u4e0a\u6642\uff0c\u5c31\u80fd\u523a\u6fc0\u80f0\u5cf6\u7d20\u4e4b\u5408\u6210\nC. \u8461\u8404\u7cd6\u78f7\u5316 ( phosphorylation )\u662f\u8461\u8404\u7cd6\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e4b\u901f\u7387\u6c7a\u5b9a\u4e4b\u6b65\u9a5f\nD. \u7d93\u7531GLUT2 transportor\u9032\u5165\u03b2\u7d30\u80de\nE. \u7576\u03b2\u7d30\u80de\u819c\u4e0a\u7684ATP-sensitive K+ channel \u53d7\u523a\u6fc0\u6642\uff0c\u6703\u4f7f\u03b2\u7d30\u80de\u5206\u6ccc\u80f0\u5cf6\u7d20\n": "(E)", "100-7.\n\u5c0d\u65bc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u4e0d\u5b9c\nA. \u5c0d\u65bc\u764c\u672b\u75c5\u4eba\u6216\u5b58\u6d3b\u671f\u4e0d\u9577\u7684\u75c5\u4eba\u53ef\u653e\u5bec\u7cd6\u5c3f\u75c5\u4e4b\u63a7\u5236\u6a19\u6e96\nB. \u7cd6\u5c3f\u75c5\u4e4b\u63a7\u5236\u4ee5\u907f\u514d\u4f4e\u8840\u7cd6\u70ba\u9996\u8981\u8003\u91cf\nC. \u5c0d\u65bc\u5e74\u8f15\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4ee5\u6108\u63a5\u8fd1\u6b63\u5e38HbA1C\u70ba\u6a19\u7684\nD. \u5c0d\u65bc\u4f4f\u9662\u75c5\u4eba\u70ba\u907f\u514d\u4f4e\u8840\u7cd6\u4ee5sliding scale\u4f86\u63a7\u5236\nE. \u76ee\u524d\u53f0\u7063\u7cd6\u5c3f\u75c5\u5b78\u6703\u7684\u8840\u7cd6\u6cbb\u7642\u6a19\u7684HbA1C\u70ba6.5%\n": "(D)", "100-8.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u5fc3\u8840\u7ba1\u75be\u75c5\u4f75\u767c\u75c7\u4e4b\u6558\u8ff0\u4e0b\u5217\u4f55\u8005\u70ba\u771f\uff0c\u9664\u4e86\nA. \u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4e4b\u51a0\u5fc3\u75c7\u4e4b\u767c\u751f\u7387\u53ca\u6b7b\u4ea1\u7387\u7686\u6bd4\u975e\u7cd6\u5c3f\u75c5\u4eba\u591a2-4\u500d\nB. \u8840\u8102\u3001\u8840\u58d3\u4e4b\u63a7\u5236\u9054\u5230\u9810\u9632\u51a0\u5fc3\u75c7\u767c\u751f\u7387\uff0c\u6bd4\u8840\u7cd6\u4e4b\u63a7\u5236\u4f86\u5f97\u91cd\u8981\nC. UKPDS\u7d50\u675f\u5f8c\u5ef6\u9577\u89c0\u5bdf\u8b49\u660e\u65e9\u671f\u8840\u7cd6\u7684\u63a7\u5236\u5c0d\u65bc\u665a\u671f\u51a0\u5fc3\u75c7\u4e4b\u767c\u751f\u6709\u6e1b\u5c11\u4e4b\u6548\u679c\nD. Aspirin\u5c0d\u65bc\u6b21\u7d1a\u9810\u9632\u5fc3\u8840\u7ba1\u75be\u75c5\u6709\u6548\nE. Sulfonylurea\u5df2\u88ab\u8b49\u660e\u53ef\u589e\u52a0\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u98a8\u96aa\n": "(E)", "100-9.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u4f75\u9ad8\u8840\u58d3\u6cbb\u7642\u4e4b\u6558\u8ff0\uff0c\u4e0b\u5217\u4f55\u8005\u6700\u6b63\u78ba\r1) \u9664\u4e86\u751f\u6d3b\u578b\u614b\u4e4b\u6539\u8b8a\u5916\uff0cAngiotensin Converting Enzyme Inhibitor(ACEI)\u6216Angiotensin Receptor Blocker(ARB)\u61c9\u8a72\u512a\u5148\u4f7f\u7528\r2) \u03b2 blocker\u53cathiazide\u5c0d\u80f0\u5cf6\u7d20\u6297\u6027\u53ca\u8840\u8102\u6709\u4e0d\u5229\u5f71\u97ff\r3) Dihydropyridine\u985e\u9223\u96e2\u5b50\u963b\u65b7\u5291\u512a\u65bcNon-Dihydropyridine\u985e\r4) \u5c0d\u6709Macroalbuminuria\u4e4b\u75c5\u4eba\u8840\u58d3\u6a19\u7684\u70ba130/80 mm Hg\r5) Thiazide\u3001\u03b2 blocker\u3001ACEI\u3001ARB\u5c0d\u65bc\u5fc3\u808c\u6897\u585e\u6216stroke\u6709\u6b63\u9762\u6548\u679c\r6) \u03b1 blocker\u5c0d\u6709\u81ea\u5f8b\u795e\u7d93\u75c5\u8b8a\u75c5\u4eba\u6703\u589e\u52a0\u59ff\u614b\u6027\u4f4e\u8840\u58d3\u98a8\u96aa\nA. 1+3+5\nB. 2+4+6\nC. 1+2+6\nD. 2+3+4\nE. 4+5+6\n": "(C)", "100-10.\n\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\u90a3\u4e9b\u8f03\u4e0d\u6703\u589e\u52a0\u9ad4\u91cd\r1.Glimepiride\r2.Metformin\r3.Pioglitazone\r4.Sitagliptin\r5.Acarbose\r6.Repaglinide\nA. 1+3+5\nB. 2+4+6\nC. 2+4+5\nD. 1+2+6\nE. 3+4+5\n": "(C)", "101-1.\n45\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u9032\u5165ICU\uff0c\u55e3\u5f8c\u767c\u73fe\u983b\u767c\u5fc3\u5ba4\u4e0d\u6574\u8108\u4f7f\u7528Amiodarone\uff0c\u7b2c5\u5929\u51faICU\u524d\u62bd\u8840\u6aa2\u67e5T4 3.0 \u03bcg/dl\u3001T3 30 ng/dl\u3001\rTSH 0.6 \u03bcU/ml\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u9069\u7576\uff1a\nA. \u7d66\u4e88thyroxine 25 \u03bcg qd \u6cbb\u7642\nB. \u505c\u7528 Amiodarone\nC. \u53ef\u8f49\u81f3\u666e\u901a\u75c5\u623f\u89c0\u5bdf\u5373\u53ef\nD. \u5b89\u6392\u7532\u72c0\u817aI-131 uptake\u53ca scan\nE. \u5b89\u6392\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6aa2\u67e5\n": "(C)", "101-2.\n20\u6b72\u5973\u5927\u5b78\u751f\u56e0\u5fc3\u60b8\u3001\u767c\u71d2\u3001\u5026\u6020\u4e8c\u5929\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u5de6\u9838\u67091.5\u00d72 \u516c\u5206\u786c\u584a\u3001\u58d3\u75db(+)\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u9451\u5225\u529b\u6700\u9ad8\ufe30\nA. free T4\u3001hsTSH\nB. I-131 uptake and scan\nC. ESR\u3001CRP\nD. Fine needle aspiration cytology\nE. Ultrasound of thyroid\n": "(D)", "101-3.\n45\u6b72\u5973\u6027\u56e0\u5026\u6020\u3001\u7121\u529b\u3001\u4fbf\u79d8\u3001\u9ad4\u91cd\u589e\u52a0\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u8eab\u9ad8160\u516c\u5206\u3001\u9ad4\u91cd60\u516c\u65a4\u3001\u81c9\u90e8\u7565\u70ba\u6d6e\u816b\u3001\u84bc\u767d\uff0c\u8840\u58d3 146/92 mmHg\u3001PR 58/min\uff0c regular \u62bd\u8840\u6aa2\u67e5\u767c\u73fe\u98ef\u524d\u8840\u7cd6100 mg/dl\u3001\u81bd\u56fa\u9187 260 mg/dl\u3001\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187 160 mg/dl\uff0cNa 128 mM\u3001K 4.0 mM\u3001CK 1500 U/L\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\ufe30\nA. \u7d66\u4e88statin\u6cbb\u7642\nB. \u7d66\u4e88Angiotensin Receptor Blocker\nC. \u6e2cUrine sodium\u3001protein\nD. \u6e2c\u8840\u4e2d free T4\u3001hsTSH\nE. \u6e2c\u8840\u4e2d ACTH\u3001cortisol\n": "(D)", "101-4.\n\u627f\u4e0a\u984c\uff0c\u7d93\u9069\u7576\u6cbb\u7642\u75c5\u4eba\u6062\u5fa9\u826f\u597d\uff0c\u4e09\u500b\u6708\u5f8c\u75c5\u4eba\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u5bb6\u4eba\u9001\u4f86\u6025\u8a3a\uff0c\u64da\u5bb6\u4eba\u63cf\u8ff0\u75c5\u4eba3\u5929\u524d\u611f\u5192\u767c\u71d2\u5f8c\uff0c\u98df\u617e\u4e0d\u632f\u9010\u6f38\u865b\u5f31\uff0c\u75c5\u4eba\u6bcf\u5929\u4ecd\u7e7c\u7e8c\u670d\u7528\u4e0a\u6b21\u4f4f\u9662\u4e4b\u85e5\u7269\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73feB.T. 36.5\u2103\u3001BP 90/60 mmHg\u3001PR 112/min\uff0cregular\u62bd\u8840\u6aa2\u67e5 Hb 11 g/dl\u3001WBC 6000/\u03bcl\u3001platelet 200 K/\u03bcl\u3001Na 117 mM/L\u3001K 3.4 mM/L\u3001Ca 2.0 mM/L\u3001P 2.5 mg/dl\u3001CK 40 U/L\u3001\u8840\u7cd6 85 mg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u9069\u7576\ufe30\nA. \u6e2cUrine sodium\nB. \u6e2c\u8840\u4e2d free T4\u3001hsTSH\nC. \u6e2c\u8840\u4e2d ACTH\u3001cortisol\nD. \u6e2c\u8840\u4e2d 25 Vit D\u3001iPTH\nE. \u6e2c\u8840\u4e2d GOT\u3001GPT\n": "(C)", "101-5.\n55\u6b72\u7537\u6027\u6700\u8fd13\u500b\u6708\u958b\u59cb\u6709\u6f6e\u7d05\u3001\u6d41\u6c57\u3001\u547c\u5438\u56f0\u96e3\u4e4b\u767c\u4f5c\uff0c\u8d77\u521d\u5f88\u8f15\u5fae\uff0c\u4f46\u8fd11\u500b\u6708\u4f86\u89ba\u5f97\u52a0\u91cd\uff0c\u66fe\u56e0\u4e0a\u8ff0\u75c7\u72c0\u5230\u904e\u6025\u8a3a\uff0c\u4f46\u7d93\u75c7\u72c0\u6cbb\u7642\u5373\u6062\u5fa9\uff0c\u4e09\u661f\u671f\u524d\u9084\u56e0\u61f7\u7591\u6025\u6027\u76f2\u8178\u708e\u958b\u5200\u4f46\u75c7\u72c0\u7686\u7121\u6539\u5584\uff0c\u4e8c\u5929\u524d\u5167\u8996\u93e1\u6aa2\u67e5\u767c\u73fe\u5341\u4e8c\u6307\u8178\u6f70\u760d\u3001\u80c3\u708e\uff0c\u8179\u8d85\u767c\u73fe\u809d\u5be6\u8cea\u6027\u75be\u75c5 ( parenchymal disease ) \uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u53f3\u814e\u4e0a\u817a\u67093.5 cm\u816b\u7624\uff0c\u7d93\u5167\u5206\u6ccc\u6aa2\u67e5\uff0ccortisol\u3001ACTH\u3001catecholamine\u3001aldosterone\u3001plasma renin activity\u3001 DHEAS\u7686\u70ba\u6b63\u5e38\uff0c\u8acb\u554f\u60a8\u5982\u4f55\u8655\u7f6e\uff1f\nA. \u6b64\u70ba\u7121\u529f\u80fd\u6027\u816b\u7624\uff0c\u53ef\u63a1\u75c7\u72c0\u6cbb\u7642\nB. \u4e0d\u8ad6\u6709\u7121\u529f\u80fd\uff0c\u7167\u6703\u958b\u5200\u6cbb\u7642\nC. \u5148\u7167\u6703\u7cbe\u795e\u79d1\u6392\u9664\u7cbe\u795e\u65b9\u9762\u75be\u75c5\nD. \u6b64\u70ba\u7537\u6027\u66f4\u5e74\u671f\u53ef\u7d66\u4e88\u96c4\u6027\u7d20\u6cbb\u7642\nE. 6\u500b\u6708\u5f8c\u518d\u505a\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(B)", "101-6.\n42\u6b72\u7537\u6027\u91ab\u5e2b\u65bc22\u5e74\u524d\u88ab\u8a3a\u65b7Graves' \u6c0f\u75c7\uff0c\u4f46\u56e0\u85e5\u7269\u526f\u4f5c\u7528 ( \u7662\u75b9 ) \u4e26\u672a\u898f\u5247\u670d\u85e5\uff0c\u5076\u800c\u6703\u6709\u5fc3\u60b8\u3001\u8e81\u71b1\u60c5\u5f62\uff0c\u4f4f\u9662\u524d3\u5929\u6709\u5fc3\u60b8\u3001\u5641\u5fc3\u3001\u547c\u5438\u56f0\u96e3\u3002\u4f4f\u9662\u524d\u4e00\u5929\u51fa\u73fe\u767c\u71d2\u3001\u5750\u7acb\u547c\u5438\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\uff0cBP 90/59 mmHg\u3001PR 150/min\uff0cLVEF 29 %\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u4e0d\u6070\u7576\ufe30\nA. \u4f7f\u7528\u5927\u5291\u91cfhydrocortisone\nB. \u4f7f\u7528Lugol solution \u5f8c\u52a0\u4e0a\u5927\u5291\u91cf propylthiouracil\nC. \u7d66\u4e88Dopamine infusion + Digoxin IV\nD. Blood culture\u5f8c\u7d66\u4e88\u5ee3\u6548\u6027\u6297\u751f\u7d20\nE. \u8003\u616e\u63a1\u7528ECMO\n": "(B)", "101-7.\n30\u6b72\u5973\u6027\u81ea\u89ba\u9838\u90e8\u816b\u8139\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e26\u7121\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u6216\u4f4e\u4e0b\u4e4b\u75c7\u72c0\uff0c\u89f8\u8a3aThyroid Gr I \u5de6\u5074\u6709\u7c73\u7c92\u5927\u5c0f\u4e4b\u7d50\u7bc0\uff0c\u8acb\u554f\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u975e\u5fc5\u8981\ufe30\nA. free T4\u3001hsTSH\nB. AntiTPO\u3001Antithyroglobulin Ab\nC. I-131 uptake & scan\nD. ultrasound of  thyroid\nE. Fine needle aspiration of  thyroid\n": "(C)", "101-8.\n25\u6b72\u7537\u6027\u5728\u7c43\u7403\u6bd4\u8cfd\u4e2d\u660f\u5012\uff0c\u9001\u4f86\u6025\u8a3a\u5fc3\u96fb\u5716\u5448\u73fe\u5fc3\u623f\u986b\u52d5\uff0c\u8840\u58d3 180/100 mmHg\uff0c\u7d93\u904e10\u5206\u9418\uff0c\u5fc3\u96fb\u5716\u6062\u5fa9\u6b63\u5e38\uff0c\u8840\u58d3 130/80 mmHg\uff0c\u75c5\u4eba\u6558\u8ff06\u500b\u6708\u524d\u6709\u985e\u4f3c\u767c\u4f5c\uff0c\u6700\u8fd1\u9ad4\u91cd\u6e1b\u5c112\u516c\u65a4\uff0c\u5bb6\u65cf\u53f2\u7236\u89aa\u6709\u9ad8\u8840\u58d3\uff0c\u5927\u59ca\u66fe\u63a5\u53d7\u526f\u7532\u72c0\u817a\u816b\u7624\u5207\u9664\uff0c\u4e00\u5144\u4e8c\u59b9\u7686\u5065\u5eb7\uff0c\u8eab\u9ad4\u6aa2\u67e5\u9664\u4e86\u5716127\u6240\u793a\u4e26\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30Na 138 mM/L\u3001K 4.0 mM/L\u3001Cl 102 mM/L \u3001Ca 2.5 mM/L\u3001P 3.5 mg/dl\u3001AC glucose 112 mg/dl\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u70ba\u6700\u9069\u7576\ufe30\r(1)\u62bd\u8840\u6aa2\u67e5Albumin\u3001total protein\u3001BUN\u3001Cr\u3001GOT\u3001GPT\u3001ALP\r(2)\u62bd\u8840\u6aa2\u67e5HbA1C\u3001AC\u3001PC\r(3)\u62bd\u8840\u6aa2\u67e5plasma metanephrine\r(4)\u62bd\u8840\u6aa2\u67e5iPTH\r(5)\u62bd\u8840\u6aa2\u67e5Calcitonin\r(6)\u5b89\u6392Holter EKG \u6aa2\u67e5\nA. (1)+(2)+(3)\nB. (2)+(4)+(6)\nC. (3)+(4)+(5)\nD. (5)+(6)+(1)\nE. (2)+(3)+(4)\n": "(C)", "101-9.\n22\u6b72\u7537\u6027\u5927\u5b78\u751f\u8fd1\u534a\u5e74\u4f86\u89ba\u5f97\u53e3\u6e34\u3001\u591a\u5c3f\uff0c1\u5929\u559d\u51b7\u98f2\u7d045\u516c\u5347\uff0c\u9ad4\u91cd\u589e\u52a0\u8fd110 Kg\uff0c\u4f86\u8a3a\u8eab\u9ad4\u6aa2\u67e5\u7121\u7279\u5225\u767c\u73fe\uff0cBP 126/82 mmHg\u3001PR 80/min regular\uff0c\u62bd\u8840\u6aa2\u67e5 Na 140 mM/L\u3001K 3.5 mM/L\u3001Urinalysis protein ( - )\uff0csugar ( - )\uff0c\u60a8\u89ba\u5f97\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u70ba\u8a3a\u65b7\u6240\u5fc5\u8981\ufe30\r(1)Water deprivation test\r(2)dDAVP test\r(3)plasma Osm.\r(4)HbA1C\r(5)MRI of sella\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(E)", "101-10.\n28\u6b72\u7537\u6027\u696d\u52d9\u54e1\u56e0\u4e0b\u80a2\u7121\u529b\u7121\u6cd5\u7ad9\u7acb\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u6700\u8fd1\u696d\u52d9\u58d3\u529b\u5927\u5e38\u5931\u7720\uff0c\u4f46\u98df\u617e\u4e0d\u932f\u53ea\u662f\u9ad4\u91cd\u4e26\u672a\u589e\u52a0\uff0c\u6628\u65e5\u53c3\u52a0\u805a\u9910\uff0c\u4eca\u65e9\u672c\u4f86\u8981\u505a\u696d\u52d9\u5831\u544a\u4f46\u4eca\u65e9\u767c\u73fe\u7121\u6cd5\u7ad9\u7acb\u3002\u8eab\u9ad4\u6aa2\u67e5\u767c\u73feBP 140/70 mmHg\u3001PR 100/min regular\uff0c\u7532\u72c0\u817a\u4e26\u7121\u660e\u986f\u816b\u5927\uff0c\u4e0b\u80a2\u808c\u529b1/5\uff0cDTR\u4e0b\u80a2\u7121\u6cd5\u505a\u51fa\uff0c\u4e0a\u80a2 ( + + )\u3001Barbinski sign ( - )\uff0c\u4e0b\u5217\u6aa2\u67e5\u4f55\u8005\u5fc5\u8981\ufe30\r(1)free T4\u3001hsTSH\r(2)Na\u3001K\r(3)MRI of spinal cord\r(4)Psychiatry consultation\r(5)Neurology consultation\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(A)", "101-1.\n\u4f9d\u64da\u4e2d\u83ef\u6c11\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0c\u4e0b\u5217\u90a3\u4e9b\u4eba\u5c1a\u4e0d\u9808\u505a\u7cd6\u5c3f\u75c5\u548c\u7cd6\u5c3f\u75c5\u524d\u671f\u7684\u7be9\u6aa2 ?\nA. 28\u6b72\u5973\u6027\u53bb\u5e74\u751f\u7522\uff0c\u5b30\u5152\u91cd4500\u516c\u514b\uff0cBMI\u70ba26 Kg/\u33a1  \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nB. 26\u6b72\u5973\u6027\u88ab\u8a3a\u65b7\u70ba\u591a\u56ca\u6ce1\u5375\u5de2\u75c7\uff0cBMI\u70ba24 Kg/\u33a1  \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nC. 32\u6b72\u7537\u6027\uff0c\u8fa6\u516c\u5ba4\u5de5\u4f5c\uff0c\u5065\u6aa2\u767c\u73feHbA1C 5.8 %\uff0cBMI\u70ba23 Kg/\u33a1 \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nD. 66\u6b72\u7537\u6027\uff0c\u53bb\u5e74\u525b\u9000\u4f11\uff0c\u5065\u6aa2\u767c\u73feHbA1C 5.6 %\uff0cBMI\u70ba23 Kg/\u33a1\uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\nE. 23\u6b72\u5927\u5b78\u751f\uff0c\u7236\u6bcd\u7686\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0cBMI 25 Kg/\u33a1 \uff0c\u6b64\u5916\u7121\u5176\u4ed6\u7cd6\u5c3f\u75c5\u98a8\u96aa\u56e0\u5b50\n": "(C)", "101-2.\n\u4e0b\u5217\u90a3\u4e00\u9805\u975e\u8a3a\u65b7\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u7684\u5fc5\u8981\u689d\u4ef6\ufe30\nA. \u7a7a\u8179\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 0.5 ng/ml\nB. \u5347\u7cd6\u7d20\u523a\u6fc0\u5f8c6\u5206\u9418\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6 < 1.8 ng/ml\nC. \u5347\u7cd6\u7d20\u523a\u6fc0\u8a66\u9a576\u5206\u82070\u5206\u8840\u6e05C-\u80dc\ufffdT\u6fc3\u5ea6\u76f8\u5dee < 0.7 ng/ml\nD. \u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\nE. Anti-GAD65 \u967d\u6027\n": "(D)", "101-3.\n\u4e0b\u5217\u90a3\u4e00\u85e5\u7269\u6700\u6613\u5f15\u8d77\u4f4e\u8840\u7cd6\nA. Metformin\nB. Pioglitazone\nC. Glinide \u985e\nD. DDP-4 inhibitor\nE. \u03b1- Glucosidase inhibitor\n": "(C)", "101-4.\n\u76ee\u524d\u8a8d\u70ba\u80c3\u7e5e\u9053\u624b\u8853\u53ef\u4f7f\u7cd6\u5c3f\u75c5\u7de9\u89e3\u4e4b\u6a5f\u8f49\u70ba\u4e0b\u5217\u5404\u9805\uff0c\u9664\u4e86\nA. \u98f2\u98df\u9650\u5236\nB. Ghrelin \u4e0a\u5347\nC. \u5341\u4e8c\u6307\u8178\u9694\u7d55\nD. \u4e0b\u8178\u9053\u8377\u723e\u8499\u4e0a\u5347\nE. \u98df\u617e\u4e0b\u964d\n": "(B)", "101-5.\n\u4e0b\u5217\u90a3\u4e00\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u589e\u52a0\u9aa8\u9b06\u75c7\u98a8\u96aa ?\nA. Metformin\nB. Sulfonylurea\nC. Pioglitazone\nD. DDP - 4 inhibitor\nE. \u03b1- glucosidase inhibitor\n": "(C)", "101-6.\n\u4e0b\u5217\u90a3\u4e9b\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u88ab\u5efa\u8b70\u7528\u4f86\u6cbb\u7642\u9910\u5f8c\u9ad8\u8840\u7cd6\uff0c\u9664\u4e86\nA. Glinide\nB. \u03b1- Glucosidase inhibitor\nC. Metformin\nD. DDP - 4 inhibitor\nE. Ultrashort acting insulin\n": "(C)", "101-7.\n\u6839\u64da\u6211\u570b\u6210\u4eba\u9aa8\u9b06\u75c7\u9632\u6cbb\u6307\u5f15\uff0c\u4e0b\u5217\u90a3\u4e9b\u4eba\u8f03\u6c92\u6709\u505a\u9aa8\u5bc6\u5ea6\u7be9\u6aa2\u4e4b\u5fc5\u8981\u6027\nA. 65\u6b72\u4ee5\u4e0a\u7537\u6027\nB. \u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u75c7\u4e4b30\u6b72\u5973\u6027\nC. \u60a3\u6709\u985e\u98a8\u6fd5\u95dc\u7bc0\u708e\u4f7f\u7528\u985e\u56fa\u9187\u60a3\u8005\nD. \u672a\u4f8610\u5e74\u4e4b\u9ad6\u90e8\u9aa8\u6298\u98a8\u96aa4%\u4ee5\u4e0a\u8005\nE. 65\u6b72\u4ee5\u4e0a\u5a66\u5973\n": "(A)", "101-8.\n29\u6b72\u5973\u6027\u6709\u50e7\u5e3d\u74e3\u812b\u5782\u53ca\u659c\u8996\u8853\u5f8c\u75c5\u53f2\uff0c\u6700\u8fd18\u500b\u6708\u4f86\u6709\u65b7\u65b7\u7e8c\u7e8c\u660f\u7761\u72c0\u6cc1\uff0c\u767c\u751f\u6642\u4f75\u6709\u6d41\u53e3\u6c34\u3001\u56db\u80a2\u7121\u529b\u986b\u6296\u4e4b\u60c5\u5f62\uff0c\u5403\u904e\u4e00\u4e9b\u6771\u897f\u5f8c\u5c31\u53ef\u6062\u5fa9\uff0c\u8acb\u554f\u60a8\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u8f03\u6b63\u78ba\ufe30\r(1) \u75c5\u4eba\u7b26\u5408 Whipple's Triad\r(2) \u809d\u3001\u814e\u529f\u80fd\u6aa2\u67e5\u70ba\u5fc5\u8981\r(3) 72\u5c0f\u6642fasting test \u6aa2\u67e5 C- peptide\u3001glucose\u3001insulin \u70ba\u5fc5\u8981\r(4) \u6e2c\u5b9a\u8840\u4e2dsulfonylurea \u6fc3\u5ea6\u70ba\u5fc5\u8981\r(5) \u82e5\u61f7\u7591\u80f0\u5cf6\u7d20\u7624\u6642\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u5927\u90e8\u5206\u53ef\u5b9a\u4f4d\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(B)", "101-9.\n40\u6b72\u7537\u6027\u4e3b\u8a34\u5168\u8eab\u9aa8\u982d\u75db\u7121\u6cd5\u884c\u8d70\u4f86\u8a3a\uff0c\u4ed6\u91cf\u8eab\u9ad8\u6642\u767c\u73fe\u534a\u5e74\u4f86\u6e1b\u5c113\u516c\u5206\uff0c\u810a\u690eX - \u5149\u767c\u73feT10\u524d\u5f91 < \u5f8c\u5f91\uff0c\u9aa8\u5bc6\u5ea6 Lumbar spine T score - 2.6\u3001Hip T score ( \u5de6 ) - 2.8\uff0c( \u53f3 ) -2.9 \uff0c\u62bd\u8840\u6aa2\u67e5 Alb 4.0 g/dl\u3001globulin 2.5 g/dl\u3001ALP 150 U/L ( normal < 80 )\u3001Ca 9.0 mg/dl\u3001P 2.0 mg/dl\u3001iPTH 70 pg/ml\uff0curinalysis \u7121glucose\u3001amino acid\u3001\u86cb\u767d, \u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\r(1) \u6b64\u75c5\u4eba\u70ba osteoporosis \u6709 compression fracture\r(2) \u6b64\u75c5\u4eba\u70ba\u9aa8\u9ad3 ( \u8840\u6db2 ) \u75be\u75c5\u9020\u6210osteoporosis\r(3) \u6e2c\u91cf\u5c3f\u78f7\u70ba\u5fc5\u8981\r(4) \u6e2c\u91cf fibroblast growth factor 23\u6709\u52a9\u8a3a\u65b7\r(5) \u6b64\u75c5\u4eba\u70ba\u60e1\u6027\u816b\u7624\u8f49\u79fb\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "101-10.\n\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\u4e4b\u6cbb\u7642\u70ba\u6070\u7576\r(1) \u80f0\u5cf6\u7d20\u5b9c\u4f7f\u75284 - dose intensify \u6cbb\u7642\r(2) \u975c\u8108\u8f38\u6db2\u521d\u59cb\u5b9c\u5feb\u901f\u5927\u91cf\u751f\u7406\u98df\u9e7d\u6c34 ( 10-20 ml/kg )\r(3) \u9240\u96e2\u5b50\u4e4b\u88dc\u5145\u70ba\u5fc5\u8981\uff0c\u9664\u975e\u8840\u9240 > 5 mM/L \u53ef\u66ab\u7de9\r(4) \u4fc3\u767c\u56e0\u5b50\u5fc5\u9808\u7a4d\u6975\u5c0b\u627e\u4e26\u6cbb\u7642\r(5) \u4e00\u822c\u8840\u7cd6\u4e0b\u964d\u5f8c\u8840\u4e2d Ketone \u81ea\u7136\u6d88\u5931\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(B)", "102-1.\n48\u6b72\u5973\u6027\u56e0\u5065\u6aa2\u767c\u73fe\u7532\u72c0\u817a\u816b\u4f86\u6c42\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u75c5\u4eba\u7532\u72c0\u817a\u5448\u7b2c\u4e00\u5ea6\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30free T4 1.07 ng/dl\u3001hsTSH 7.5\u03bcU/ml\u3001thyroglobulin 100 ng/ml\u3001antiTPO 400 IU/ml\u3002\u4e0b\u5217\u8655\u7f6e\u53ca\u5176\u7406\u7531\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u75c5\u4eba\u7532\u72c0\u817a\u6a5f\u80fd\u4f4e\u4e0b\u5373\u523b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\nB. \u75c5\u4eba\u7532\u72c0\u817a\u816b\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nC. \u75c5\u4ebaantiTPO\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\u4ee5\u6e1b\u5c11\u767c\u708e\nD. \u75c5\u4ebathyroglobulin\u9ad8\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE. \u7532\u72c0\u817a\u7d20\u6cbb\u7642\u7121\u76ca\uff0c\u89c0\u5bdf\u5373\u53ef\n": "(E)", "102-2.\n68\u6b72\u5973\u6027\u6709\u9577\u671f\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u4f7f\u7528Glimepiride\u53cametformin\uff0c\u8fd1\u4e00\u5e74\u4f86\u56e0\u814e\u529f\u80fd\u4e0d\u826f\u505c\u7528metformin\uff0c\u53e6\u6709\u9ad8\u8840\u58d3\uff0c\u63a7\u5236\u4e2d\uff0c\u534a\u5e74\u4f86\u67093\u6b21\u610f\u8b58\u4e0d\u6e05\uff0c\u6700\u8fd11\u6b21\u662f6\u661f\u671f\u524d\u67d0\u4e00\u534a\u591c\uff0c\u8840\u7cd6\u70ba20 mg/dl\uff0c\u6b64\u5f8c\u4e0d\u518d\u670d\u7528\u4efb\u4f55\u964d\u8840\u7cd6\u85e5\uff0c1\u5e74\u524d\u56e0\u5fc3\u623f\u986b\u52d5\u958b\u59cb\u670d\u7528Amiodarone\uff0c\u75c5\u4eba\u8acb\u6c42\u5168\u8eab\u6aa2\u67e5\uff0c\u8840\u58d3 176/70 mmHg\uff0c\u4e0b\u80a2\u9707\u52d5\u611f\u89ba\u6d88\u5931\uff0c\u4e26\u6709Romberg's sign\uff0c\u773c\u5e95\u80cc\u666f\u8996\u7db2\u819c\u75c5\u8b8a\uff0c\u5be6\u9a57\u5ba4\u6aa2\u67e5\ufe30\u7a7a\u8179\u8840\u7cd6135 mg/dl\u3001HbA1C 6.5%\u3001Na 141 mM\u3001K 4.4 mM\u3001Cr 1.9 mg/dl\u3001TSH 24 \u03bcU/ml\u3001urine protein +++\u3002 \u60a8\u6703\u5efa\u8b70\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\uff1f\nA. \u958b\u59cbLautus insulin 1\u59291\u6b21\u6cbb\u7642\nB. \u56de\u5fa9Glimepiride\u4f7f\u7528\nC. \u958b\u59cb\u7528Pioglitazone\nD. \u4f7f\u7528Novonorm\nE. \u958b\u59cbthyroxine\u6cbb\u7642\n": "(E)", "102-3.\n54\u6b72\u5973\u6027\uff0c5\u5e74\u524d\u505c\u7d93\uff0c\u7d048\u500b\u6708\u524d\u6015\u71b1\u3001\u5fc3\u60b8\u3001\u9ad4\u91cd\u6e1b\u8f155.5 Kg\u3001\u624b\u6296\uff0c\u9ad4\u6aa2\u767c\u73feGrade 1\u7532\u72c0\u817a\u816b\uff0c\u9aa8\u5bc6\u5ea6\u6aa2\u67e5\u767c\u73fe\u8170\u690eT score -1.8 \u3001\u80a1\u9aa8 -2.4\uff0c\u62bd\u8840\u6aa2\u67e5\uff0c\u90a3\u4e00\u9805\u8f03\u7b26\u5408\u6b64\u75c5\u4eba\u4e4b\u7d50\u679c?\nA. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n      \u2191                 \u2193                    \u2191                           \u2191\nB. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n      \u2193                 \u2191                    \u2191                           \u2193\nC. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2191                  \u2191                    \u2191                           \u2191\nD. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2191                  \u2193                    \u2193                           \u2193\nE. \u6e38\u96e2\u9223   \u526f\u7532\u72c0\u817a\u7d20  osteocalcin  N - telopeptide\r\n     \u2193                  \u2193                    \u2193                          \u2191\n": "(A)", "102-4.\n72\u6b72\u5973\u6027\u56e0\u767c\u751f\u610f\u8b58\u4e0d\u6e05\u4f4f\u9662\uff0c\u5979\u5152\u5b50\u6558\u8ff0\u75c5\u4eba3\u5929\u524d\u611f\u5192\u670d\u7528\u666e\u62ff\u75bc(acetaminophen)\u53ca\u5927\u91cf\u6c34\uff0c\u9ad4\u6aa2\u767c\u73fe\u9ad4\u6eab38.5 \u2103\u3001\u8108\u640f100/min\u3001\u8840\u58d3140/85 mmHg\uff0c\u4e8c\u5074\u80ba\u6709\u56c9\u97f3( rales ) \u4e26\u7121\u6c34\u816b\uff0c\u80f8\u90e8X\u5149\u767c\u73fe\u4e8c\u5074\u6709\u6d78\u6f64\u584a\uff0c\u62bd\u8840\ufe30Na 110 mM\u3001BUN 15 mg/dl\u3001glucose 96 mg/dl\u3001\u8840\u6f3f\u6ef2\u900f\u58d3230  mOsm\uff0c\u5c3f\u6db2400 mOsm\uff0c \u5c3f\u6db2 Na 15 mM \u3002\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6b63\u78ba\uff1f\nA. \u7981\u6c34\u89c0\u5bdf\nB. \u7d66\u4e88demeclocycline\nC. \u7d66\u4e88\u751f\u7406\u98df\u9e7d\u6c34\nD. \u7d66\u4e883% \u98df\u9e7d\u6c34\nE. \u7d66\u4e883% \u98df\u9e7d\u6c34\u4f75\u7528furosemide 20 mg q12h\n": "(D)", "102-5.\n16\u6b72\u5c11\u5973\u56e0\u539f\u767c\u6027\u7121\u6708\u7d93\u4f86\u8a3a\uff0c\u8eab\u9ad8165.1\u516c\u5206\uff0c\u9ad4\u91cd85\u516c\u65a4\uff0c\u5169\u624b\u5f35\u958b167\u516c\u5206\uff0c\u8840\u58d3 102/60 mmHg\uff0c\u5916\u9670\u767c\u80b2\u6b63\u5e38\uff0c\u9aa8\u76e4\u8154\u8d85\u97f3\u6ce2\u6c92\u6709\u5b50\u5bae\uff0c\u5169\u5074\u5375\u5de21.5x4.2x1.3 cm (\u5de6)\uff0c 1.3x4.4x1.2 cm (\u53f3)\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u53ef\u78ba\u7acb\u8a3a\u65b7?\nA. FSH\u3001LH\nB. Karyotype \u5206\u6790\nC. MRI of Pelvis\nD. ACTH stimulation test\nE. DHEA-S\u53ca17OH-progesterone\n": "(B)", "102-6.\n64\u6b72\u7537\u6027\u5065\u5eb7\u6aa2\u67e5\u5168\u8eabMRI\u767c\u73fe5mm\u8166\u5782\u817a\u816b\u7624\uff0c\u5176\u4ed6\u751f\u5316\u6aa2\u67e5\u7686\u6b63\u5e38\uff0c\u62bd\u8840\ufe30ACTH ( 8AM) 20 pg/ml\u3001cortisol 14 \u03bcg/dl\u3001\rFSH 4 mIU/ml\u3001testosterone 427 ng/dl\u3001free T4 1.1 ng/dl\u3001prolactin 14 ng/ml\u3002\u60a8\u7684\u5efa\u8b70\u662f\nA. \u8f49\u4ecb neurosurgeon\nB. \u8f49\u4ecb radiotherapy\nC. \u7d66\u4e88Octreotide\nD. \u4e0d\u9808\u6cbb\u7642\nE. \u7d66\u4e88Dostinex\n": "(D)", "102-7.\n57\u6b72\u5973\u6027\u9577\u671f\u56e0\u80cc\u75db\u3001\u80a9\u75db\u524d\u5f80\u8a3a\u6240\u6ce8\u5c04\u301d\u6b62\u75db\u91dd\u301e\uff0c1\u5e74\u4f86\u9ad4\u91cd\u589e\u52a09\u516c\u65a4\uff0c\u5448\u73fe\u6708\u4eae\u81c9\uff0c8AM cortisol \u53caACTH\u7686\u6e2c\u4e0d\u5230\uff0c\u76ee\u524d\u4f7f\u7528Dexamethasone 0.5 mg qd\u3001Celebrex 200 mg bid\u3001gabapentin 600 mg qid\u53caNexium 20 mg qd\uff0c\u56e0\u75c5\u4eba\u89ba\u5f97\u6108\u4f86\u6108\u75b2\u5026\u3001\u7121\u529b\u800c\u4f86\u8a3a\u3002\u4e0b\u5217\u90a3\u4e00\u9805\u63aa\u65bd\u662f\u6700\u6070\u7576?\nA. \u505a\u8166\u5782\u817aMRI\u4e86\u89e3\u8166\u5782\u817a\u662f\u5426\u840e\u7e2e\nB. \u6162\u6162\u6e1b\u5c11\u7cd6\u76ae\u7d20\u7528\u91cf\uff0c\u958b\u59cb\u5fa9\u5065\u6cbb\u7642\nC. \u589e\u52a0Dexamethasone \u81f31.0 mg bid\nD. \u505c\u7528gabapentin\nE. \u505aCRH test \u4e86\u89e3\u8166\u5782\u817a\u76ae\u4fc3\u7d20\u7d30\u80de\u4e4b\u529f\u80fd\n": "(B)", "102-8.\n65\u6b72\u7537\u6027\u4e8c\u5e74\u524d\u767c\u73fe\u5de8\u5927\u8166\u5782\u817a\u816b\u7624\uff0c\u63a5\u53d7\u7d93\u8776\u978d\u816b\u7624\u5207\u9664\u8853\uff0c\u8853\u5f8c\u75c5\u7406\u8b49\u5be6\u7121\u529f\u80fd\u6027\u816b\u7624\uff0c\u56e0\u5c1a\u6709\u6b98\u9918\u816b\u7624\u518d\u63a5\u53d7\u653e\u5c04\u7dda\u6cbb\u7642\uff0c\u4e4b\u5f8c\u4fbf\u63a5\u53d7\u6fc0\u7d20\u7f6e\u63db\u6cbb\u7642\u3002\u7d04\u534a\u5e74\u524d\u75c5\u4eba\u611f\u89ba\u5168\u8eab\u9178\u75db\u5c24\u5176\u808b\u9aa8\uff0c\u7d93Tc 99 m \u9aa8\u982d\u6383\u63cf\u767c\u73fe\u591a\u8655\u71b1\u9ede\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30Ca 2.3 mM\u3001P 1.8 mg/dl\u3001iPTH 120 pg/ml\u3001 ALP 658 U/ml\uff0c \u8acb \u554f\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u6070\u7576\uff1f(1)\u5b89\u6392 In-111 Octreotide scan (2)\u62bd\u8840\u6e2c\u5b9aFGF-23 (3)\u62bd\u8840\u6e2c\u5b9a 25 Vit D (4)\u7d66\u4e88Joulie solution (5)\u7d66\u4e881, 25 Vit D3 (6) \u5b89\u6392\u9aa8\u982d biopsy\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(6)\nD. (5)+(6)+(1)\nE. (2)+(4)+(6)\n": "(B)", "102-9.\n32\u6b72\u5973\u6027\u56e0\u767c\u71d2\u3001\u547c\u5438\u56f0\u96e3\u4f86\u9662\u6025\u8a3a\uff0c\u4e3b\u8a34\u4e0a\u8ff0\u75c7\u72c0\u5df2\u4e00\u5929\uff0c\u8eab\u9ad4\u6aa2\u67e5\u9ad4\u6eab39.4 \u2103\u3001\u5fc3\u8df3175/min \u4e0d\u898f\u5247\uff0c \u547c\u5438\u6bcf\u520630\u6b21\uff0c\u8840\u58d3197/127  mmHg\uff0c\u7d50\u819c\u4e0d\u84bc\u767d\uff0c\u7121\u9ec3\u75b8\uff0c\u7532\u72c0\u817a\u7b2c2\u5ea6\u816b\u5927\u3001\u67d4\u8edf\uff0c\u9838\u975c\u8108\u64f4\u5f35\uff0c\u5728\u5fc3\u5c16\u6709\u7b2c2\u5ea6\u5fc3\u6536\u7e2e\u96dc\u97f3\uff0c\u5728\u5de6\u4e0b\u80ba\u6709\u56c9\u97f3\uff0c\u4e26\u7121\u809d\u813e\u816b\u5927\uff0c\u56db\u80a2\u51b0\u51b7\uff0c\u5169\u8173\u6709\u6c34\u816b\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30T4 14 \u03bcg/dl\u3001TSH < 0.001 \u03bcU//ml\u3001cortisol 20\u03bcg/dl \uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6b63\u78ba\uff1f(1)\u96d6\u6709\u7532\u72c0\u817a\u6a5f\u80fd\u4ea2\u9032\u4f46\u53ef\u6392\u9664\u7532\u72c0\u817a\u98a8\u66b4 (2)\u6392\u9664\u814e\u4e0a\u817a\u529f\u80fd\u4f4e\u4e0b\uff0c\u4e0d\u9808\u7d66\u4e88\u7cd6\u76ae\u7d20 (3)\u6b64\u4f8b\u7d66\u4e88 propylthiouracil \u6bd4 Methimazole \u70ba\u4f73 (4)\u6b64\u4f8b\u7d66\u4e88Digoxin \u6bd4Amiodarone \u9069\u7576\r(5)\u62bd\u8840\u6aa2\u67e5epinephrine \u53canorepinephrine\u7686\u5347\u9ad8\u4e14\u8840\u58d3\u9ad8\u61c9\u5148\u7d66\u4e88\u03b1- \u963b\u65b7\u5291\nA. (1)+(3)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "102-10.\n37\u6b72\u7537\u6027\u56e0\u534a\u591c\u767c\u751f\u80f8\u60b6\u3001\u5192\u51b7\u6c57\u4f86\u9662\u6025\u8a3a\uff0c\u4e3b\u8a34\u524d1\u5929 \u665a\u4e0a10\u6642\u767c\u751f\u5641\u5fc3 \u3001\u4e0b\u7009\u4e00\u6b21\uff0c\u534a\u591c2\u6642\u4fbf\u767c\u751f\u4e0a\u8ff0\u75c7\u72c0\u3002\u8eab\u9ad4\u6aa2\u67e5\uff1a\u8840\u58d3175/105 mmHg\u3001  \u8108\u640f88/min\uff0c\u4f46\u505aEKG\u5448sinus tachycardia (\u5fc3\u8df3 141/min )\uff0cST-T depression V4 - V6 \uff0c\u62bd\u8840 WBC 14.4 K/\u03bcl\u3001neutrophil 85.4 %\uff0c\u5fc3\u81df\u8d85\u97f3\u6ce2\u986f\u793a\u5fc3\u623f\u3001\u5fc3\u5ba4\u6b63\u5e38\u5927\u5c0f\uff0c\u4f46LV hypokinesia ( LVEF 50% )\uff0c\u56e0\u6b64\u7d66\u4e88\u6297\u8840\u5c0f\u677f\u85e5\u7269\u53ca\u4f4e\u5206\u5b50\u91cfHeparin\uff0c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u5728\u5165\u9662\u5f8c8\u5c0f\u6642\u9032\u884c\uff0c\u986f\u793a\u7121\u660e\u986f\u51a0\u72c0\u52d5\u8108\u72f9\u7a84\uff0c\u8853\u5f8c \u75c5\u4eba\u8840\u58d3\u4e0b\u964d\u81f3\u6536\u7e2e\u58d3 70 mmHg\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u9069\u7576\ufe30(1) \u75c5\u4eba\u70ba\u6025\u6027\u75c5\u6bd2\u6027\u5fc3\u808c\u708e\uff0c\u62bd\u8840\u6aa2\u67e5\u75c5\u6bd2\u6297\u9ad4 (2)\r\u521d\u6642\u75c5\u4eba\u8840\u58d3\u9ad8\u3001\u5fc3\u8df3\u5feb\u4ee5\u03b2\u963b\u65b7\u5291\u4f86\u964d\u58d3\u662f\u9996\u9078\uff0c\u6216\u53ef\u907f\u514d\u5f8c\u7e8c\u4f75\u767c\u75c7 (3) \u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u96d6\u70ba\u9670\u6027\u4ecd\u4e0d\u80fd\u6392\u9664\u5fc3\u808c\u6897\u585e(4)\u75c5\u4eba\u8840\u58d3\u3001\u5fc3\u8df3\u6d6e\u52d5\u751a\u5927\uff0c\u55dc\u927b\u7d30\u80de\u7624\u6aa2\u67e5\u70ba\u5fc5\u8981 (5)\u6b64\u4f8b\u5fc3\u56e0\u6027\u4f11\u514b\u70ba\u53ef\u9006\u6027\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(D)", "102-1.\n62\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u5df214\u5e74\uff0c\u76ee\u524d\u4f7f\u7528metformin 1000 mg bid\uff0cGlimepiride 4 mg qd\uff0c\u9ad8\u8840\u58d3\u4f7f\u7528irbesartan 150 mg qd\u3001trichlormethiazide 2 mg qd\u3001Atenolol 50 mg qd\u3001\u9ad8\u8840\u8102\u4f7f\u7528atorvastatin 40 mg qd \u53c8\u6709\u51a0\u5fc3\u75c7\uff0c\u4f7f\u7528Nitrate\u53caAspirin 80 mg qd \uff0c\u9ad4\u6aa2\u8eab\u9ad8177\u516c\u5206\u3001\u9ad4\u91cd90Kg\u3001\u8840\u58d3 130/82 mmHg\uff0c\u5176\u9918\u7121\u7279\u5225\u767c\u73fe\uff0c\u62bd\u8840\ufe30HbA1C 8.1%\u3001Cr 1.3 mg/dl\u3001LDL 74 mg/dl\uff0c\u75c5\u4eba\u5728\u5bb6\u5076\u800c\u4f7f\u7528\u8840\u7cd6\u6a5f\u76e3\u6e2c\u8840\u7cd6\uff0c\u60a8\u958b\u4e86Lantus 16 u hs\uff0c\u8acb\u554f\u70baLantus\u5291\u91cf\u8abf\u6574\u4e4b\u8840\u7cd6\u76e3\u6e2c\u6700\u6070\u7576\u7684\u662f\ufe30\nA. \u98ef\u524d\u53ca\u98ef\u5f8c2\u5c0f\u6642\nB. \u6709\u4f4e\u8840\u7cd6\u4e4b\u61f7\u7591\u6642\nC. \u98ef\u524d\u53ca\u7761\u524d\nD. \u7a7a\u8179\nE. \u65e9\u3001\u665a\u9910\u524d\n": "(D)", "102-2.\n64\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c519\u5e74\uff0c\u56e0\u53f3\u8173\u816b\u53ca\u75db\u4f86\u8a3a\uff0c\u5df2\u77e5\u4f75\u767c\u75c7\u6709\u5468\u908a\u795e\u7d93\u75c5\u8b8a\u3001\u975e\u589e\u751f\u6027\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\u3001\u9ad8\u8840\u58d3\u3001\u9ad8\u8840\u8102\u53ca\u5468\u908a\u8840\u7ba1\u75be\u75c5\u3002\u75c5\u4eba\u4e3b\u8a34\u4e00\u5929\u524d\u53f3\u8173\u8e1d\u75bc\u75db\uff0c\u4eca\u5929\u7d05\u816b\u53ca\u8df3\u8e8d\u6642\u6709\u4e9b\u4e0d\u9069\uff0c\u53bb\u5e74\u66fe\u6709\u7b2c\u4e8c\u8dbe\u53d7\u50b7\u767c\u708e\u7d93\u6cbb\u7642\u5df2\u75ca\u7652\u3002\u76ee\u524d\u85e5\u7269\u6709metformin 500mg t.id\u3001 Glimepiride 4 mg qd\u3001pioglitazone 30 mg qd\u3001hydrochlorothiazide/valsartan 25/80 mg qd\u3001simvastatin 40 mg hs\u3001 Aspirin 100 mg qd\uff0c\u9ad4\u6aa2\u767c\u73fe\u8eab\u9ad8160\u516c\u5206\u3001\u9ad4\u91cd80\u516c\u65a4\u3001\u8840\u58d3140/86 mmHg\uff0c\u5c40\u90e8\u767c\u73fe\u53f3\u8173\u7d05\u816b\uff0c\u5468\u908a\u8108\u640f\u7686\u6b63\u5e38\u7121\u660e\u986f\u5916\u50b7\u4f46\u4e0b\u80a2\u9707\u52d5\u611f\u6d88\u5931\uff0c\u62bd\u8840\ufe30HbA1C 7.6 %\u3001Cr 1.2\rmg/dl\u3001LDL 84 mg/dl\u3001uric acid 6.8 mg/dl\uff0cWBC 12,000/\u03bcL\uff0c\u53f3\u8173X\u5149\u6aa2\u67e5\u7121\u7279\u5225\u767c\u73fe\u4f46\u6709\u4e00\u4e9b\u8840\u7ba1\u9223\u5316\uff0c\u4e0b\u5217\u90a3\u4e00\u6b65\u9a5f\u6700\u6070\u7576\uff1a\nA. \u53f3\u8173\u8e1d\u56fa\u5b9a7\u5929\u4e26\u6e1b\u5c11\u627f\u91cd\nB. \u505a\u53f3\u8173MRI\nC. \u505a\u810a\u690e\u3001\u80a1\u9aa8BMD\u6aa2\u67e5\nD. \u505a\u8840\u6db2\u57f9\u990a\u4e26\u7d66\u6297\u751f\u7d20\nE. Tc 99m\u9aa8\u982d\u6383\u63cf\n": "(B)", "102-3.\n52\u6b72\u7537\u6027\u56e0\u65e9\u6668\u88ab\u5bb6\u4eba\u767c\u73fe\u53e3\u9f52\u4e0d\u6e05\u4f86\u6025\u8a3a\uff0c one-touch\u767c\u73fe\u8840\u7cd645mg/dL\u7d93\u8461\u8404\u7cd6\u6ce8\u5c04\u6062\u5fa9\u6b63\u5e38\uff0c\u80f8\u90e8X\u5149\u767c\u73fe\u53f3\u5074\u6709\u4e00\u808b\u819c\u816b\u7624\u7d045\u516c\u5206\uff0c\u75c5\u4eba\u7981\u98df4\u5c0f\u6642\u5f8c\u53c8\u767c\u751f\u4f4e\u8840\u7cd6\u73fe\u8c61\uff0c\u62bd\u8840\u6aa2\u67e5\ufe30\u8840\u7cd639 mg/dl\u3001Insulin < 0.1\u03bcU/ml\u3001C-peptide < 0.1 ng/ ml\uff0c\u7d93glucagon\u6ce8\u5c04\u5f8c10\u5206\u8840\u7cd6\u5347\u70ba65 mg/dl\u800c\u6062\u5fa9\uff0c\u57fa\u65bc\u4e0a\u8ff0\u6aa2\u67e5\u7d50\u679c\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u6070\u7576\uff1a\nA. Pancreas CT\nB. \u91cd\u6e2cinsulin\uff0cc-peptide\nC. \u6e2c\u5b9a\u8840\u4e2d\u964d\u8840\u7cd6\u85e5\u7269\u6fc3\u5ea6\nD. \u6e2c\u5b9aIGF-2\nE. CT-guided biopsy of pleural lesion\n": "(D)", "102-4.\n81\u6b72\u7537\u6027\u4f4f\u5728\u5b89\u990a\u9662\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u53f2\u7528\u98f2\u98df\u63a7\u5236\uff0c\u5176\u4ed6\u75c5\u53f2\u6709\u51a0\u5fc3\u75c7\u3001\u5fc3\u8870\u7aed\u3001\u9ad8\u8840\u58d3\u7528Nitrate\u53caACEI\u6cbb\u7642\uff0c\u75c5\u4eba\u56e0\u8840\u58d3\u964d\u4f4e\u53ca\u610f\u8b58\u60e1\u5316\u88ab\u9001\u4f86\u6025\u8a3a\uff0c\u75c5\u4eba\u55dc\u7761\uff0c\u53e3\u4e7e\u3001\u76ae\u4e7e\u3001\u8840\u58d396/74 mmHg\u3001\u8108\u640f104/min\u3001one-touch > 500 mg/dl\uff0c\u56e0\u6b64\u7d66\u4e88IV\u53caSC RI 10u\uff1b\u62bd\u8840\u6aa2\u67e5\ufe30glucose 815 mg/dl\u3001K 6.1 mM\u3001Na 145 mM\u3001BUN 80mg/dl \u3001Cr 3.5 mg/dl \u3001Blood gas\ufe30pH 7.32 \u3001PCO2 33 mmHg\u3001HCO3 19 mEq/L\u3001PO2 78 mmHg\uff0c\u56e0\u6b64\u653e\u7f6e\u4e2d\u592e\u975c\u8108\u5c0e\u7ba1\u5f8c\u958b\u59cb\u751f\u7406\u98df\u9e7d\u6c34\u704c\u6ce8\uff0c2\u5c0f\u6642\u7d66\u4e861.5\u516c\u5347\uff0c\u4f46\u8840\u58d3\u4e0b\u964d\u81f384/70 mmHg\uff0c\u8acb\u554f\u6b64\u75c5\u4eba\u8840\u58d3\u4e0b\u964d\u4e4b\u539f\u56e0\u70ba\ufe30\nA. Insulin\nB. IV fluid\u4e4b\u9ad4\u7a4d\u6d41\u5931\nC. IV fluid\u4e4b\u6ef2\u900f\u58d3\nD. \u6025\u6027\u5fc3\u808c\u6897\u585e\nE. \u4e73\u9178\u4e2d\u6bd2\n": "(A)", "102-5.\n54\u6b72\u7537\u6027\u6700\u8fd1\u9ad4\u6aa2\u767c\u73fe\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u4ed6\u7684\u6bcd\u89aa\u53ca\u59ca\u59ca\u4ea6\u6709\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u7236\u89aa\u572860\u6b72\u6642\u6b7b\u65bc\u5fc3\u808c\u6897\u585e\uff0c\u75c5\u4eba\u9664\u4e86\u670d\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\u5916\u6c92\u6709\u5176\u4ed6\u85e5\u7269\uff0c\u9ad4\u6aa2\uff1aBMI 28.3 Kg/m2 \u3001\u8840\u58d3145/88 mmHg\uff0c\u62bd\u7159\u4e00\u59291\u5305\uff0c\u8840\u6db2\u751f\u5316\uff1a HDL 37 mg/dl\u3001LDL 142 mg/dl\u3001CHO 220 mg/dl\u3001TG 210 mg/dl\u3001 HbA1C 8.2 %\u3001Cr 1.0 mg/dl\u3001fasting glucose 144 mg/dl\u3002\u8acb\u554f\u9664\u4e86\u751f\u6d3b\u578b\u614b(\u98f2\u98df\u3001\u904b\u52d5\u3001\u505c\u6b62\u62bd\u7159)\u5916\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u9069\u7576\uff1f\nA. \u7d66\u4e88Metformin 500 mg bid\uff0c\u82e5\u53ef\u8010\u53d7\uff0c\u589e\u81f31000 mg bid\nB. \u7d66\u4e88Glyburide 5 mg bid\nC. \u7d66\u4e88Simvastatin 20 mg hs\nD. \u7d66\u4e88Pioglitazone 30 mg qd\nE. \u7d66\u4e88Exenatide 5 mg sc bid\n": "(C)", "102-6.\n37\u6b72\u5973\u6027\u70ba\u7b2c1\u578b\u7cd6\u5c3f\u75c519\u5e74\uff0c\u56e0\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48 ( dorsiflex ) \u4f86\u8a3a\uff0c\u6700\u8fd1\u8ffd\u8e64\u9664\u4e86\u773c\u5e95\u6709\u4e00\u4e9b\u5c0f\u8840\u7ba1\u7624\u4ee5\u5916\u7121\u5176\u4ed6\u4f75\u767c\u75c7\uff0c\u9ad4\u6aa2\u767c\u73fe\u7532\u72c0\u817a2\u5ea6\u816b\u5927\uff0c\u5de6\u8db3\u7121\u6cd5\u80cc\u5c48\uff0c\u611f\u89ba\u4e5f\u55aa\u5931\uff0c\u53f3\u4e0b\u80a2\u5247\u70ba\u6b63\u5e38\uff1b \u819d\u53cd\u5c04\u4e8c\u5074\u7686\u6b63\u5e38\uff0c\u4e0b\u5217\u90a3\u4e00\u9805\u6aa2\u67e5\u6700\u6070\u7576?\nA. \u7532\u72c0\u817a\u529f\u80fd\u6aa2\u67e5\nB. \u795e\u7d93\u50b3\u5c0e\u6aa2\u67e5\nC. \u8166\u810a\u9ad3\u6db2\u86cb\u767d\u96fb\u6cf3\nD. \u8170\u90e8\u6838\u78c1\u5171\u632f\nE. \u985e\u98a8\u6fd5\u56e0\u5b50\u6e2c\u5b9a\n": "(B)", "102-7.\n57\u6b72\u7537\u6027\u88ab\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7d041\u5e74\uff0c\u76ee\u524d\u7528\u85e5\ufe30Metformin 1000mg bid\u3001Glyburide 10 mg bid\u3001rosuvastatin 20 mg qd\uff0c\u4e0d\u62bd\u7159\uff0c\u5076\u800c\u559d1\u7f50\u5564\u9152\uff0c\u9ad4\u6aa2\ufe30\u8840\u58d3126/74 mmHg\u3001\u8108\u640f 84/min\u3001BMI 25 Kg/M2 \uff0c\u62bd\u8840\u6aa2\u67e5\ufe30TSH 1.2\u03bcU/ml\u3001HbA1C 9.6 %\u3001CHO 302 mg/dl\u3001LDL 104 mg/dl\u3001TG 803 mg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u6070\u7576\uff1f\nA. \u7d66\u4e88Niacin\nB. \u7d66\u4e88Pioglitazone\nC. \u7d66\u4e88Insulin\nD. \u7d66\u4e88Fenofibrate\nE. \u7d66\u4e88Ezetimibe\n": "(C)", "102-8.\n\u4e0b\u5217\u90a3\u4e9b\u4eba\u8f03\u9069\u5408\u7528\u80f0\u5cf6\u7d20\u63a7\u5236\uff0c\u8acb\u9078\u6700\u6070\u7576\u7b54\u6848: (1)\u65b0\u767c\u73fe\u7cd6\u5c3f\u75c5\u6709\u4e09\u591a\u75c7\u72c0 (2)\u7cd6\u5c3f\u75c5\u53f220\u5e74\uff0c\u670d\u7528\u4e09\u7a2e\u53e3\u670d\u964d\u7cd6\u5291\uff0c\u8fd1\u534a\u5e74HbA1C \uff1e 8.0 % (3)\u809d\u786c\u5316 Child A \u75c5\u4eba (4) BMI 36 Kg/M2 \uff0c\u7121\u6cd5\u4ee5metformin + sulfonylurea\u63a7\u5236\u4e4b\u7cd6\u5c3f\u75c5\u75c5\u4eba (5)\u6025\u6027\u5fc3\u808c\u6897\u585e\u5728\u51a0\u5fc3\u75c7\u52a0\u8b77\u75c5\u623f\u75c5\u4eba\uff0c\u65b0\u767c\u73fe\u7cd6\u5c3f\u75c5\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(A)", "102-9.\n\u4e0b\u5217\u90a3\u4e9b\u7cd6\u5c3f\u75c5\u4eba\u8f03\u9069\u5408\u8840\u7cd6\u63a7\u5236\u6307\u6a19\u8a2d\u65bcHbA1C \uff1e 7.0 % (1)65\u6b72\u5973\u6027BMI 28 Kg/M2 \uff0c\u5df2\u6709\u7cd6\u5c3f\u75c510\u5e74\uff0c\u7368\u5c45\u81ea\u4e3b (2)65\u6b72\u5973\u6027\u6709\u8996\u7db2\u819c\u75c5\u8b8a\uff0cCr 2.0 mg/dl\uff0c\u624b\u8173\u9ebb\u6728 (3)65\u6b72\u7537\u6027\u6709\u5fc3\u808c\u6897\u585e\u75c5\u53f2\uff0c\u5fc3\u8870\u7aed\u55dc\u597d\u7f8e\u98df (4)65\u6b72\u5973\u6027\u6709\u5927\u8178\u764c\u4f75\u809d\u8f49\u79fb\uff0c\u8853\u5f8c\u6b63\u63a5\u53d7\u5316\u7642 (5)70\u6b72\u7537\u6027\u53bb\u5e74\u53c3\u52a0\u9ad8\u9f61\u99ac\u62c9\u677e\u8cfd\u5f97\u734e (\u61c9\u9078\u51fa\u6240\u6709\u6b63\u78ba\u7b54\u6848)\nA. (1)+(2)+(3)\nB. (2)+(3)\nC. (3)+(4)\nD. (2)+(3)+(4)\nE. (1)+(3)+(5)\n": "(C)", "102-10.\n\u4e0b\u5217\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u8207\u9aa8\u8cea\u758f\u9b06\u75c7\u4e4b\u95dc\u4fc2\uff0c\u4f55\u8005\u6b63\u78ba \ufe56(1)\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u80a5\u80d6\u591a\uff0c\u9aa8\u627f\u91cd\u8f03\u5927\uff0c\u4e0d\u6613\u9aa8\u6298 (2)\u7cd6\u5c3f\u75c5\u5728\u9aa8\u6298\u98a8\u96aa\u8a55\u4f30\u5de5\u5177( FRAX ) \u516c\u5f0f\u5167\u52a0\u4ee5\u8003\u616e (3)\u7cd6\u5c3f\u75c5\u7528\u85e5 thiazolidinedione \u6703\u9020\u6210\u9aa8\u8cea\u758f\u9b06\u75c7 (4)\u7cd6\u5c3f\u75c5\u5f15\u8d77\u4e4b\u7cd6\u5316\u7d42\u7aef\u7522\u7269\u9020\u6210\u9aa8\u8cea\u8b8a\u5dee (5)\u4f7f\u7528 metformin\u65e2\u53ef\u6e1b\u5c11\u5fc3\u8840\u7ba1\u75be\u75c5\u4e5f\u6e1b\u5c11\u9aa8\u6298\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "103-1.\n45\u6b72\u7537\u6027\u75c5\u4eba\u5728\u5065\u6aa2\u6642\u767c\u73fe\u6709\u4e00FDG-PET positive \u7684\u9838\u90e8\u71b1\u9ede\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u7532\u72c0\u817a\u5de6\u5074\u7d041 \u516c\u5206\u7d50\u7bc0\uff0c\u62bd\u8840\u6aa2\u67e5free T4\u6b63\u5e38\u3001hsTSH \u504f\u4f4e\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u9996\u5148\u8981\u505a?\nA. \u5efa\u8b70\u958b\u5200\u5207\u9664\nB. \u6e2cAnti TPO\uff0cAntithyroglobulin Ab\nC. Fine needle aspiration (FNA) of thyroid\nD. I-131 uptake and scan\nE. \u5c40\u90e8\u6ce8\u5c04\u9152\u7cbe\n": "(D)", "103-2.\n63\u6b72\u5973\u6027\u56e0\u4e73\u764c\u505a\u8853\u524d\u8a55\u4f30\u767c\u73fe\u8840\u6db2BUN 24 mg/dl\u3001Cr 1.1 mg/dl\u3001Ca 11.1 mg/dl\u3001P 3.5 mg/dl\u3001Alb 3.9 g/dl\u3001iPTH 96 pg/ml(10-65 pg/ml)\uff0cBone scan \u6b63\u5e38\uff0c\u8853\u5f8c\u8840\u9223\u70ba11.3 mg/dl\u3001iPTH 92 pg/ml\u30011,25 Vit D3 61 pg/ml (16-65 pg/mL)\u3001Urine Ca 362 mg/day\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u9ad8\u8840\u9223\u539f\u56e0?\nA. \u4e73\u764c\u8f49\u79fb\nB. \u7570\u4f4d\u6027PTH\u5206\u6ccc\nC. \u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7\nD. \u4e73\u764c\u904e\u5ea6\u9032\u884c1\u03b1 hydroxylation\nE. \u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\u9ad8\u8840\u9223\u75c7\n": "(C)", "103-3.\n47\u6b72\u5973\u6027\u52a0\u62ff\u5927\u56de\u570b\u50d1\u80de\u56e0\u9ad4\u6aa2\u767c\u73feTSH 4.5\u03bcU/ml\uff0c\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6709\u591a\u98460.5-0.7cm \u7d50\u7bc0\u800c\u5c31\u8a3a\uff0c\u7532\u72c0\u817a\u89f8\u6478\u6bd4\u6b63\u5e38\u7a0d\u5927\u3001\u7a0d\u786c\uff0c\u62bd\u8840\u6aa2\u67e5Anti TPO 242 IU/ml (< 10 IU/mL)\uff0c\u4e0b\u5217\u90a3\u9805TSH \u6fc3\u5ea6\u4ee5\u4e0a\uff0c\u4f60\u6703\u958b\u59cbthyroxine \u6cbb\u7642\uff1f\nA. 1.5 \u03bcU/ml\nB. 11.5 \u03bcU/ml\nC. 7.5 \u03bcU/ml\nD. 3.9 \u03bcU/ml\nE. 18 \u03bcU/ml\n": "(B)", "103-4.\n32\u6b72\u5973\u6027\u56e0\u8179\u75db\u5728\u6025\u8a3a\u7167\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe1.5\u516c\u5206\u5de6\u5074\u814e\u4e0a\u817a\u7624(3.5 Hu)\uff0c\u5979\u9ad4\u91cd\u7a69\u5b9a\uff0cBMI 31.2 Kg/M2\uff0c3\u5e74\u524d\u767c\u73fe\u9ad8\u8840\u58d3\uff0c\u76ee\u524d\u670d\u7528Amlodipine 10 mg qd\uff0cRamipril 10 mg qd\uff1b\u8840\u58d3144/82 mmHg\uff0c\u62bd\u8840(4PM)  Na 143 meq/L\u3001K 3.6 meq/L\uff0cplasma metanephrine\u6b63\u5e38\uff0cplasma aldosterone 6.9 ng/dl\uff0cplasma renin activity (PRA) < 0.6  ng/ml/hr\uff0covernight Dexamethasone suppression test cortisol 0.8 \u03bcg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u4f73\uff1f\nA. \u6aa2\u67e5 midnight cortisol\nB. \u91cd\u6aa28AM plasma aldosterone and PRA\nC. \u6e2c24 urine catecholamine\nD. \u505a\u814e\u4e0a\u817a\u6838\u78c1\u5171\u632f\nE. \u6e2c24 urine cortisol\n": "(B)", "103-5.\n76\u6b72\u5973\u6027\u56e0\u8dcc\u5750\u5730\u4e0a\u81f4T11\u58d3\u8feb\u6027\u9aa8\u6298\u4f86\u8a3a\uff0c\u5979\u6709\u9ad8\u8840\u58d3\u53ca\u98df\u9053\u9006\u6d41\u670d\u85e5\u63a7\u5236\uff0c\u6bcd\u89aa\u572870\u591a\u6b72\u6642\u4e8c\u5074\u5927\u817f\u9aa8\u6298\uff0c\u5979\u6bcf\u5929\u670d\u7528\u9223\u72471000 mg \u4e26\u4f7f\u7528\u591a\u7a2e\u7dad\u4ed6\u547d\uff0c\u5979\u4e3b\u8a34\u5df2\u7d93\u77ee\u4e865-6\u516c\u5206\uff0c\u9ad4\u6aa2\u767c\u73fe\u6709\u4e9b\u99dd\u80cc\u5916\u7121\u5176\u4ed6\u7570\u5e38\uff0c\u62bd\u8840\u6aa2\u67e525 Vit D 33 ng/ml (15-80 ng/ml)\u3001iPTH 32 pg/ml (10-65 pg/ml)\uff0c\u751f\u5316\u6aa2\u67e5\u53ca\u96fb\u89e3\u8cea\u7686\u6b63\u5e38\uff0c\u60a8\u8a8d\u70ba\u6700\u597d\u7684\u6cbb\u7642\u662f?\nA. oral bisphosphonate\nB. \u589e\u52a0\u53e3\u670d\u9223\u7247\nC. \u76ae\u4e0b\u6ce8\u5c04rh PTH\nD. \u4f7f\u7528Nasal calcitonin\nE. \u589e\u52a0Vit D \u5291\u91cf\n": "(C)", "103-6.\n25\u6b72\u5973\u6027\u56e0\u80a5\u80d6\u53ca\u7cd6\u5c3f\u75c5\u75c7\u60e1\u5316\u4f86\u8a3a\uff0c\u76ee\u524dBMI 42 Kg/M2\uff0c18\u6b72\u6642\u88ab\u8a3a\u65b7\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u8d77\u5148\u7528\u98f2\u98df\u63a7\u5236\uff0c\u76f4\u81f32\u5e74\u524d\u9808\u4f7f\u7528metformin\uff0cHbA1C 4\u500b\u6708\u524d\u70ba7.2%\uff0c\u6700\u8fd1\u56e0\u76ae\u75b9\u4f7f\u7528\u985e\u56fa\u9187\uff0c\u9ad4\u6aa2\u767c\u73fe\u8eab\u9ad4\u6709\u591a\u8655\u4e7e\u766c\u75b9\u584a\uff0c\u8840\u58d3150/85 mmHg \uff0c \u7121\u5176\u4ed6\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u7a7a\u8179\u8840\u7cd6204 mg/dl\u3001HbA1C 9.5%\uff0c\u4e0b\u5217\u90a3\u4e00\u63aa\u65bd\u6700\u91cd\u8981?\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u6e2c8AM cortisol\nC. \u6e2c\u8840\u6e05 ferritin\u53caTIBC\nD. \u6e2cAnti-insulin\u53caglutamic acid decarboxylase Ab\nE. \u8f49\u4ecb\u505a\u80c3\u7e5e\u9053\u624b\u8853\n": "(B)", "103-7.\n37\u6b72\u7537\u6027\u4e3b\u8a34\u56e0\u4e0b\u80a2\u7121\u529b\u65e9\u4e0a\u7121\u6cd5\u8d77\u5e8a\uff0c\u4f46\u5230\u4e86\u65e9\u4e0a10\u6642\u5c31\u81ea\u7136\u597d\u4e86\u3002\u75c5\u53f2\u4e2d\u75c5\u4eba\u900f\u9732\u8fd12\u500b\u6708\u9ad4\u91cd\u6e1b\u8f153\u516c\u65a4\u4f46\u98df\u617e\u6975\u4f73\uff0c\u4ed6\u5426\u8a8d\u6709\u5fc3\u60b8\uff0c\u8eab\u9ad4\u6aa2\u67e5\u8840\u58d3136/56 mmHg\u3001\u8108\u640f90/\u5206\u3001\u898f\u5247\u3001\u7532\u72c0\u817a\u6b63\u5e38\u5927\u5c0f\uff0c\u76ae\u819a\u7d30\u7dfb\u6eab\u6696\uff0c\u808c\u529b\u6aa2\u67e5\u5927\u817f\u808c\u529b4/5\uff0c\u4e0a\u81c24/5\uff0c\u5176\u99185/5\uff0c\u8acb\u554f\u6700\u6709\u53ef\u80fd\u7684\u8a3a\u65b7\u662f?\nA. \u539f\u767c\u6027\u919b\u56fa\u916e\u8840\u75c7\nB. \u7532\u72c0\u817a\u9ad8\u80fd\u75c7\u4f75\u808c\u75c5\u8b8a\nC. \u7532\u72c0\u817a\u6bd2\u6027\u5468\u671f\u6027\u7671\u7613\nD. \u7570\u4f4d\u6027\u76ae\u4fc3\u7d20\u75c7\u5019\u7fa4\nE. \u4f7f\u7528\u5229\u5c3f\u5291\u6e1b\u80a5\n": "(C)", "103-8.\n74\u6b72\u7537\u6027\u56e0\u5026\u6020\u3001\u98df\u617e\u5dee\uff0c\u9ad4\u91cd\u6e1b\u8f15\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 17 Kg/M2\u3001\u8840\u58d3130/70 mmHg\u3001\u8108\u640f 54/min\uff0c\u81c9\u90e8\u7a0d\u6709\u6d6e\u816b\uff0c\u773c\u7d50\u819c\u7a0d\u84bc\u767d\uff0c\u5176\u9918\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5\uff1aHb 9.0 gm/dl\u3001WBC 4000/\u03bcl\u3001platelet 80,000/\u03bcl\u3001Na 125 mM\u3001K 3.6 mM\u3001T-CHO 260 mg/dl\u3001LDL 145 mg/dl\u3001BUN 35 mg/dl\u3001Cr 1.5 mg/dl\u3001free T4 0.6 ng/dl (0.8-2.4ng/dl)\u3001hsTSH 0.1 \u03bcU/ml (0.4-4.2\u03bcU/ml )\uff1b\u5927\u4fbf\u6aa2\u67e5\u7121\u6f5b\u8840\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1f\r(1)\t\u7d66\u4e883% NaCl solution\r(2)\t\u7d66\u4e88statin \u6cbb\u7642\r(3)\t\u5373\u523b\u88dc\u5145thyroxine 125\u03bcg/day\r(4)\t\u6e2c\u5b9a8AM cortisol\u3001ACTH\r(5)\t\u505asella MRI\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(D)", "103-9.\n50\u6b72\u4e2d\u5e74\u7537\u6027\u4e3b\u8a34\u967d\u840e\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 27 Kg/M2\u3001\u8840\u58d3140/90 mmHg\uff0c\u5176\u9918\u7121\u7279\u5225\u767c\u73fe\uff0c\u4e0b\u5217\u90a3\u4e9b\u8377\u723e\u8499\u6aa2\u67e5\u6700\u9069\u7576\uff1f(1) FSH (2) LH (3) Testosterone (4) prolactin (5) Dehydroepiandrosterone (DHEAS)\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(B)", "103-10.\n25\u6b72\u5973\u6027\u56e0\u9ad4\u6aa2\u767c\u73fe\u9ad8\u8840\u58d3\u4f86\u8a3a\uff0c\u5bb6\u65cf\u53f2\u6bcd\u89aa\u56e0\u7532\u72c0\u817a\u816b\u958b\u5200\u5f8c\uff0c\u76ee\u524d\u4f7f\u7528thyroxine\u88dc\u5145\uff0c\u7236\u89aa\u4ea6\u6709\u9ad8\u8840\u58d3\uff0c\u65bc\u67d0\u6b21\u8eca\u798d\u958b\u5200\u4e2d\u6b7b\u4ea1\uff0c\u4e00\u500b\u59ca\u59ca\u56e0\u526f\u7532\u72c0\u817a\u9ad8\u80fd\u75c7\u958b\u5200\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u8840\u58d3160/100 mmHg\u3001\u8108\u640f 72/min\uff0c\u7532\u72c0\u817a\u6709grade1\u816b\u5927\uff0c\u9918\u8005\u7121\u7279\u5225\u767c\u73fe\uff0c\u4e0b\u5217\u63aa\u65bd\u4f55\u8005\u6700\u9069\u7576\uff1f(1) \u6e2c\u5b9aNa\u3001K\u3001Cl (2) \u6e2c\u5b9aplasma aldosterone\u53caplasma rennin activity (3) \u6e2c\u5b9aUrine metanephrine (4) \u6e2c\u5b9aAlb\u3001Ca\u3001P\u3001iPTH (5) \u505aRET oncogene\u6aa2\u67e5\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (4)+(5)+(1)\nE. (5)+(1)+(2)\n": "(C)", "103-1.\n58\u6b72\u7537\u6027\uff0c\u670913\u5e74\u7cd6\u5c3f\u75c5\u53f2\u53ca\u9577\u671fCAD\uff0c5\u5e74\u524d\u653e\u7f6e\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u6709sulfonylurea\u3001metformin\u3001hydrochlorothiazide\u3001ACEI\u53caAspirin\u3001atorvastatin\u3002\u6700\u8fd11\u5e74\u4ed6\u52a0\u5f37\u98f2\u98df\u53ca\u904b\u52d5\uff0c\u6e1b\u91cd4\u516c\u65a4\uff0c\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3126 / 72 mmHg\uff0cBMI 30 Kg/M2\uff0c\u8170\u570d99\u516c\u5206\uff0c\u5176\u4ed6\u6b63\u5e38\uff1b\u62bd\u8840HbA1C 7.0 %\u3001CHO 174 mg/dl\u3001LDL 66 mg/dl\u3001TG 376 mg/dl\uff0curine ACR (microalbumin creatinine ratio) 25\u03bcg/gm\uff0c\u4e0b\u5217\u54ea\u4e00\u7a2e\u6cbb\u7642\u6700\u6070\u7576\uff1a\nA. Fenofibrate\nB. Pioglitazone\nC. Insulin glargine\nD. Low carbohydrate diet\nE. Exenatide\n": "(A)", "103-2.\n80\u6b72\u7537\u6027\u56e0\u5026\u6020\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\ufe30BMI 26 Kg/M2\uff0c\u8840\u58d3140 / 90 mmHg\uff0c\u4e0b\u80a2\u6709\u8f15\u5fae\u6c34\u816b\uff0c\u9918\u7121\u7279\u6b8a\u767c\u73fe\uff0c\u62bd\u8840\u6aa2\u67e5Cr 2.5 mg/dl\u3001GOT 30u/L\u3001GPT 25u/L\u3001HbA1C 7.8 %\u3001glucose AC150 mg/dl\uff0c\u5c3f\u6aa2protein(++)\uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u63a7\u5236\u5916\uff0c\u4f55\u8005\u6700 \u9069\u5b9c\uff1f\nA. \u521d\u767c\u73fe\u7cd6\u5c3f\u75c5\u4ee5\u80f0\u5cf6\u7d20\u6ce8\u5c04\u70ba\u4f73\nB. Metformin\nC. Pioglitazone\nD. Linagliptin\nE. Glimepiride\n": "(D)", "103-3.\n29\u6b72\u5973\u6027\u670910\u5e74\u7b2c1\u578b\u7cd6\u5c3f\u75c5\u75c5\u53f2\u4f86\u8a3a\uff0c\u6700\u8fd11-2\u5e74HbA1C 7\u223c8%\uff0c\u773c\u5e95\u6aa2\u67e5\u904e\u6578\u6b21\u4f46\u90fd\u8aaa\u6b63\u5e38\uff0c\u76ee\u524d\u4f7f\u7528\u98ef\u524d\u77ed\u6548\u53ca\u7761\u524dInsulin glargine(Lantus)\uff0c\u6bcf\u661f\u671f\u4ecd\u67093-4\u6b21\u8f15\u5fae\u4f4e\u8840\u7cd6\uff0c\u5176\u4ed6\u85e5\u7269\u53ea\u6709\u907f\u5b55\u4e38\uff0c\u8eab\u9ad4\u6aa2\u67e5BMI 22 Kg/M2\uff0c\u8840\u58d3125/75 mmHg\uff0c\u5de6\u773c\u773c\u5e95\u6709\u4e00microaneurysm \u5468\u908a\u795e\u7d93\u6aa2\u67e5\u6b63\u5e38\uff0c\u62bd\u8840HbA1C 7.4%\uff0cCHOL 156 mg/dl\u3001LDL 95 ng/ dl\u3001TG 78 mg/ dl\u3001urine ACR (microalbumin creatinine ratio) 45 \u03bcg/gm\uff0c\u60a8\u7684\u5efa\u8b70\u662f\uff1a\nA. \u5373\u523b\u7d66\u4e88ACEI\nB. \u5373\u523b\u7d66\u4e88ARB\nC. \u56de\u8a3a\u505a\u5c3f\u6db2\u611f\u67d3\u7be9\u6aa2\nD. 4-6\u661f\u671f\u5f8c\u518d\u505aurine ACR \u6aa2\u67e5\nE. \u505c\u6b62\u53e3\u670d\u907f\u5b55\u4e38\u6539\u7528\u5176\u4ed6\u907f\u5b55\u63aa\u65bd\n": "(D)", "103-4.\n62\u6b72\u7537\u6027\u6709\u4e2d\u98a8\u3001\u5fc3\u623f\u986b\u52d5\u3001\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u7236\u89aa56\u6b72\u6642\u6b7b\u65bc\u5fc3\u808c\u6897\u585e\uff0c\u5f1f\u5f1f58\u6b72\u56e0\u51a0\u5fc3\u75c7\u505a\u7e5e\u9053\u624b\u8853\uff0c\u4ed6\u56e0\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u670d\u7528Simvastatin\u3001Atorvastatin \u90fd \u56e0\u808c\u8089\u9178\u75db\u7121\u6cd5\u4f7f\u7528\uff0c\u4ed6\u4e5f\u56e0\u6f6e\u7d05\u7121\u6cd5\u4f7f\u7528Niacin\u3001gemfibrozil (Lopid)\u9020\u6210\u8178\u80c3\u4e0d\u9069\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u70baimipramine hydrochloride (Tofranil)\u3001Lisinopril\u3001Diltiazem\u3001Warfarin\u53cadiuretic\uff0c\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3 114/71 mmHg\u3001BMI 30.4 Kg/M2\u3001\u8170\u570d102\u516c\u5206\uff0c\u4e8c\u5074\u9838\u52d5\u8108\u96dc\u97f3\uff0c\u5de6\u5074\u504f\u7671\uff0c\u62bd\u8840\u7a7a\u8179\u8840\u7cd6 98 mg/dl\u3001TSH 2.7 \u03bcU/ml\u3001CK 57 U/L\u3001CHO 304 mg/dl\u3001LDL 218 mg/dl\u3001TG 258 mg/dl\u3001HDL 34\rmg/dl\uff0c\u4e0b\u5217\u90a3\u4e00\u500b\u63aa\u65bd\u662f\u6700\u4f73\u7684\u7b2c\u4e00\u6b65\uff1f\nA. \u7d66\u4e88Bezafibrate\nB. Therapeutic lifestyle change Diet\nC. \u7d66\u4e88rosuvastatin (Crestor)\nD. \u7d66\u4e88Ezetimibe\nE. \u7d66\u4e88Pravastatin\n": "(E)", "103-5.\nACCORD\u3001ADVANCE\u3001VADT\u81e8\u5e8a\u8a66\u9a57\u767c\u73fe\u5617\u8a66\u964d\u4f4eHbA1C\u63a5\u8fd16% \u6216 6.5%\uff0c\u53cd\u800c\u9020\u6210\u6b7b\u4ea1\u7387\u4e0a\u5347\uff0c\u6700\u4e3b\u8981\u539f\u56e0\u4f55\u5728?\nA. \u524c\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\u8a98\u767c\u764c\u75c7\u767c\u751f\nB. \u5fc3\u808c\u6897\u585e\u767c\u751f\u7387\u589e\u52a0\nC. \u8166\u5352\u4e2d\u767c\u751f\u7387\u589e\u52a0\nD. \u4f4e\u8840\u7cd6\u81f4\u5fc3\u5f8b\u4e0d\u6574\u767c\u751f\u7387\u589e\u52a0\nE. \u75c5\u4eba\u62b5\u6297\u529b\u964d\u4f4e\n": "(D)", "103-6.\n\u76ee\u524d\u5df2\u77e5Pioglitazone\u4e4b\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u5404\u9805\uff0c\u9664\u4e86\nA. \u6c34\u816b\nB. \u5fc3\u808c\u6897\u585e\nC. \u809d\u529f\u80fd\u8b8a\u5316\nD. \u9aa8\u9b06\nE. \u9ad4\u8102\u589e\u52a0\n": "(B)", "103-7.\n62\u6b72\u7537\u6027\u56e0\u6025\u6027\u5fc3\u808c\u6897\u585e\u4f4f\u9662\u88ab\u767c\u73fe\u6709\u7cd6\u5c3f\u75c5\uff0c\u51a0\u72c0\u52d5\u8108\u651d\u5f71\u767c\u73fe\u591a\u8840\u7ba1\u75be\u75c5\u9808\u9032\u884c\u7e5e\u9053\u624b\u8853\uff0c\u75c5\u4eba\u5728\u624b\u8853\u524d\u5f8c\u4ee5\u2163.\u80f0\u5cf6\u7d20\u704c\u6ce8\u63a7\u5236\u8840\u7cd6\uff0c\u4f4f\u9662\u4e2dLVEF   \u70ba30%\uff0c\u7121\u5fc3\u5f8b\u4e0d\u6574\u3001HbA1C 12%\u3001Cr 1.0 mg/ dl\uff0c\u4f4f\u9662\u4e2d\u63a5\u53d7\u71df\u990a\u5e2b\u885b\u6559\uff0c\u51fa\u9662\u524d\u6539\u670d\u7528Glipizide 5 mg bid\uff0c\u5176\u4ed6\u85e5\u7269\u5c1a\u6709Carvedilol 12.5 mg bid\u3001Atorvastatin (Lipitor) 20 mg qd\u3001Aspirin 75 mg qd\u3001ramipril (Tritace) 10 mg qd\u3001isosorbide 5-mononitrate (Ismo-20) 1/2\uff03bid\u3001furosemide (Lasix)40 mg qd\uff0c\u8acb\u554f\u6cbb\u7642\u6b64\u75c5\u4eba\u4e4b\u7cd6\u5c3f\u75c5\u61c9\u5982\u4f55\u8f03\u597d\uff1f\nA. \u505c\u7528Glipizide \u6539\u7528Metformin\nB. \u7e7c\u7e8cGlipizide\u53e6\u52a0Pioglitazone\nC. \u7e7c\u7e8cGlipizide\u53e6\u52a0Metformin\nD. \u7e7c\u7e8cGlipizide\u53e6\u52a0Insulin\nE. \u505c\u7528Glipizide\u6539\u7528Insulin\n": "(E)", "103-8.\n\u4e0b\u5217\u6709\u95dcincretin\u4e4b\u6558\u8ff0\u4f55\u8005\u6b63\u78ba\uff1f(1) GIP\u7531duodenum L cell \u5206\u6cccGLP-1\u7531Ileum K cell \u5206\u6ccc (2) GIP\u53ef\u523a\u6fc0insulin \u53caglucagon\u5206\u6ccc (3) GLP-1\u53ef\u523a\u6fc0insulin \u5206\u6ccc\u4f46\u6291\u5236glucagon\u5206\u6ccc (4) GIP\u53caGLP-1\u7686\u53ef\u88abDDP-4\u5206\u89e3 (5)\u5728\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u75c5\u4eba\u6ce8\u5c04GIP\u4ecd\u53ef\u964d\u4f4e\u8840\u7cd6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (5)+(1)\n": "(C)", "103-9.\n\u6709\u95dc\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u75c5\u8b8a\u4e4b\u7167\u8b77\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f (1) \u738b\u5973\u58eb\u5927\u5b781\u5e74\u7d1a\u65b0\u751f\uff0c18\u6b72\uff0c\u9ad4\u6aa2\u767c\u73fe\u70ba\u7b2c1\u578b\u7cd6\u5c3f\u75c5\uff0c\u9808\u7acb\u523b\u505a\u521d\u6b21\u6563\u77b3\u5b8c\u6574\u773c\u79d1\u6aa2\u67e5(2) \u674e\u5973\u58eb50\u6b72\u505c\u7d93\u75c7\u5019\u7fa4\uff0c\u9ad4\u6aa2\u767c\u73fe\u70ba\u7b2c2\u578b\u7cd6\u5c3f\u75c5\uff0c\u9808\u7acb\u5373\u505a\u521d\u6b21\u6563\u77b3\u5b8c\u6574\u773c\u79d1\u6aa2\u67e5 (3) \u984c(1)\u4e2d\u4e4b\u738b\u5973\u58eb\u5927\u5b78\u7562\u696d\uff0c\u521d\u6b21\u61f7\u5b55\u61c9\u65bcsecond trimester\u505a\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u6aa2\u67e5\uff0c\u4e26\u65bc\u61f7\u5b55\u4e2d\u5bc6\u5207\u8ffd\u8e64\u81f3\u751f\u7522\u5f8c1\u5e74(4) \u4f7f\u7528Aspirin\u589e\u52a0\u8996\u7db2\u819c\u51fa\u8840\u7684\u98a8\u96aa\uff0c\u4f46\u5c0d\u4fdd\u8b77\u6cbb\u7642\u5fc3\u81df\u7684\u75c5\u4eba\u4e26\u975e\u7981\u5fcc(5) \u96f7\u5c04\u5149\u51dd\u56fa\u6cd5\u5c0d\u9ec3\u6591\u90e8\u6c34\u816b\u4e5f\u53ef\u6e1b\u5c11\u8996\u529b\u55aa\u5931\u7684\u98a8\u96aa(6) \u8996\u7db2\u819c\u75c5\u8b8a\u70ba\u5c0f\u8840\u7ba1\u75c5\u8b8a\u8207\u75c5\u4eba\u5927\u8840\u7ba1\u75c5\u8b8a\u7121\u95dc\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (1)+(3)\nE. (2)+(5)\n": "(E)", "103-10.\n\u6709\u95dc\u7cd6\u5c3f\u75c5\u814e\u75c5\u8b8a\u4e4b\u7167\u8b77\u6307\u5f15\uff0c\u4e0b\u5217\u4f55\u8005\u6b63\u78ba\uff1f(1)\u8840\u58d3\u6b63\u5e38\u4e0b\u4f7f\u7528ACEI\u6216ARB\uff0c\u5c0d\u814e\u75c5\u8b8a\u4e0d\u50c5\u7121\u6548\u4e14\u6613\u6709\u526f\u4f5c\u7528(2)\u61c9\u7a4d\u6975\u6cbb\u7642\u9ad8\u8840\u58d3\u4e26\u7dad\u6301\u5728130/80 mmHg \u4ee5\u4e0b(3)\u61c9\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u4e26\u7dad\u6301HbA1C\u57286.5%\u4ee5\u4e0b(4)\u82e5\u75c5\u4eba\u8840\u6e05\u808c\u9150\u9178\u5df2\u4e0a\u5347\uff0c\u5247\u6bcf\u4e09\u500b\u6708\u5fc5\u9808\u8981\u6aa2\u67e5\u4e00\u6b21\u8840\u6e05\u808c\u9150\u9178(creatrimine)(5)\u82e5\u75c5\u4eba\u767c\u751f\u5de8\u91cf\u86cb\u767d\u5c3f\u61c9\u589e\u52a0\u86cb\u767d\u8cea\u651d\u53d6( >1.0 gm/Kg )\uff0c\u88dc\u5145\u6d41\u5931\u86cb\u767d\u4ee5\u907f\u514d\u6c34\u816b(6)\u5373\u4f7f\u5df2\u662fESRD\u4ecd\u61c9\u7a4d\u6975\u63a7\u5236\u8840\u8102\u7570\u5e38\uff0c\u4f7fLDL\u572870 mg/dl\u4ee5\u4e0b\nA. (1)+(2)\nB. (3)+(4)\nC. (5)+(6)\nD. (2)+(4)\nE. (1)+(5)\n": "(D)", "104-1.\n69\u6b72\u7537\u6027\u6709chronic stable angina pectoris\uff0c\u534a\u5e74\u524d\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u767c\u73fe\u55ae\u4e00\u8840\u7ba1\u51a0\u5fc3\u75c7\uff08\u5de6\u524d\u4e0b\u652f\uff09\uff0c\u75c5\u4eba\u76ee\u524d\u4f7f\u7528Atenolol 100 mg qd \u53caAspirin 80 mg qd\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u76ae\u819a\u4e7e\u71e5\u6709\u4e9b\u6d6e\u816b\uff0c\u62bd\u8840\u767c\u73fe\u81bd\u56fa\u9187320 mg/dl\uff0cLDL 166 mg/dl\uff0c HDL 34 mg/dl\uff0c hsTSH 62 uU/ml\uff0cfree T4 0.4ng/dl\uff0c\u4e0b\u5217\u6cbb\u7642\u65b9\u5f0f\u90a3\u4e00\u7a2e\u6700\u597d\uff1f\nA. \u7d66\u4e88\u9810\u9632\u6027anticoagulant\u6cbb\u7642\u53ca\u7532\u72c0\u817a\u7d20100 ug qd\nB. \u7d66\u4e88\u7532\u72c0\u817a\u7d2075 ug qd\u53ca\u4e09\u7898\u7532\u7d2025 ug qd\nC. \u7d66\u4e88\u7532\u72c0\u817a\u7d20100 ug qd\u53ca Cortisone Acetate 25 mg qd\nD. \u7d66\u4e88\u7532\u72c0\u817a\u7d20100 ug qd\u53castatin\nE. \u7d66\u4e88\u7532\u72c0\u817a\u7d2025ug qd\n": "(E)", "104-2.\n69\u6b72\u5973\u6027\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c520\u5e74\uff0cBMI 41.7 kg/M2\uff0c\u7528Glimepiride 2 mg qd \u63a7\u5236\uff0c\u4f466\u500b\u6708\u5167\u767c\u751f3\u6b21\u4f4e\u8840\u7cd6\uff0c\u9808\u4f4f\u9662\u6cbb\u7642\uff0c\u56e0\u6b64\u505c\u7528Glimepiride\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u795e\u7d93\u75c5\u8b8a\u53caRomberg's sign(+)\uff0c\u8840\u58d3175/70 mmHg\uff0c\u7532\u72c0\u817a\u6709GrI\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5AC 134 mg/dl\uff0c Cr 1.9mg/dl\uff0c HbA1c 6.8%,\uff0cmicroalb/Cr=3130 mg/g\uff0c K 4.4 mEq/L\uff0c TSH 24.0 uU/ml\u3002\u4e0b\u5217\u6cbb\u7642\u4e2d\uff0c\u60a8\u6703\u5efa\u8b70\u54ea\u4e00\u9805\uff1f\nA. \u6539\u70baNPH insulin hs\nB. \u6062\u5fa9Glimepiride\nC. \u6539\u7528Pioglitazone\nD. \u6539\u7528Repaglinide\nE. \u958b\u59cb\u7532\u72c0\u817a\u7d20\u6cbb\u7642\n": "(E)", "104-3.\n25\u6b72\u7537\u6027\u56e0\u9ad4\u6aa2\u767c\u73fe\u9ad8\u8840\u9223\u4f86\u8a3a\uff0c\u75c5\u4eba\u4e3b\u8a34\u5065\u5eb7\u72c0\u6cc1\u826f\u597d\uff0c\u672a\u66fe\u6709\u5c3f\u8def\u7d50\u77f3\u75c5\u53f2\uff0c\u4ed6\u4e5f\u672a\u670d\u7528\u7dad\u4ed6\u547dD\u53ca\u9223\u7247\uff0c\u9ad4\u6aa2BMI 27.5 kg/M2\uff0c\u8840\u58d3122/84 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5 Alb 4.0 gm/dl\uff0cCr 0.9 mg/dl\uff0cALK phosphatase 120 U/L\uff0c Ca 11.1 mg/dl\uff0c P 3.0 mg/dl\uff0ciPTH 49 pg/ml\uff0cUrine Ca 70 mg/day\uff0c\u6700\u53ef\u80fd\u8a3a\u65b7\u662f\uff1f\nA. Sarcoidosis\nB. VitD intoxication\nC. Primary hyperparathyroidism\nD. Familial hypocalciuric hypercalcemia\nE. Hypercalcemia of malignancy\n": "(D)", "104-4.\n56\u6b72\u5973\u6027\u56e0\u5076\u7136\u767c\u73fe\u53f3\u9838\u6709\u816b\u584a\uff0c\u9ad4\u6aa2\u767c\u73fe\u662f\u53f3\u5074\u7532\u72c0\u817a\u7d50\u7bc0\uff0c\u8d85\u97f3\u6ce2\u767c\u73fe\u70ba2X2\u516c\u5206\u5468\u908a\u5e73\u6ed1\uff0c\u7d30\u91dd\u7a7f\u523a\u662ffollicular neoplasm\uff0c\u62bd\u8840\u6aa2\u67e5free T4  1.71 ng/dl,\uff0chsTSH 0.1 uU/ml\uff0c\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u70ba\u6700\u9069\u7576\uff1f\nA. I-131 uptake & scan\nB. \u7532\u72c0\u817a\u7d20\u6291\u5236\u6cbb\u7642\nC. \u89c0\u5bdf\u8ffd\u8e64\nD. \u958b\u5200\u5207\u9664\nE. \u9838\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(A)", "104-5.\n36\u6b72\u7537\u6027\u56e0\u4e0b\u80a2\u7121\u529b\u4f86\u6025\u8a3a\uff0c\u4ed6\u6700\u8fd1\u88ab\u767c\u73fe\u6709\u9ad8\u8840\u58d3\uff0c\u4ee5\u5229\u5c3f\u5291\u63a7\u5236\uff0c\u6b64\u5916\u7121\u7279\u5225\u75c5\u53f2\u3002\u9ad4\u6aa2\u767c\u73fe\u8840\u58d3150/90 mmHg\uff0c\u62bd\u8840\u6aa2\u67e5 Na 143 mEq/L\uff0cK 2.6 mEq/L\uff0cCL 100 mEq/L\uff0cplasm Aldosterone\uff08PA\uff09 29 ng/dl\uff0cplasma renin activity \uff08PRA\uff09<0.6 ng/ml/h \uff0c\u4e0b\u5217\u90a3\u4e00\u6aa2\u67e5\u6700\u6070\u7576\uff1f\nA. saline suppression test \u6e2cPA\nB. \u6e2c\u8840\u4e2d18-hydroxycorticosterone\nC. postural stimulation test\u6e2cPA, cortisol, PRA, K\nD. adrenal venous sampling \u6e2cPA\u53ca cortisol\nE. CT of adrenal gland\n": "(A)", "104-6.\n60\u6b72\u7537\u6027\u56e0\u8033\u9cf4\u505a\u4e86\u982d\u90e8\u6838\u78c1\u5171\u632f\uff0c\u767c\u73fe\u8166\u4e0b\u5782\u9ad4\u6709\u4e005mm\u817a\u7624\u800c\u4f86\u8a3a\uff0c\u9664\u4e86\u8033\u9cf4\u5916\u75c5\u4eba\u4e26\u7121\u5176\u4ed6\u4e0d\u9069\uff0c\u5916\u89c0\u4ea6\u7121\u5167\u5206\u6ccc\u75be\u75c5\u5916\u89c0\u3002\u62bd\u8840\u6aa2\u67e5 Cortisol 8 AM 15ug/dl\uff0cplasma ACTH 20 pg/ml\uff0c FSH 4 IU/L\uff0c LH 5 IU/L\uff0cfree T4 1.1 ng/dl\uff0cTestosterone 427 ng/dl\uff0c IGF-1 165 ng/ml\uff0cTSH 1.0 uU/ml\u3002\u4e0b\u5217\u8655\u7f6e\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. Transsphenoidal surgery\nB. gamma-knife radiotherapy\nC. No treatment\nD. Octreotide therapy\nE. Dostinex therapy\n": "(C)", "104-7.\n55\u6b72\u5973\u6027\u4e00\u5e74\u524d\u958b\u59cb\u56e0\u8170\u9178\u80cc\u75db\u63a5\u53d7\u4e0d\u660e\u85e5\u7269\u6cbb\u7642\uff0c\u6bcf\u6b21\u670d\u7528\u5f8c\u9178\u75db\u6d88\u5931\uff0c\u4e0d\u7528\u5e7e\u5929\u5f8c\u9178\u75db\u53c8\u4f86\uff0c\u4e00\u5e74\u4f86\u9ad4\u91cd\u589e\u52a020\u516c\u65a4\uff0c\u5713\u81c9\uff0c\u76ae\u819a\u8b8a\u8584\uff0c\u6642\u611f\u5026\u6020\uff0c\u62bd\u8840\u6aa2\u67e5ACTH 8AM <10 pg/ml\uff0cCortisol 3.0 ug/dl\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u70badexamethasone 0.5mg gd\uff0c Celebrex 200 mg b.i.d.\uff0cNexium 20 mg qd\uff0cgabapentin 600mg q.i.d.\u3002\u4e0b\u5217\u63aa\u65bd\u90a3\u4e00\u9805\u6700\u6070\u7576\uff1f\nA. \u505a\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\nB. \u505aATCH stimulation test\nC. \u589e\u52a0Dexamethasone \u70ba1 mg b.i.d.\nD. \u505c\u6b62\u4f7f\u7528gabapentin\nE. \u6162\u6162tapper \u7cd6\u76ae\u7d20\u4e26\u505a\u5fa9\u5065\n": "(E)", "104-8.\n60\u6b72\u7537\u6027\u6709\u9ad8\u8840\u58d3\u75c5\u53f220\u5e74\uff0c\u6700\u8fd12\u5e74\u8840\u58d3\u96e3\u4ee5\u63a7\u5236\uff0c\u76ee\u524d\u964d\u8840\u58d3\u85e5\u70baamlodipine 10mg\uff0cBetaloc 100 mg qd\uff0cLosartan 100 mg qd\uff0cClonidine 0.1 mg qd\uff0chydrochlorothiazide 25 mg qd\uff0c\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u767c\u73fe\u53f3\u5074\u814e\u4e0a\u817a3\u516c\u5206\u816b\u7624\u3002\u8acb\u554f\u5728\u8a55\u4f30\u6b64\u816b\u7624\u9808\u505a\u90a3\u4e00\u4e9b\u6aa2\u67e5\u5c0d\u8a3a\u65b7\u6700\u6709\u5e6b\u52a9\uff1f\r(1) BUN\u3001Cr\r(2) Na\u3001K\u3001CL\r(3) plasma aldosterone\uff0cplasma renin activity\r(4) \u814e\u4e0a\u817a\u816b\u7624\u7d30\u91dd\u7a7f\u523a\r(5) Overnight 1 mg dexamethasone suppression test\r(6) MIBG Scan\r(7) Plasma metanephrine\nA. (1)+(2)+(3)+(4)\nB. (2)+(3)+(4)+(5)\nC. (3)+(4)+(5)+(6)\nD. (3)+(5)+(7)\nE. (2)+(4)+(6)\n": "(D)", "104-9.\n58\u6b72\u5973\u6027\u6700\u8fd1\u5fc3\u60b8\u3001\u9ad4\u91cd\u6e1b\u8f155 Kg/3\u6708\uff0c\u6015\u71b1\uff0c\u62bd\u8840\u6aa2\u67e5 Free T4 2.3ng/dl hsTSH<0.01 uU/ml\uff0c\u56e0\u80cc\u75db\u505aBMD\uff08\u8170\u690e\uff09T score -2.7\uff0c\u6b64\u75c5\u4eba\u4e4b\u9aa8\u9b06\u75c7\uff0c\u4e0b\u5217\u8840\u6db2\u6aa2\u67e5\u4f55\u8005\u6b63\u78ba\uff1f\nA. Ionized Ca\u2191    PTH\u2193    Osteocalcin\u2191    N-Telopeptide\u2191\nB. Ionized Ca\u2193    PTH\u2191    Osteocalcin\u2191    N-Telopeptide\u2191\nC. Ionized Ca\u2191    PTH\u2191    Osteocalcin\u2191    N-Telopeptide\u2191\nD. Ionized Ca\u2191    PTH\u2193    Osteocalcin\u2193    N-Telopeptide\u2193\nE. Ionized Ca\u2193    PTH\u2193    Osteocalcin\u2193    N-Telopeptide\u2193\n": "(A)", "104-10.\n29\u6b72\u5973\u6027\u56e0\u9ad4\u91cd\u57282\u5e74\u5167\u589e\u52a030kg\u4f86\u8a3a\uff0c\u8eab\u9ad4\u6aa2\u67e5\u767c\u73fe\u6709\u4e2d\u592e\u6027\u80a5\u80d6\uff0c\u5713\u81c9\u53ca\u4e0b\u8179\u7d2b\u8272\u689d\u7d0b\uff0c\u8840\u58d3150/100 mmHg\uff0c\u4e0b\u5217\u54ea\u4e9b\u6aa2\u67e5\u70ba\u5fc5\u8981\r(1) serum ACTH\r(2) Urine free cortisol\r(3) Plasma metanephrine\r(4) overnight dexamethasone suppression test\r(5) low dose dexamethasone suppression test\r(6) high dose dexamethasone suppression test\nA. (1)+(2)+(3)\nB. (2)+(5)+(6)\nC. (1)+(5)+(6)\nD. (3)+(4)+(5)\nE. (2)+(4)+(6)\n": "(B)", "104-1.\n63\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c514\u5e74\uff0c\u4ee5\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u63a7\u5236\uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u98ef\u524d\u8840\u7cd6150-160 mg/dl\uff0c\u98ef\u5f8c\u8840\u7cd6200 mg/dl\uff0cHbA1c 8.5%\uff0c\u4e3b\u6cbb\u91ab\u5e2b\u4f7f\u7528Lantus 10 u hs\u4f86\u6539\u5584\u8840\u7cd6\uff0c\u8acb\u554f\u8840\u7cd6\u8ffd\u8e64\u4f86\u8abf\u6574\u4ee5\u4f55\u8005\u70ba\u6e96\uff1f\nA. \u65e9\u98ef\u524d\u8840\u7cd6\nB. \u65e9\u98ef\u5f8c\u8840\u7cd6\nC. \u7761\u524d\u8840\u7cd6\nD. \u665a\u98ef\u524d\u8840\u7cd6\nE. \u6253\u91dd\u5f8c2\u5c0f\u6642\n": "(A)", "104-2.\n64\u6b72\u7537\u6027\u7b2c2\u578b\u7cd6\u5c3f\u75c518\u5e74\uff0c\u6709\u8996\u7db2\u819c\u75c5\u8b8a\u3001\u795e\u7d93\u75c5\u8b8a\u3001\u5468\u908a\u8840\u7ba1\u75c5\u8b8a\uff0c2\u5929\u524d\u56e0\u5927\u8173\u8dbe\uff08\u53f3\uff09\u53d7\u50b7\uff0c\u73fe\u8173\u638c\u53ca\u8e1d\u90e8\u7d05\u816b\u75bc\u75db\uff0c\u4e0b\u4e00\u6b65\u8655\u7f6e\u4f55\u8005\u6700\u4f73\uff1f\nA. \u8e1d\u90e8\u56fa\u5b9a7\u5929\uff0c\u4e4b\u5f8c\u8f15\u5ea6\u91cd\u529b\u627f\u64d4\nB. \u505a\u8173\u8e1d\u6838\u78c1\u5171\u632f\nC. \u505a\u810a\u690e\u3001\u4e0b\u80a2\u9aa8\u5bc6\u5ea6\nD. \u505a\u8840\u6db2\u57f9\u990a\u4e26\u7d66\u6297\u751f\u7d20\nE. Tc 99 m\u9aa8\u982d\u6383\u7784\n": "(B)", "104-3.\n56\u6b72\u7537\u602710\u500b\u6708\u524d\u88ab\u767c\u73fe\u7cd6\u5c3f\u75c5\uff0c\u98ef\u524d151 mg/dl\uff0c\u98ef\u5f8c289 mg/dl\uff0c\u8840\u58d3 170/99 mmHg\uff0c BMI 27 kg/M2\uff0cCHO 210 mg/dl\uff0cTG 287 mg/dl\uff0c\uff0cHbA1c 7.4%\uff0c\u7d66\u4e88ACEI\uff0cmetformin\u3001glipizide \u53ca\u98f2\u98df\u6cbb\u7642\uff0c3\u500b\u6708\u5f8c\uff0cHbA1c 8.3\uff05\uff0cBMI 26 kg/M2\uff0c\u7d93\u85e5\u7269\u8abf\u6574\u5f8c\u8840\u58d3\u5df2\u6b63\u5e38\uff0c\u4f46HbA1c 9.1%\uff0c\u76ee\u524d\u4ed6\u4f7f\u7528metformin 1000 mg b.i.d.\uff0crosuvastatin 10 mg qd\uff0c\u4f86\u8a3a\u62bd\u8840\u6aa2\u67e5 TSH 1.2uU/ml\uff0cHbA1c 9.5%\uff0cCHO 302 mg/dl\uff0cHDL 37 mg/dl\uff0cLDL 140 mg/dl\uff0cTG 803 mg/dl\u3002\u4f60\u5efa\u8b70\u7528\u90a3\u4e00\u85e5\u7269\u4f86\u6cbb\u7642\uff1f\nA. Niacin\nB. Pioglitazone\nC. Insulin\nD. Fenofibrate\nE. Ezetimibe\n": "(C)", "104-4.\n35\u6b72\u5973\u6027\u56e0\u65b7\u65b7\u7e8c\u7e8c\u767c\u751f\u4f4e\u8840\u7cd6\u75c7\u72c0\u5df2\u67091\u5e74\u4f86\u8a3a\uff0c\u6700\u8fd1\u4e00\u661f\u671f\u524d\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u6025\u8a3a\uff0c\u8840\u7cd6\u70ba39 mg/dl\u3002\u5728\u9580\u8a3a\u7a7a\u8179\u62bd\u8840\u6aa2\u67e5 AC 61 mg/dl\uff0cinsulin 4uU/ml\uff0cC-peptide 0.9 ng/ml\uff0ccortisol 16 ug/dl\uff0cIGF-1 300 ng/ml\uff0cTSH 1.2uU/ml\uff0c\u6700\u6070\u7576\u8655\u7f6e\u70ba\uff1a\nA. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nB. \u4f4f\u9662\u505a72 hour fasting test\nC. \u53e3\u670d\u8461\u8404\u7cd6\u8010\u6027\u8a66\u9a57\nD. \u8f49\u4ecb\u5916\u79d1\u624b\u8853\nE. Selective arterial calcium stimulation test\n": "(B)", "104-5.\n81\u6b72\u7537\u6027\u6709\u7cd6\u5c3f\u75c5\u53f2\uff0c\u53ea\u4f7f\u7528\u98f2\u98df\u63a7\u5236\uff0c\u76f8\u95dc\u75be\u75c5\u6709CAD\u3001CHF\u3001\u9ad8\u8840\u58d3\uff0c\u4ed6\u88ab\u9001\u4f86\u6025\u8a3a\u56e0\u610f\u8b58\u4e0d\u6e05\u670924\u5c0f\u6642\uff0c\u9ad4\u6aa2BP 96/74 mmHg\uff0cPR 104/min\uff0cone touch \u8840\u7cd6 > 500 mg/dl\uff0c\u62bd\u8840\u6aa2\u67e5\u8840\u7cd6800 mg/dl\uff0cNa 150 mEq/L\uff0cK 6.1 mEq/L\uff0cBUN 80 mg/dl\uff0cCr 3.5 mg/dl\uff0c\u52d5\u8108\u8840PH 7.32\uff0cPCO2 33mg Hg\uff0cPO2 78 mmHg\uff0cBicarbonate 19 meq/L\uff0c\u4e0b\u5217\u8f38\u6db2\u4f55\u8005\u70ba\u4f73\uff1f\nA. Normal saline I.V.\nB. Half saline I.V.\nC. Lactate Ringer I.V.\nD. N/G distilled water\nE. 5% glucose water + Regular insulin IV\n": "(A)", "104-6.\n65\u6b72\u7537\u6027\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u5728\u9580\u8a3a\u4ed6\u56e0\u7cd6\u5c3f\u75c5\u670d\u7528Amaryl 3mg b.i.d\uff0cmetformin 850 mg b.i.d\uff0c\u9ad8\u8840\u8102\u670d\u7528Lipitor 20 mg qd\uff0c\u9ad8\u8840\u58d3\u670d\u7528Aprovel 150 mg qd\uff0c\u8eab\u9ad4\u6aa2\u67e5\u7a0d\u6709\u6c23\u5598\uff0c\u8840\u58d398/66 mmHg\uff0c\u9ad4\u91cd 80KG\uff0c\u80f8\u90e8X\u5149\u5de6\u5074\u80ba\u708e\uff0c\u5176\u4ed6\u7121\u7279\u5225\u767c\u73fe\u3002\u62bd\u8840\u6aa2\u67e5Random glucose 276 mg/dl\uff0cNa 132 mEq/L\uff0cK 3.8 mEq/L\uff0cCr 1.7 mg/dl\uff0cWBC 18600/uL\uff0cHbA1c \u4e00\u500b\u6708\u524d\u5728\u9580\u8a3a\u70ba8.3%\uff0c\u8acb\u554f\u4e0b\u5217\u90a3\u4e00\u8655\u7f6e\u8f03\u6070\u7576\uff1f\nA. \u52a0Lactus 16 u hs.\nB. \u52a0Pioglitazone\nC. \u505c\u7528Metformin\u53caAmaryl\uff0c\u7528Lactus 16 U hs\u53ca\u6bcf\u9910\u524dRI\uff08\u7d04\u7565\u517116 U)\nD. \u505c\u7528Metformin\u53caAmaryl\uff0c\u5168\u90e8\u7528RI sliding scale\u63a7\u5236\u8840\u7cd6\nE. \u505c\u7528Metformin\uff0c\u52a0\u4e0asliding scale regular insulin\uff08\u8840\u7cd6 > 150 mg/dl\uff09\n": "(C)", "104-7.\n65\u6b72\u7537\u6027\u56e0\u6162\u6027\u6dcb\u5df4\u7403\u767d\u8840\u75c5\u63a5\u53d7\u5316\u7642\uff0c\u4f4f\u9662\u4e2d\u767c\u73fe\u7cd6\u5c3f\u75c5\uff0c\u8840\u7cd6\u4ecb\u65bc230-280 mg/dl\uff0cBMI 19.5 kg/M2\uff0c\u9ad4\u6aa2\u767c\u73fe\u813e\u816b\u5927\uff0cGr 2/6 \u6536\u7e2e\u5fc3\u96dc\u97f3\u53ca\u58d3\u4e0b\u6027\u8173\u6c34\u816b\uff0c\u62bd\u8840\u6aa2\u67e5\u8840\u7d05\u7d208 gm/dl\uff0cHbA1c 6.3\uff05\uff0cWBC 18600/uL\uff0cAlbmin 2.9 g/dl\uff0cCr 1.0 mg/dl\uff0cAC 178 mg/dl\u3002\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6700\u6070\u7576\uff1f\nA. \u82e5\u98f2\u98df\u3001\u904b\u52d5\u7121\u6cd5\u65bc1\u500b\u6708\u5167\u6539\u5584\uff0c\u4fbf\u958b\u59cb\u4f7f\u7528\u964d\u8840\u7cd6\u85e5\u7269\nB. HbA1c\u5c1a\u5728\u6b63\u5e38\u7bc4\u570d\uff0c\u66ab\u4e0d\u9808\u6cbb\u7642\nC. \u9ad8\u8840\u7cd6\u662f\u5be6\u9a57\u5ba4\u5931\u8aa4\u5f15\u8d77\nD. HbA1c\u56e0\u8ca7\u8840\u800c\u4e0d\u6e96\u78ba\nE. HbA1c\u56e0\u767d\u8840\u7403\u589e\u52a0\u800c\u4e0d\u6e96\u78ba\n": "(D)", "104-8.\n\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269Pioglitazone\u4f7f\u7528\u4e4b\u7981\u5fcc\u70ba?\r(1) \u9ad8\u8840\u58d3\r(2) \u814e\u8870\u7aed\u7b2c\u4e09\u671f\r(3) \u5fc3\u8870\u7aed\u7b2c\u4e09\u671f\r(4) \u809d\u529f\u80fd\u7570\u5e38\r(5) \u80a5\u80d6\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(C)", "104-9.\n\u6709\u95dc\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u539f\u5247\uff0c\u9664\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u6cbb\u7642\u5916\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6b63\u78ba?\r(1) Metformin\u662f\u5927\u90e8\u5206\u75c5\u4eba\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\u3002\r(2) Sulfonylurea\u662f\u5c0d\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u4eba\u4e4b\u7981\u5fcc\u3002\r(3) DDP-4\u6291\u5236\u5291\u5c0d\u5fc3\u81df\u6709\u76ca\u53ef\u4f7f\u7528\u65bc\u5fc3\u8870\u7aed\u7b2c\u4e09\u671f\u75c5\u4eba\r(4) \u7cd6\u5316\u8840\u8272\u7d20\u9054\u52307\uff05\u4ee5\u4e0b\u70ba\u5fc5\u8981\u9054\u6210\u4e4b\u76ee\u6a19\u3002\r(5) Pioglitazone\u662fNon-insulin dependent\u964d\u8840\u7cd6\u85e5\u7269\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (4)+(5)\nE. (1)+(5)\n": "(E)", "104-10.\n\u6839\u64da\u53f0\u7063\u7cd6\u5c3f\u75c5\u5b78\u67032012\u7cd6\u5c3f\u75c5\u7167\u8b77\u6307\u5f15\u61c9\u500b\u5225\u5316\u8003\u91cf\u8840\u7cd6\u63a7\u5236\u76ee\u6a19\u7684\u56e0\u7d20\u6709:\r(1) \u9ad4\u91cd\r(2) \u591a\u91cd\u5c0f\u8840\u7ba1\u75c5\u8b8a\r(3) \u8a8d\u77e5\u529f\u80fd\u4e0d\u8db3\r(4) \u764c\u75c7\u672b\u671f\r(5) \u793e\u7d93\u5730\u4f4d\nA. (1)+(2)+(3)\nB. (2)+(3)+(4)\nC. (3)+(4)+(5)\nD. (1)+(4)+(5)\nE. (1)+(2)+(5)\n": "(B)", "105-1.\n\u7121\u75c7\u72c0\u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\uff0c\u82e5\u7b26\u5408\u4e0b\u5217\u54ea\u4e00\u9805\uff0c\u61c9\u5efa\u8b70\u624b\u8853\u6cbb\u7642?\nA. \u5e74\u7d00\u5927\u65bc50\u6b72\nB. \u808c\u9178\u9150\u5ed3\u6e05\u7387(Creatinine clearance) <90 mL/min\nC. \u4efb\u4e00\u8655\u9aa8\u5bc6\u5ea6 T score <-2.5\nD. 24\u5c0f\u6642 \u5c3f\u9223 >= 100 mg\nE. \u8840\u9223\u6bd4\u6b63\u5e38\u53c3\u8003\u503c\u591a 1 mg/dL \u4ee5\u4e0a\n": "(E)", "105-2.\n\u4e00\u4f4d60\u6b72\u5973\u6027\u75c5\u4eba\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u75c5\u4eba\u76ae\u819a\u7c97\u4e7e\uff0c\u4e73\u982d\u984f\u8272\u6de1\uff0c\u5979\u7684\u8840\u58d3\u662f 90/60 mmHg, \u9ad4\u6eab\u70ba\u651d\u6c0f36.5\u5ea6\uff0c\u8108\u640f \u6bcf\u5206\u9418 70 \u4e0b\uff0c \u8840\u9209\u662f125 mmol/L\uff0c\u8840\u7cd6\u662f 60 mg/dL\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\r1. \u9808\u7acb\u5373\u62bd\u8840\u6aa2\u67e5 ACTH\u3001cortisol\u3001fT4\u3001TSH\r2. \u512a\u5148\u88dc\u5145 thyroxine\r3. \u512a\u5148\u88dc\u5145 hydrocortisone\r4. \u5b89\u6392\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\r5. \u9700\u8a73\u7d30\u8a62\u554f\u6708\u7d93\u53ca\u751f\u7522\u53f2\nA. 1+2+4\nB. 1+2+5\nC. 1+3+4\nD. 1+3+5\nE. 2+3+5\n": "(D)", "105-3.\n\u4e0b\u5217\u6709\u95dc\u65bc\u9ad8\u8102\u8840\u75c7\u7684\u6558\u8ff0\u54ea\u4e00\u9805\u6700\u6b63\u78ba?\r1. \u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d\u81bd\u56fa\u9187 (LDL-C)\u4e2d\u7684apolipoprotein \u4ee5 ApoB-100 \u70ba\u4e3b\r2. ApoB-100 \u4e3b\u8981\u5728\u5c0f\u8178\u88fd\u9020\r3. \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u6642\uff0c\u5e38\u53ef\u898b\u8840\u6e05\u4e2d LDL-C \u589e\u52a0\r4. \u6162\u6027\u814e\u75c5\u8b8a (chronic kidney disease) \u6642\uff0c\u5e38\u53ef\u898b\u8840\u4e2d\u4e09\u9178\u9150\u6cb9\u916f (triglyceride, TG) \u6fc3\u5ea6\u4e0b\u964d\r5. TG > 400 mg/dL\u6642\uff0c\u61c9\u8a72\u4f7f\u7528Friedewald\u516c\u5f0f\u8a08\u7b97\u8840\u6e05\u4e2d LDL-C\u6fc3\u5ea6\nA. 1+2\nB. 1+3\nC. 2+4\nD. 1+3+5\nE. 3+4+5\n": "(B)", "105-4.\n\u4e00\u4f4d45\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u4e3b\u8a34\u70ba\u524d\u9838\u90e8\u75bc\u75db\u3002\u4ed6\u7d04\u5169\u9031\u524d\u6709\u611f\u5192\uff0c\u6c92\u6709\u767c\u71d2\uff0c\u7532\u72c0\u817a\u6709\u5c40\u90e8\u816b\u5927\u4f75\u58d3\u75db\u3002\u4ed6\u7684\u767d\u8840\u7403\u70ba5.1 K/\u03bcL\uff0cfT4 \u70ba 1.9 ng/dL (\u53c3\u8003\u503c 0.89 ~ 1.76 ng/dL)\uff0cTSH\u70ba 0.36 \u03bcIU/mL (\u53c3\u8003\u503c 0.4 ~ 4\u03bcIU/mL) \uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u500b\u9078\u9805\u6700\u6b63\u78ba?\nA. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\nB. \u7d66\u4e88\u6297\u751f\u7d20\nC. \u7d66\u4e88\u7532\u72c0\u817a\u7d20\nD. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u53ca\u6297\u751f\u7d20\nE. \u7d66\u4e88\u985e\u56fa\u9187\u6216\u975e\u985e\u56fa\u9187\u6297\u767c\u708e\u85e5\u7269(NSAID)\n": "(E)", "105-5.\n\u67d0\u4e9b\u85e5\u7269\u53ef\u80fd\u5f71\u97ff\u8840\u6e05\u4e2d\u919b\u56fa\u916e(aldosterone)\u3001\u814e\u7d20(renin)\u3001aldosterone-renin ratio (ARR) \u7684\u6aa2\u6e2c\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269\u53ef\u80fd\u4f7frenin\u589e\u52a0\u3001aldosterone\u6e1b\u5c11\u3001ARR\u4e0b\u964d?\nA. \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (\u03b2-blockers)\nB. \u7532\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (\u03b1-blockers)\nC. \u8840\u7ba1\u5f35\u529b\u7d20\u8f49\u5316\u6291\u5236\u5291 (ACE inhibitors)\nD. \u9223\u96e2\u5b50\u62ee\u6297\u5291 (calcium antagonists)\nE. \u5229\u5c3f\u5291 (Diuretics)\n": "(C)", "105-6.\n\u4e00\u4f4d55\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u80f8\u75db\u53ca\u5192\u6c57\u7d04\u4e00\u5c0f\u6642\u800c\u4f86\u8a3a\uff0c\u4ed6\u7684\u8840\u58d3\u70ba205/120 mmHg\u3002\u75c5\u4eba\u904e\u53bb\u5341\u4e94\u5e74\u6709\u9ad8\u8840\u58d3\u75c5\u53f2\uff0c\u4ee5Enalapril 5mg 1# qd\u3001Losartan 50mg 0.5# qd\u3001Amlodipine 5mg 1# qd\u63a7\u5236\uff0c\u4e00\u822c\u8840\u58d3\u70ba120/80 mmHg\u3002\u75c5\u4eba\u6700\u8fd13\u500b\u6708\u4f86\u9ad4\u91cd\u6e1b\u8f156\u516c\u65a4\uff0c\u6709\u6642\u6703\u89ba\u5f97\u809a\u5b50\u4e0d\u8212\u670d\uff0c\u4e5f\u51fa\u73fe\u982d\u75db\u3001\u5fc3\u60b8\u3001\u5192\u6c57\u3001\u7126\u616e\u3001\u624b\u6296\u7b49\u75c7\u72c0\u3002\u75c5\u4eba\u7d93\u7dca\u6025\u8655\u7f6e\u5f8c\u8840\u58d3\u70ba140/90 mmHg\uff0c\u5176\u96fb\u8166\u65b7\u5c64\u5982\u9644\u5716\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\nA. \u75c5\u4eba24\u5c0f\u6642\u5c3f\u6db2\u4e2d\u4e4bnorepinephrine \u53ef\u80fd\u9060\u9ad8\u65bcepinephrine\nB. \u61c9\u8a72\u4f7f\u7528 \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u963b\u65b7\u5291 (beta-blockers) \u63a7\u5236\u8840\u58d3\nC. \u61c9\u8a72\u9650\u5236\u6c34\u5206\u651d\u53d6\u4ee5\u63a7\u5236\u8840\u58d3\nD. \u75c5\u4eba\u82e5\u6709SDHB gene mutation \u5247\u5176\u816b\u7624\u70ba\u60e1\u6027\u7684\u6a5f\u7387\u5c07\u5927\u6e1b\nE. \u75c5\u4eba\u82e5\u540c\u6642\u6709\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u5247\u5c6c\u65bc\u7b2c\u4e00\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia type 1)\n": "(A)", "105-7.\n\u4e00\u4f4d58\u6b72\u5973\u6027\u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\u3001\u7d2b\u7d0b\uff0c\u5979\u7684 8 am ACTH\u70ba 90 pg/mL (\u53c3\u8003\u503c 10 ~ 65 pg/mL)\u3001Cortisol\u70ba30 \u03bcg/dL (\u53c3\u8003\u503c 5 - 25\u03bcg/dL)\uff0c4 pm ACTH \u70ba 86 pg/mL\u3001Cortisol\u70ba 28 \u03bcg/dL (\u53c3\u8003\u503c 2.5 - 12.5\u03bcg/dL)\uff0c\u7d66\u4e88 dexamethasone 2 mg qid \u5169\u5929\u5f8c\uff0c\u5176 cortisol level\u70ba25\u03bcg/dL\u3002 \u75c5\u4eba\u7684\u8840\u9240\u6fc3\u5ea6\u70ba 2.8 mmol/L (\u53c3\u8003\u503c 3.5-5.1 mmol/L)\u3001LDH \u70ba400 u/L (\u53c3\u8003\u503c 140~271 u/L)\uff0c\u8acb\u554f\u4e0b\u5217\u6558\u8ff0\u54ea\u4e00\u9805\u6700\u9069\u7576?\nA. \u61c9\u5b89\u6392\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB. \u61c9\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nC. \u61c9\u5b89\u6392\u80f8\u90e8\u81f3\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nD. \u61c9\u5b89\u6392bilateral inferior petrosal sinus sampling\nE. \u61c9\u8a73\u7d30\u8a62\u554f\u7528\u85e5\u53f2\u4e26\u505c\u7528\u985e\u56fa\u9187\n": "(C)", "105-8.\n\u91dd\u5c0d\u5c3f\u5d29\u75c7(diabetes insipidus, DI)\u7684\u9451\u5225\u8a3a\u65b7\u6240\u505a\u7684\u9650\u6c34\u6e2c\u9a57 (fluid deprivation test) \u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u6e1b\u5c11\nB. \u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u589e\u52a0\nC. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7 (nephrogenic DI ) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u6e1b\nD. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7 (nephrogenic DI ) \u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u6e1b\u5c11\uff0c\u7d66\u4e88desmopressin\u5f8c\u5c3f\u91cf\u589e\u52a0\nE. \u5fc3\u7406\u56e0\u7d20\u5f15\u8d77\u7684\u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u65bc\u9650\u6c34\u5f8c\u901a\u5e38\u5c3f\u91cf\u4e0d\u6703\u6e1b\u5c11\n": "(A)", "105-9.\n\u9aa8\u8cea\u758f\u9b06\u75c7\u7684\u98a8\u96aa\u56e0\u7d20\u4e0d\u5305\u62ec\u4e0b\u5217\u54ea\u4e00\u9805? \u8acb\u9078\u64c7\u6700\u9069\u7576\u7684\u7b54\u6848\nA. \u8166\u4e0b\u5782\u9ad4\u529f\u80fd\u4f4e\u4e0b\nB. Vitamin D\u904e\u91cf\nC. Primary biliary cirrhosis\nD. Epilepsy\nE. Proton pump inhibitors\n": "(B)", "105-10.\n\u4e0b\u5217\u54ea\u4e00\u9805\u6709\u95dc\u65bc\u80a2\u7aef\u80a5\u5927\u75c7 (acromegaly) \u7684\u63cf\u8ff0\u662f\u6b63\u78ba\u7684?\nA. \u8840\u6e05\u4e2dIGF-1\u6fc3\u5ea6\u6703\u56e0\u5e74\u7d00\u4e0d\u540c\u800c\u6539\u8b8a\uff0c\u4e0d\u9069\u5408\u7528\u505a\u8a3a\u65b7\u4e4b\u4f9d\u64da\nB. \u751f\u9577\u6fc0\u7d20 (growth hormone, GH) \u5206\u6ccc\u6046\u5b9a\uff0c\u6e2c\u91cf\u4e00\u6b21GH\u5373\u8db3\u4ee5\u8a3a\u65b7\nC. \u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd61-2\u5c0f\u6642\u5f8c GH\u6fc3\u5ea6\u70ba1 \u03bcg/L\uff0c\u53ef\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7\nD. \u5927\u7d0425%\u7684\u80a2\u7aef\u80a5\u5927\u75c7\u75c5\u4eba\u540c\u6642\u6709\u6ccc\u4e73\u6fc0\u7d20 (prolactin) \u589e\u9ad8\nE. \u5927\u591a\u6578GH-secreting pituitary adenoma\u53ef\u4ee5\u4f7f\u7528\u85e5\u7269\u6cbb\u7642\u4e0d\u9808\u958b\u5200\n": "(D)", "105-1.\n\u674e\u5148\u751f\uff0c45\u6b72\uff0c165\u516c\u5206\uff0c76\u516c\u65a4\uff0c\u7121\u7cd6\u5c3f\u75c5\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2\uff0c\u66fe\u5169\u6b21\u65bc\u5de5\u4f5c\u6642\u660f\u5012\uff0c\u90fd\u5728\u4f11\u606f30\u5206\u9418\u5f8c\u9010\u6f38\u7526\u9192\uff0c\u5fc3\u81df\u5167\u79d1\u53ca\u795e\u7d93\u5167\u79d1\u9580\u8a3a\u6aa2\u67e5\u7121\u5fc3\u5f8b\u4e0d\u6574\u6216\u795e\u7d93\u8840\u7ba1\u75c5\u8b8a\u7570\u5e38\u767c\u73fe\u3002\u6b64\u6b21\u5728\u5ea6\u56e0\u660f\u5012\u5f8c\uff0c\u9001\u81f3\u6025\u8a3a\uff0c\u4f46\u610f\u8b58\u6301\u7e8c\u4e0d\u6e05\uff0c\u8840\u58d3\u70ba112/60mmHg\uff0c\u8108\u640f\u898f\u5f8b\u70ba66BPM\uff0c\u6025\u8a3aone-touch\u8840\u7cd6\u70ba28mg/dl\uff0c\u7d66\u4e8850%\u8461\u8404\u7cd6\u6ce8\u5c04\u53ca\u8f38\u6db2\u5f8c\u7526\u9192\uff0c\u7121\u795e\u7d93\u5b78\u8b8a\u5316\u3002\u5efa\u8b70\u4f4f\u9662\u8a3a\u6cbb\u3002\u5728\u75c5\u623f\u672a\u8f38\u6db2\u60c5\u6cc1\u4e0b\uff0c\u7a7a\u81798\u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u7d50\u679c\u70ba\u7a7a\u8179\u8840\u7cd676mg/dl, Insulin 1.8 mIU/ml, C-peptide 1.8 ng/ml, ACTH 49.5 pg/ml, Cortisol 21.6 ug/dl, IGF-1 182 ng/ml, TSH 2.8\rmIU/ml\u3002\u6b64\u6642\u61c9\u5efa\u8b70\u5148\u9032\u884c\u4f55\u9805\u6aa2\u67e5?\nA. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (MRI)\nB. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nC. 72\u5c0f\u6642 Prolong fasting test\nD. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nE. 72 \u516c\u514b\u8461\u7cd6\u7cd6\u8010\u53d7\u8a66\u9a57\n": "(C)", "105-2.\n\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u5bc6\u5207\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u53ca\u80a5\u80d6\u95dc\u4fc2\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u975e?\nA. \u4ee5\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u964d\u4f4e\u9ad4\u91cd\uff0c\u9810\u9632\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u6642\uff0c\u4eba\u9ad4\u771f\u6b63\u6e1b\u5c11\u7684\u9ad4\u91cd\u6210\u5206\u70ba\u8102\u80aa\nB. \u8eab\u9ad4\u4e2d\u5fc3\u6027\u8179\u90e8\u80a5\u80d6 (central abdominal obesity)\uff0c\u8207\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u5bc6\u5207\u76f8\u95dc\nC. \u9577\u671f\u7684\u7814\u7a76\u986f\u793a\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\uff0c\u53ef\u4ee5\u85c9\u7531\u9ad4\u91cd\u63a7\u5236\uff0c\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u4e4b\u6a5f\u7387\nD. \u7814\u7a76\u986f\u793a\uff0c\u904b\u52d5\u7684\u6642\u9593\u6108\u9577\uff0c\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u53ca\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\nE. \u7f8e\u570b\u9032\u884c\u4e4bLOOKAHEAD\u9577\u671f\u7cd6\u5c3f\u75c5\u7814\u7a76\u986f\u793a\uff0c\u5c0d\u65bc\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u964d\u4f4e\u9ad4\u91cd\u53ef\u4ee5\u4f7f\u8840\u7cd6\u53caHbA1c\u63a7\u5236\u5f97\u66f4\u597d\uff0c\u4f46\u662f\u7121\u6cd5\u964d\u4f4e\u5176\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\n": "(D)", "105-3.\n\u7b2c2\u578b\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\uff0c\u751f\u6d3b\u578b\u614b\u63a7\u5236\u662f\u5fc5\u8981\u9805\u76ee\uff0c\u4f46\u662f\u85e5\u7269\u6cbb\u7642\u5247\u662f\u98f2\u98df\u53ca\u904b\u52d5\u5916\uff0c\u4e0d\u53ef\u7f3a\u7684\u4e00\u74b0\u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\r1. Metformin\u662f\u4e00\u822c\u9078\u64c7\u6cbb\u7642\u7cd6\u5c3f\u75c5\u7684\u7b2c\u4e00\u7dda\u85e5\u7269\uff0c\u814e\u529f\u80fd\u8870\u7aed\uff0ceGFR < 30\u6642\uff0c\u4ecd\u53ef\u5b89\u5168\u4f7f\u7528\u3002\r2. Sulphonylurea\u985e\u85e5\u7269\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\uff0c\u4ee5\u53ca\u9ad4\u91cd\u4e0a\u5347\u3002\r3. \u570b\u5167\u7cd6\u5c3f\u5b78\u6703\u4e4b\u5efa\u8b70\uff0cHbA1c (\u7cd6\u5316\u8840\u8272\u7d20)\u7684\u63a7\u5236\u76ee\u6a19\u70ba7%\u4ee5\u4e0b\u3002\r4. \u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u7684\u7642\u6548\u5f88\u597d\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u6a5f\u6703\u4e5f\u8f03\u9ad8\u3002\r5. \u5c0d\u65bc\u5bb9\u6613\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u75c5\u60a3\uff0c\u61c9\u907f\u514d\u9078\u64c7\u80f0\u5cf6\u7d20\u6216GLP-1 receptor agonist \u985e\u4e4b\u91dd\u5291 \u3002\nA. 1+3\nB. 4+5\nC. 1+5\nD. 2+3\nE. 3+5\n": "(C)", "105-4.\n\u4f9d\u76ee\u524dWHO\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0c\u6709\u95dc\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u4e4b\u5be6\u9a57\u5ba4\u6a19\u6e96\uff0c\u4e0b\u5217\u4f55\u8005\u6709\u8aa4?\nA. \u7a7a\u8179\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 126 mg/dl\nB. \u53e3\u670d\u8461\u8404\u7cd6\u8a66\u9a57 (OGTT)2\u5c0f\u6642\u5f8c\u4e4b\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 200mg/dl\nC. \u7cd6\u5316\u8840\u8272\u7d20\u503c\u5927\u65bc\u6216\u7b49\u65bc 6.5 %\nD. \u96a8\u6a5f\u6e2c\u8a66\u8840\u7cd6 (Random blood glucose) \u5927\u65bc\u6216\u7b49\u65bc 160 mg/dl\nE. \u7a7a\u8179\u8840\u7cd6\u4e4b\u5b9a\u7fa9\u70ba\u81f3\u5c118\u5c0f\u6642\u672a\u9032\u98df\u4efb\u4f55\u98df\u7269\n": "(D)", "105-5.\n\u674e\u5148\u751f\uff0c68\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f210\u5e74\uff0c\u4e0d\u898f\u5247\u4f7f\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5728\u9580\u8a3a\u4e5f\u4e0d\u9858\u610f\u63a5\u53d7\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u3002\u5fc3\u81df\u8870\u7aed NYHA Class III\uff0c\u65bc\u5fc3\u81df\u5167\u79d1\u8ffd\u8e64\u6cbb\u7642\uff0c\u6700\u8fd1\u534a\u5e74\u7121\u62bd\u8840\u5831\u544a\u3002\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u8840\u7cd6\u70ba628 mg/dl\uff0c\u9209\u96e2\u5b50 148 mEq/L\uff0c\u9240\u96e2\u5b50 3.8 mEq/L\uff0c\u5c3f\u7d20\u6c2e 92 mg/dl\uff0c\u808c\u9178\u9150 3.9 mg/dl\uff0c\u52d5\u8108\u8840\u4e4bPh\u503c\u70ba7.28\uff0cPaO2 82 mmHg\uff0cPaCO2 36 mmHg\uff0cBicarbomate 12 mEq/L\u3002\u8840\u58d3\u70ba 88/58 mmHg\uff0c\u8108\u640f\u70ba 108 bpm\u3002\u5728\u76e3\u8996 urine output \u4e4b\u524d\u63d0\u4e0b\uff0c\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u6700\u9069\u7576?\nA. Lactate Ringer solution\nB. 0.9% Normal saline solution\nC. 0.45% Half saline solution\nD. 5% Glucose/Dextrose solution with regular insulin intravenous  infusion\nE. 0.9% Normal saline solution with regular insuin intravenous infustion\n": "(B)", "105-6.\n\u5f35\u5148\u751f\uff0c55\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f210\u5e74\uff0c\u66fe\u56e0coronary arter disease\u9032\u884c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\uff0c\u4e26\u7f6e\u653e\u652f\u67b6\u3002\u76ee\u524d\u4ee5\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70baARB + CCB\uff0c\u964d\u8840\u8102\u85e5\u7269\u70ba Atorvasatain 40mg qd\u3002\u76ee\u524d\u4e4b\u9ad4\u91cd\u70ba76\u516c\u65a4\uff0c\u8eab\u9ad8180\u516c\u5206\uff0cLDL\u70ba62 mg/dl\uff0cHDL \u70ba39mg/dl\uff0cTG\u70ba 682 mg/dl\uff0c\u672c\u6b21HbA1c \u70ba6.9%\uff0c\u5c3f\u6db2\u4e4bMicroalbumin/creatinine ratio\u6b63\u5e38\u3002\u5c0d\u6b64\u75c5\u60a3\u800c\u8a00\uff0c\u61c9\u6709\u4f7f\u7528\u4e0b\u5217\u4f55\u9805\u85e5\u7269\u4e4b\u5fc5\u8981?\nA. Ezetimibe\nB. Pioglitazone\nC. Fenofibrate\nD. GLP-1 receptor agonist, Liraglutide\nE. Nicotic acid\n": "(C)", "105-7.\n\u738b\u5973\u58eb\uff0c58\u6b72\uff0c\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u6297\u751f\u7d20\u4f7f\u75285\u5929\u5f8c\uff0c\u75c5\u6cc1\u7a69\u5b9a\uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662\u3002\u76ee\u524d\u9ad4\u6eab\u70ba\u651d\u6c0f36.2\u5ea6\uff0c\u8840\u58d3 126/82 mmHg\uff0c\u8108\u640f\u70ba76 bpm\u3002\u6709\u8840\u7cd6\u7570\u5e38\u4e4b\u500b\u4eba\u53f2\u7d042\u5e74\uff0c\u4f46\u672a\u66fe\u63a5\u53d7\u6cbb\u7642\uff0c\u5165\u9662\u96a8\u6a5f\u62bd\u8840\u8840\u7cd6\u70ba186 mg/dl\uff0cHbA1c \u70ba 8.6 %\uff0c\u4f4f\u9662\u7b2c\u4e94\u5929\u4e4b\u6668\u9593\u7a7a\u8179\u62bd\u8840\u8840\u7cd6\u70ba 154 mg/dl\uff0c\u81ea\u5099\u65e9\u9910\u5f8c2\u5c0f\u6642\u62bd\u8840\u8840\u7cd6\u70ba 216 mg/dl\uff0cCr 0.7 mg/dl (eGFR 78), BUN 16 mg/dl,  Na 135 mEqL, K 3.9 mEq/L\u3002\u76ee\u524d\u4ea6\u7121\u7cd6\u5c3f\u75c5\u81e8\u5e8a\u75c7\u72c0\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u6709\u8aa4?\nA. \u5728\u76ee\u524d\u75c5\u6cc1\u7a69\u5b9a\u4e0b\u61c9\u8003\u616e\u7d66\u4e88Metformin\u85e5\u7269\u6cbb\u7642\nB. \u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u885b\u6559\u53ca\u57fa\u672c\u904b\u52d5\u6307\u5c0e\nC. \u5efa\u8b70\u75c5\u60a3\u61c9\u6709\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6(Self-Monitoring blood glucose, SMBG)\u4e4b\u89c0\u5ff5\nD. \u5efa\u8b70\u5b89\u6392\u53e3\u670d\u8461\u8404\u7cd6\u8010\u53d7\u6e2c\u8a66 (OGTT)\u9032\u4e00\u6b65\u78ba\u8a3a\u7cd6\u5c3f\u75c5\nE. \u5efa\u8b70\u61c9\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u6aa2\u67e5\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\n": "(D)", "105-8.\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u6cbb\u7642\u904e\u7a0b\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u4f4e\u8840\u7cd6\u72c0\u6cc1\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u6839\u64daDCCT (Diabetes Control and COmplications Trial)\uff0c\u4ee5\u80f0\u5cf6\u7d20\u7a4d\u6975\u63a7\u5236\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\uff0c\u53ef\u6709\u6548\u7684\u964d\u4f4e\u7cd6\u5c3f\u75c5\u773c\u75c5\u8b8a\u3001\u814e\u75c5\u8b8a\u53ca\u795e\u7d93\u75c5\u8b8a\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u7684\u60c5\u6cc1\u4e5f\u5f88\u5e38\u898b\nB. \u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u4e4bACCORD, ADVANCE\u7814\u7a76\u767c\u73fe\uff0c\u4f7f\u7528\u85e5\u7269\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u4f4e\u8840\u7cd6\u73fe\u8c61\u4e26\u4e0d\u5e38\u898b\nC. \u7576\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u6642\uff0c\u591a\u6578\u53e3\u670d\u85e5\u7269\u70baSulphonylurea\nD. \u4f7f\u7528Basal insulin (\u57fa\u790e\u80f0\u5cf6\u7d20) \u767c\u751f\u4f4e\u8840\u7cd6\u7684\u60c5\u6cc1\u8f03\u5c11\uff0c\u4f46\u662f\u4f7f\u7528\u9910\u524d\u80f0\u5cf6\u7d20 (Prandial insulin)\u6642\uff0c\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u660e\u986f\u589e\u52a0\nE. \u4f4e\u8840\u7cd6\u7684\u75c7\u72c0\uff0c\u5305\u62ec\u5fc3\u5f8b\u4e0d\u6574\u3001\u795e\u7d93\u5b78\u75c7\u72c0\u3001\u751a\u81f3\u62bd\u6410\u3001\u660f\u8ff7\n": "(B)", "105-9.\n\u76ee\u524d\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\u4e2d\u4e4b\u91dd\u5291\uff0c\u9664\u80f0\u5cf6\u7d20\u5916\uff0c\u4e5f\u6709GLP-1 receptor agonist\u91dd\u5291\u85e5\u7269\uff0c\u8207DPP-4 inhibitors \u5747\u70baIncretin \u985e\u85e5\u7269\u3002\u4ee5\u4e0b\u6709\u95dcIncretin\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u6b63\u78ba?\r1. GLP-1 (Glucagon like peptide-1) \u7531\u8178\u9053\u4e4bL cell\u5206\u6ccc\u3002\r2. GLP-1 \u53ef\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\uff0c\u4f46\u4e5f\u523a\u6fc0\u6607\u7cd6\u6fc0\u7d20 (Glucagon)\u5206\u6ccc\u3002\r3. \u4f7f\u7528GLP-1 receptor agonist\u6cbb\u7642\u7cd6\u5c3f\u75c5\u60a3\u8005\u6642\uff0c\u4e5f\u6709\u660e\u986f\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u6548\u679c\u3002\r4. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e5f\u9069\u7528GLP-1 receptor agonist\u3002\r5. \u4f7f\u7528GLP-1 receptor agonist\u53ef\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u4e4b\u98df\u617e\u53ca\u5ef6\u7de9\u672a\u6392\u7a7a\u6642\u9593\u3002\nA. 1+2+3\nB. 2+3+5\nC. 1+3+5\nD. 3+4+5\nE. 1+2+4\n": "(C)", "105-10.\nTZD\u985e\u85e5\u7269\uff0c\u662f\u4e00\u7a2e\u80f0\u5cf6\u7d20\u589e\u654f\u5291\uff0c\u4f46\u662f\u4f7f\u7528\u6642\uff0c\u9808\u6ce8\u610f\u5176\u526f\u4f5c\u7528\uff0c\u4ee5Pioglitazone\u800c\u8a00\uff0c\u4e0b\u5217\u6558\u8ff0\u4f55\u8005\u70ba\u5176\u4f7f\u7528\u6642\uff0c\u5fc5\u9808\u7559\u610f\u4e4b\u526f\u4f5c\u7528?\r1. \u6c34\u816b (edema)\r2. \u5fc3\u808c\u6897\u585e\r3. \u9ad4\u91cd\u53ca\u8eab\u9ad4\u8102\u80aa\u589e\u52a0\r4. \u5931\u61b6\r5. \u9aa8\u8cea\u758f\u9b06\u3002\nA. 1+3+4\nB. 2+3+5\nC. 3+4+5\nD. 1+3+5\nE. 1+2+5\n": "(D)", "106-1.\n\u4e00\u4f4d53\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u5176\u8840\u9223\u503c\u70ba2.7 mmol/L (\u53c3\u8003\u503c 2.15~2.58 mmol/L), \u526f\u7532\u72c0\u817a\u8377\u723e\u8499\u70ba 45 pg/mL (\u53c3\u8003\u503c12.0~65.0 pg/mL)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u9808\u5217\u70ba\u9451\u5225\u8a3a\u65b7?(1)\u6162\u6027\u8089\u82bd\u816b\u75c5 (Chronic granulomatous disease)\uff1b(2)\u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\u9ad8\u8840\u9223\u75c7 (familial hypocalciuric hypercalcemia)\uff1b(3)\u725b\u5976\uff0d\u9e7c\u5291\u75c7 (Milk-alkali syndrome)\uff1b(4)\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b (Hypothyroidism)\uff1b(5)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(4)\nB. (2)+(3)+(5)\nC. (1)+(2)+(3)\nD. (3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(C)", "106-2.\n\u6709\u95dc\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u7684\u7279\u6027\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba?(1)\u7532\u72c0\u817a\u9ad3\u8cea\u764c(Medullary thyroid carcinoma)\u7d04\u4f54\u6240\u6709\u7532\u72c0\u817a\u764c\u7684 5 ~ 10% \uff1b(2)\u7d0420% \u7532\u72c0\u817a\u9ad3\u8cea\u764c\u75c5\u4eba\u6709\u5bb6\u65cf\u75c5\u53f2\uff1b(3)\u7b2c\u4e8c\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624(Multiple endocrine neoplasia, MEN, type 2) \u75c5\u4eba\u5e38\u898b\u6709 \u7532\u72c0\u817a\u9ad3\u8cea\u764c\u3001\u814e\u4e0a\u817a\u76ae\u8cea\u816b\u7624\u3001\u526f\u7532\u72c0\u817a\u816b\u7624\uff1b(4)\u7b2c\u4e8c\u578b\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (MEN type2)\u7684\u5bb6\u4eba\u61c9\u8a72\u505a\u57fa\u56e0\u7be9\u6aa2\uff0c\u82e5\u6709RET\u57fa\u56e0\u7a81\u8b8a\uff0c\u61c9\u7b49\u75c5\u4eba\u6210\u5e74\u5f8c\u5efa\u8b70\u7532\u72c0\u817a\u5207\u9664\uff1b(5)\u7532\u72c0\u817a\u9ad3\u8cea\u764c\u53ef\u80fd\u6709\u7570\u4f4d\u6027\u4fc3\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20(ectopic ACTH) \u5206\u6ccc\u800c\u5c0e\u81f4\u5eab\u6b23\u5f0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(5)\nC. (2)+(3)+(4)\nD. (3)+(4)+(5)\nE. (1)+(5)\n": "(B)", "106-3.\n\u4e00\u4f4d64\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u5df2\u6709\u591a\u5e74\u9ad8\u8840\u58d3\uff0c\u6700\u8fd1\u534a\u5e74\u4f86\u8840\u58d3\u4e0d\u6613\u63a7\u5236\uff0c\u4e14\u5e38\u6709\u9663\u767c\u6027\u5fc3\u60b8\u3001\u982d\u75db\u3001\u5192\u6c57\u7b49\u75c7\u72c0\uff0c\u4f60\u61f7\u7591\u75c5\u4eba\u6709\u55dc\u916a\u7d30\u80de\u7624(pheochromocytoma)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u75c5\u4eba\u539f\u4f86\u6709\u4f7f\u7528\u7684\u5229\u5c3f\u5291(diuretics)\u53ca\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269(tricyclic antidepressants)\u5c0d\u6aa2\u9a57\u4e0d\u6703\u5f71\u97ff\uff0c\u6240\u4ee5\u4e0d\u9700\u8981\u5148\u66ab\u505c\u4f7f\u7528\nB. \u6e2c\u91cf\u8840\u6f3f\u4e2d\u7684\u6e38\u96e2\u5f8c\u814e\u4e0a\u817a\u9ad3\u7d20(Plasma free metanephrines)\u5177\u6709\u6700\u9ad8\u7684\u7279\u7570\u6027\uff0c\u4f46\u5e38\u6703\u6709\u56e0\u975c\u8108\u62bd\u8840\u6642\u9020\u6210\u7684\u507d\u967d\u6027(venipuncture-induced false-positive)\u7d50\u679c\nC. \u75c5\u4eba\u6709\u5fc3\u60b8\u75c7\u72c0\uff0c\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u4e59\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b2-adrenergic blockers)\uff0c\u4ee5\u907f\u514d\u5fc3\u8df3\u904e\u901f\uff0c\u9020\u6210\u5371\u96aa\nD. \u7d04\u670910%\u7684\u55dc\u916a\u7d30\u80de\u7624\u662f\u60e1\u6027\u7684\uff0c\u9664\u4e86\u958b\u5200\u4ee5\u5916\uff0c\u53ef\u4ee5\u8003\u616e\u4ee5200 mCi\u7684131 I-MIBG \u6cbb\u7642\nE. \u5927\u7d04\u670925-33% \u7684\u55dc\u916a\u7d30\u80de\u7624\u75c5\u4eba\u6709\u8ddf\u907a\u50b3\u6709\u95dc\u7684\u57fa\u56e0\u7a81\u8b8a\uff0c\u5176\u4e2d\u6709SDHB\u57fa\u56e0\u7a81\u8b8a\u7684\uff0c\u7522\u751f\u60e1\u6027\u8b8a\u5316\u7684\u53ef\u80fd\u6027\u6700\u4f4e\n": "(D)", "106-4.\n\u4e0b\u5217\u54ea\u4e00\u9805\u964d\u8840\u58d3\u85e5\u6703\u4f7f\u8840\u6f3f\u919b\u56fa\u916e\u6fc3\u5ea6 (Plasma aldosterone concentration , PAC)\u8207\u8840\u6e05\u5f35\u529b\u7d20\u6d3b\u6027(plasma renin activity, PRA)\u6bd4\u503c(Aldosterone-renin-ratio, ARR) \u4e0a\u5347?\nA. \u4e59\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b2-adrenergic blockers)\nB. \u7532\u578b\u814e\u4e0a\u817a\u53d7\u9ad4\u6291\u5236\u5291 (\u03b1-adrenergic blockers)\nC. \u8840\u7ba1\u7dca\u5f35\u7d20\u8f49\u63db\ufffdC\u6291\u88fd\u5291 (angiotensin-converting enzyme inhibitors, ACEi)\nD. \u9223\u96e2\u5b50\u62ee\u6297\u5291 (calcium antagonists)\nE. \u5229\u5c3f\u5291 (diuretics)\n": "(A)", "106-5.\n\u6709\u95dc\u8166\u4e0b\u5782\u9ad4\u529f\u80fd\u6aa2\u67e5\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u662f\u6b63\u78ba\u7684\uff1f\r(\u53c3\u8003\u503c: \u6ccc\u4e73\u6fc0\u7d20\uff08Prolactin\uff091.9~25 ng/m\uff2c\uff1b\u751f\u9577\u6fc0\u7d20\uff08Growth hormone, GH\uff09 < 8 ng/mL\uff1b\u76ae\u8cea\u9187\uff08cortisol\uff098 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff097.4~57.3 pg/mL; \u9240\uff08potassium, K\uff093.5~5.1 mmol/L\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.89~1.76 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.4~4 \u03bcIU/mL)\nA. \u7d66\u4e88\u53e3\u670d75\u514b\u8461\u8404\u7cd6\uff0cGH\u57280\u5206\u300130 \u5206\u300160\u5206\u5225\u70ba15 ng/mL\u300114 ng/mL\u300112 ng/mL\uff0c\u53ef\u4ee5\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7(acromegaly)\u3002\nB. \u75c5\u4eba\u7684\u6ccc\u4e73\u6fc0\u7d20\u503c\u70ba 50 ng/mL\uff0c\u53ef\u4ee5\u8a3a\u65b7\u70ba\u6ccc\u4e73\u6fc0\u7d20\u7624(prolactinoma)\u3002\nC. \u75c5\u4eba\u76848 am cortisol \u70ba30 \u03bcg/dL\uff0c\u665a\u4e0a 11 pm \u7d66\u4e88 \u53e3\u670ddexamethasone 1 mg \u5f8c\uff0c\u7b2c\u4e8c\u5929\u4e0a\u5348 8 am \u7684cortisol \u503c\u70ba 18 \u03bcg/dL\uff0c\u53ef\u4ee5\u6392\u9664\u5eab\u6b23\u6c0f\u75c7\u3002\nD. \u75c5\u4eba8 am ACTH 96 pg/mL\u3001cortisol 28 \u03bcg/dL\uff1b4 pm cortisol 25 \u03bcg/dL\uff1b\uff2b 2.7 mmol/L\uff1b\u9808\u5c0f\u5fc3\u662f\u5426\u6709 ectopic ACTH syndrome\u3002\nE. \u75c5\u4eba\u7684 fT4 \u70ba 0.86 ng/dL\u3001TSH 9 \u03bcIU/mL\uff0c\u6b64\u75c5\u4eba\u53ef\u80fd\u6709\u7532\u72c0\u817a\u523a\u6fc0\u7d20\u7624\u3002\n": "(D)", "106-6.\n\u6709\u95dc\u5c3f\u5d29\u75c7\uff08diabetes insipidus, DI\uff09\u7684\u8a3a\u65b7\u8207\u6cbb\u7642\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6b63\u78ba\uff1f\nA. \u5c3f\u5d29\u75c7\u7684\u5b9a\u7fa9\u70ba\u5728\u4e0d\u9650\u6c34\u7684\u60c5\u6cc1\u4e0b\uff0c\u6bcf\u5929\u6bcf\u516c\u65a4\u9ad4\u91cd\u5c3f\u91cf\u5927\u65bc60 mL (\u4f8b\u5982: 70\u516c\u65a4\u91cd\uff0c\u5c3f\u91cf\u8d85\u904e\u6bcf\u5929 4200 mL)\u4e14\u5c3f\u6ef2\u900f\u58d3\u5c0f\u65bc250 mosmol/L\u3002\nB. \u75c5\u4eba\u6709\u5c3f\u5d29\u75c7\uff0c\u4e14\u5176plasma arginine vasopressin (AVP) < 1 pg/mL\uff0c\u61c9\u8a72\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\u3002\nC. \u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u5982\u679c\u5176\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u5f71\u50cf\u986f\u793a\u5176\u5f8c\u8449\u6709\u767d\u767d\u4eae\u9ede\uff0c\u4e00\u5b9a\u662f\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI)\u3002\nD. \u61f7\u7591\u6709\u5c3f\u5d29\u75c7\u7684\u75c5\u4eba\u5728\u505a\u9650\u6c34\u6e2c\u8a66\u6642\uff0c\u5c3f\u91cf\u6e1b\u5c11\uff0c\u5c3f\u6ef2\u900f\u58d3\u589e\u52a0\uff0c\u6b64\u75c5\u4eba\u6bd4\u8f03\u50cf\u662f\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI)\u3002\nE. \u814e\u6e90\u6027\u5c3f\u5d29\u75c7(nephrogenic DI)\u61c9\u8a72\u4f7f\u7528desmopressin (DDAVP)\u6cbb\u7642\u3002\n": "(B)", "106-7.\n\u4e00\u4f4d70 \u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u4f11\u514b\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5176\u6aa2\u9a57\u503c\u5982\u4e0b: Na 125 mmol/L\u3001glucose AC 68 mg/dL\u3001ACTH 20 pg/mL\u3001cortisol 10 \u03bcg/dL\u3001fT4 0.5 ng/dL\u3001TSH 0.1 \u03bcIU/mL\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6cbb\u7642\u61c9\u8a72\u512a\u5148\u7d66\u4e88\uff1f\r(\u53c3\u8003\u503c: \u76ae\u8cea\u9187\uff08cortisol\uff098 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff097.4~57.3 pg/mL; \u9209 (sodium, Na) 136~145 mmol/L\uff1b \u7a7a\u8179\u8840\u7cd6 (glucose AC) 70~100 mg/dL\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.89~1.76 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.4~4 \u03bcIU/mL)\nA. Hydrocortisone, intravenous\nB. Thyroxine\nC. 3% NaCl\nD. 50% glucose water (G/W)\nE. Prednisolone, per os\n": "(A)", "106-8.\n\u4e0b\u5217\u56e0\u7d20\u53ef\u80fd\u9020\u6210euthyroid hyperthyroxinemia\uff0c\u9664\u4e86?\nA. Resistance to thyroid hormone\nB. Pregnancy\nC. Amiodarone\nD. Liver cirrhosis\nE. Malnutrition\n": "(E)", "106-9.\n\u4e00\u4f4d25\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u524d\u9838\u90e8\u816b\u75db\u4f86\u8a3a\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u7532\u72c0\u817a\u6709\u816b\u584a\u3001\u5177\u58d3\u75db\uff0c\u4f46\u7121\u76ae\u819a\u7d05\u71b1\u73fe\u8c61\u3002\u75c5\u4eba\u5169\u9031\u524d\u6709\u4e0a\u547c\u5438\u9053\u611f\u67d3\u75c7\u72c0\u3002\u5979\u7684\u6aa2\u9a57\u6578\u503c\u5982\u4e0b: fT4 2.0 ng/dL (\u53c3\u8003\u503c: 0.89~1.76 ng/dL)\u3001TSH 0.3 \u03bcIU/mL (\u53c3\u8003\u503c 0.4~4 \u03bcIU/mL)\u3001WBC 7800 /\u03bcL\u3002\u8d85\u97f3\u6ce2\u6aa2\u67e5\u986f\u793a\u58d3\u75db\u8655\u6709\u5c40\u90e8\u4f4e\u8ff4\u97f3\u5ea6\u8b8a\u5316\u3001\u7d30\u91dd\u7a7f\u523a\u7d30\u80de\u5b78\u6aa2\u67e5\u986f\u793a\u6709\u591a\u6838\u6027\u5de8\u7d30\u80de (multinucleated giant cell)\uff0c\u8acb\u554f\u61c9\u8a72\u7d66\u4e88\u4e0b\u5217\u54ea\u4e9b\u8655\u7f6e?\nA. \u7d66\u4e88\u6297\u751f\u7d20\u6cbb\u7642\nB. \u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u6cbb\u7642\nC. \u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642\nD. \u61c9\u8a72\u7acb\u5373\u5b89\u6392\u98df\u9053\u651d\u5f71 (esophagogram)\nE. \u61c9\u8a72\u7acb\u5373\u5b89\u6392\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(C)", "106-10.\n\u4e00\u4f4d43\u6b72\u7537\u6027\u75c5\u4eba\u88ab\u8a3a\u65b7\u6709\u7532\u72c0\u817a\u4e73\u7a81\u764c(thyroid papillary cancer)\uff0c\u5176\u816b\u7624\u67092.5\u516c\u5206\uff0c\u5df2\u7d93\u6709\u5c40\u90e8\u8edf\u7d44\u7e54\u4fb5\u72af\u53ca\u9838\u90e8\u6dcb\u5df4\u817a\u8f49\u79fb\u4f46\u7121\u9060\u7aef\u8f49\u79fb\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba?\nA. \u6b64\u75c5\u4eba\u7684\u764c\u75c7\u5206\u671f\u5c6c\u65bc\u7b2c\u4e09\u671f\nB. \u6b64\u75c5\u4eba\u7684\u4e94\u5e74\u5b58\u6d3b\u7387\u5927\u7d04\u70ba70%\nC. \u624b\u8853\u5f8c\u61c9\u8a72\u7d66\u4e882-5 mCi\u7684\u653e\u5c04\u6027\u7898\u505a\u6383\u63cf\uff0c\u78ba\u5b9a\u662f\u5426\u6709\u9060\u7aef\u8f49\u79fb\u5f8c\u518d\u8003\u616e\u662f\u5426\u9700\u8981\u7d66\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642\nD. \u7d93\u904e\u624b\u8853\u53ca\u5fc5\u8981\u7684\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5f8c\uff0c\u61c9\u8a72\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u88dc\u5145\uff0c\u4ee5\u7dad\u6301\u75c5\u4eba\u7684\u7532\u72c0\u817a\u529f\u80fd\u65bc\u6b63\u5e38\u7bc4\u570d\uff0c\u5176TSH\u61c9\u8a72\u8d8a\u4f4e\u8d8a\u597d\nE. \u75c5\u4eba\u63a5\u53d7\u6cbb\u7642\u5291\u91cf\u7684\u653e\u5c04\u6027\u7898\u5f8c\u4e4b\u6383\u63cf\u6c92\u6709\u770b\u5230\u6709\u651d\u53d6\u653e\u5c04\u6027\u7898\u7684\u75c5\u7076\uff0c\u5176thyroglobulin \u70ba 20 ng/mL\uff0c\u6b64\u75c5\u4eba\u53ef\u4ee5\u78ba\u5b9a\u6c92\u6709\u7532\u72c0\u817a\u764c\u518d\u767c\n": "(D)", "106-1.\n\u9673\u5973\u58eb\uff0c56\u6b72\uff0c160\u516c\u5206\uff0c80\u516c\u65a4\uff0c\u8fd1\u5e74\u4f86\u5e38\u767c\u751f\u98e2\u9913\u611f\uff0c\u4f46\u662f\u5403\u6771\u897f\u5373\u53ef\u6539\u5584\u98e2\u9913\u4e4b\u4e0d\u9069\u3002\u5169\u5e74\u5167\u9ad4\u91cd\u589e\u52a015\u516c\u65a4\u3002\u6700\u8fd1\u4e09\u6b21\u56e0\u7121\u610f\u8b58\u660f\u5012\uff0c\u88ab\u9001\u5230\u6025\u8a3a\u5c31\u91ab\uff0c\u5728\u8f38\u6ce850%\u8461\u8404\u7cd6\u6db2\u5f8c\u5373\u7526\u9192\u3002\u672c\u6b21\u70ba\u7b2c\u4e09\u6b21\u5230\u6025\u8a3a\uff0c\u6025\u8a3a\u8840\u7cd6\u7d00\u9304\u70ba32 mg/dL\uff0c\u8840\u58d3\u70ba116/68 mmHg\uff0c\u8108\u640f\u70ba66 bpm\uff0c\u56e0\u6b64\u5efa\u8b70\u6536\u6cbb\u4f4f\u9662\u3002\u5728\u672a\u6ce8\u5c04\u8f38\u6db2\u4e4b\u4e0b\uff0c\u7a7a\u81798\u5c0f\u6642\u4e4b\u6e05\u6668\u7a7a\u8179\u8840\u7cd6\u70ba88 mg/dL\uff0cInsulin \u70ba10.6 \u03bcIU/mL (reference range, <28.8 \u03bcIU/mL)\uff0cC-peptide\u70ba 3.6  ng/mL (reference range, 0.34-4.25 mIU/mL)\u3002\u6e05\u66688\u9ede\u4e4bACTH 55.8 pg/mL (reference range, 6.0-76.0 pg/mL)\uff0cCortisol 25.6\r\u03bcg/dL (reference range, 5-25 \u03bcg/dL)\uff0cIGF-1 \u70ba 198 ng/mL (reference range, 81-225 ng/mL)\uff0cTSH \u70ba 4.8 mIU/mL (reference range, 0.34-4.25 mIU/mL)\u3002\u76ee\u524d\u61c9\u5148\u9032\u884c\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5?\nA. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (OGTT)\nB. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (MRI)\nC. 24\u5c0f\u6642\u9023\u7e8c\u5fc3\u96fb\u5716\u6aa2\u67e5\nD. 72\u5c0f\u6642\u4e4b Prolonged fasting test\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(D)", "106-2.\nBiguanides \u985e\u7684\u85e5\u7269\uff0cMetformin\u662f\u76ee\u524d\u570b\u969b\u4e0a\u5927\u591a\u6578\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u4e4b\u9996\u9078\u85e5\u7269\u5efa\u8b70\u3002\u4ee5\u4e0b\u6709\u95dcMetformin\u4e4b\u6558\u8ff0\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u4e73\u9178\u4e2d\u6bd2\u662f\u7f55\u898b\u7684Metformin\u85e5\u7269\u526f\u4f5c\u7528\uff0c\u4f46\u662f\u6b7b\u4ea1\u7387\u53ef\u905450%\nB. Metformin\u4e5f\u53ef\u80fd\u9020\u6210\u7dad\u4ed6\u547dB12 (Vitamin B12)\u4e4bmalabsorption\nC. Metfmornin\u4e4b\u4f7f\u7528\u53ef\u4ee5\u5ef6\u7de9\u7cd6\u5c3f\u75c5\u4e4b\u767c\u75c5\u75c5\u7a0b\nD. \u814e\u529f\u80fd\u4e0d\u4f73\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u5373\u4f7feGFR\u5c0f\u65bc30 ml/min/1.73\u33a1\uff0c\u4f7f\u7528Metformin\u4ecd\u7136\u662f\u5b89\u5168\u7684\nE. \u7cd6\u5c3f\u75c5\u4e4b\u5b55\u5a66\u61f7\u5b55\u6642\uff0cMetformin\u662f\u5b89\u5168\u7684\u7cd6\u5c3f\u75c5\u7528\u85e5\u9078\u64c7\u4e4b\u4e00\n": "(D)", "106-3.\n\u7cd6\u5c3f\u75c5\u65b0\u578b\u7528\u85e5\u4e2d\uff0cSGLT-2\u6291\u5236\u5291 (Sodium-glucose Co-transporter 2 inhibitor)\uff0c\u6700\u8fd1\u5169\u5e74\u5ee3\u6cdb\u4f7f\u7528\u7684\u65bc\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u3002\u4e0b\u5217\u6709\u95dcSGLT-2\u6291\u5236\u5291\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. \u6b64\u985e\u85e5\u7269\u4e0d\u6703\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc\nB. SGLT-2\u6291\u5236\u5291\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u4e3b\u8981\u662f\u6291\u5236\u5c3f\u7cd6\u4e4b\u518d\u5438\u6536\uff0c\u8b93\u8461\u8404\u7cd6\u5927\u91cf\u7684\u5f9e\u5c3f\u4e2d\u6392\u51fa\nC. \u814e\u529f\u80fdeGFR<45 ml/min/1.73\u33a1\u4ee5\u4e0b\u6642\uff0c\u4e0d\u61c9\u4f7f\u7528\u6b64\u985e\u85e5\u7269\nD. \u6b64\u985e\u85e5\u7269\u589e\u52a0\u5c3f\u7cd6\u6392\u51fa\uff0c\u56e0\u6b64\u5973\u6027\u5bb9\u6613\u6709\u6ccc\u5c3f\u9053\u611f\u67d3\u4e4b\u53ef\u80fd\u6027\uff0c\u4f46\u662f\u7537\u6027\u5247\u7121\u6b64\u56f0\u64fe\nE. \u6b64\u985e\u85e5\u7269\u5728\u964d\u8840\u7cd6\u7684\u904e\u7a0b\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad4\u91cd\u4e5f\u6703\u96a8\u4e4b\u6e1b\u8f15\n": "(D)", "106-4.\n\u9673\u5148\u751f\uff0c82\u6b72\uff0c\u8eab\u9ad8168\u516c\u5206\uff0c\u9ad4\u91cd58\u516c\u65a4\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f220\u5e74\uff0c\u76ee\u524d\u63a5\u53d7 \u4e09\u9910\u524d\u901f\u6548\u53ca\u7761\u524d\u57fa\u790e\u80f0\u5cf6\u7d20\u6cbb\u7642\u3002\u4f46\u7d93\u5e38\u6703\u6f0f\u6253\u9910\u524d\u80f0\u5cf6\u7d20\uff0c\u4e00\u500b\u6708\u524d\u4e4bHbA1c\u70ba8.8 %\uff0c\u8fd1\u4e00\u5468\u51fa\u73fe\u611f\u5192\u4e4b\u75c7\u72c0\uff0c\u6c92\u6709\u767c\u71d2\u4e4b\u7d00\u9304\uff0c\u4f46\u662f\u80c3\u53e3\u4e0d\u4f73\u3002\u6b64\u6b21\u56e0\u610f\u8b58\u72c0\u6cc1\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u70ba525 mg/dL\uff0c\u9209\u96e2\u5b50\u70ba151 mEq/L\uff0c'\u9240\u96e2\u5b50\u70ba3.5 mEq/L\uff0c\u5c3f\u7d20\u6c2eBUN\u70ba62 mg/dL\uff0c\u808c\u9178\u9150Cr\u70ba 2.6 mg/dL\u3002\u5230\u6025\u8a3a\u5f8c\u4e4b\u8840\u58d3\u70ba98/60 mmHg\uff0c\u8108\u640f\u70ba96 bpm\u3002\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u6700\u9069\u65bc\u6b64\u75c5\u60a3\u8f38\u6ce8\u53ca\u76e3\u6e2c\u5176\u5c3f\u6db2\u6392\u51fa\u91cf (Urine output)?\nA. 0.45% Half saline solution\nB. Lactate Ringer solution\nC. 0.9 % Normal Saline solution\nD. 5% Glucose solution with regular insulin intravenous infusion\nE. 0.45% Half saline solution with regular insulin intravenous infusion\n": "(C)", "106-5.\n\u5f35\u5148\u751f\uff0c50\u6b72\uff0c\u96fb\u8166\u516c\u53f8\u526f\u7e3d\u7d93\u7406\uff0c\u7cd6\u5c3f\u75c5\u53f25\u5e74\uff0c\u53bb\u5e74\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u4f4f\u9662\uff0c\u5fc3\u5c0e\u7ba1\u6aa2\u67e5\u5f8c\uff0c\u7f6e\u653e\u652f\u67b6\u3002\u76ee\u524d\u5df2\u9810\u6df7\u578b\u80f0\u5cf6\u7d20(Premix insulin) \u63a7\u5236\u8840\u7cd6\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\u65e5Valsartan 160 mg\u53caAmlodipine 5 mg\uff0c\u964d\u8840\u8102\u85e5\u7269\u70ba\u6bcf\u65e5Atorvastatin 20 mg\u3002\u6700\u8fd1HbA1c \u70ba6.5 %\uff0cLDL cholesterol\u70ba 55 mg/dL\uff0cHDL cholesterol\u70ba 35 mg/dL\uff0ctriglyceride \u70ba 756 mg/dL\uff0c\u6c92\u6709\u5fae\u91cf\u767d\u86cb\u767d\u5c3f\uff0c\u4f46\u662f\u5df2\u7d93\u51fa\u73fe\u80cc\u666f\u578b\u8996\u7db2\u819c\u75c5\u8b8a\u3002\u4e0b\u5217\u4e4b\u85e5\u7269\uff0c\u61c9\u6709\u4f7f\u7528\u4e4b\u5fc5\u8981?\nA. Sitagliptin\nB. Pioglitazone\nC. Nicotic acid\nD. Fenofibrate\nE. Acarbose\n": "(D)", "106-6.\nThiazolidinedione (TZD) \u985e\u7684\u85e5\u7269\uff0c\u5c6c\u65bc\u80f0\u5cf6\u7d20\u589e\u654f\u5291 (Insulin sensitizer)\uff0c\u7814\u7a76\u986f\u793a\u5c0d\u65bc\u5fc3\u81df\u8840\u7ba1\u53ca\u8166\u4e2d\u98a8\uff0c\u53ef\u80fd\u6709\u76f8\u7576\u9810\u9632\u6027\u7684\u610f\u7fa9\u3002\u4ee5Pioglitazone\u800c\u8a00\uff0c\u4e0b\u5217\u4f55\u8005\u70ba\u4f7f\u7528\u6b64\u85e5\u6642\uff0c\u5fc5\u9808\u7559\u610f\u7684\u526f\u4f5c\u7528?(1) \u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0\uff1b(2)\u60c5\u7dd2\u6cae\u55aa\uff1b(3)\u6c34\u816b\uff1b(4)\u9aa8\u8cea\u758f\u9b06\uff1b(5) \u5931\u7720\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (2)+(3)+(4)\nD. (1)+(3)+(4)\nE. (3)+(4)+(5)\n": "(D)", "106-7.\n\u4f4e\u8840\u7cd6\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u904e\u7a0b\u4e2d\u3001\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005\u76f8\u95dc\u75be\u75c5\u6216\u4f7f\u7528\u7279\u5b9a\u85e5\u7269\u6cbb\u7642\u6642\u5e38\u898b\u7684\u4f75\u767c\u75c7\uff0c\u4e0b\u5217\u4f55\u8005\u662f\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u539f\u56e0?(1) \u4e0d\u7576\u4f7f\u7528\u80f0\u5cf6\u7d20\u6216\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff1b(2)\u80a2\u7aef\u80a5\u5927\u75c7\uff1b(3)\u80c3\u5207\u9664\u624b\u8853\u5f8c (Post-gastric bypass surgery)\uff1b(4)\u814e\u4e0a\u817a\u6a5f\u80fd\u4e0d\u8db3 (Adrenal insufficiency)\uff1b(5)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's syndrome)\nA. (1)+(2)+(4)\nB. (2)+(3)+(4)\nC. (1)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(C)", "106-8.\n\u7cd6\u5c3f\u75c5\u60a3\u8005\u6cbb\u7642\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u975e\u5e38\u9700\u8981\u6ce8\u610f\u7684\u8b8a\u5316\u3002\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u4f4e\u8840\u7cd6\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4ee5\u80f0\u5cf6\u7d20\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\uff0c\u53ef\u4ee5\u6709\u6548\u5730\u964d\u4f4e\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u814e\u75c5\u8b8a\uff0c\u4f46\u662f\u4f4e\u8840\u7cd6\u56e0\u80f0\u5cf6\u7d20\u4e4b\u7a4d\u6975\u4f7f\u7528\uff0c\u767c\u751f\u7387\u4e5f\u8f03\u9ad8\nB. \u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u6700\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u4e4b\u53e3\u670d\u85e5\u7269\u70ba\u786b\u80fa\u985e (Sulfonylurea)\u85e5\u7269\nC. \u65b0\u578b\u7684\u7cd6\u5c3f\u75c5\u85e5\u7269\u5982DPP-4 inhibitor \u53ca SGLT-2 inhibitor\uff0c\u56e0\u5176\u85e5\u7269\u6a5f\u8f49\u7279\u6b8a\uff0c\u56e0\u6b64\u4e0d\u6703\u767c\u751f\u4f4e\u8840\u7cd6\nD. \u4f7f\u7528\u591a\u6b21\u9910\u524d\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\uff0c\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u6a5f\u7387\uff0c\u8f03\u57fa\u790e\u80f0\u5cf6\u7d20\u70ba\u9ad8\nE. \u7cd6\u5c3f\u75c5\u60a3\u7684\u7cd6\u5c3f\u75c5\u53f2\u6108\u4e45\uff0c\u53ef\u80fd\u56e0\u81ea\u4e3b\u795e\u7d93\u75c5\u8b8a\uff0c\u7522\u751f Hypoglycemia unawareness\uff0c\u800c\u7121\u660e\u986f\u81ea\u89ba\u6027\u7684\u75c7\u72c0\n": "(C)", "106-9.\n\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\u4e2d\uff0c\u751f\u6d3b\u578b\u614b\u63a7\u5236\u662f\u5fc5\u8981\u7684\u3002\u4f46\u662f\u85e5\u7269\u6cbb\u7642\u4e5f\u4e0d\u53ef\u6216\u7f3a\u3002\u4e0b\u5217\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?(1)Metformin\u70ba\u7cd6\u5c3f\u75c5\u7b2c\u4e00\u7dda\u7528\u85e5\uff0ceGFR < 30 ml/min/1.73\u33a1\u6642\uff0c\u4ecd\u53ef\u5b89\u5168\u4f7f\u7528\uff1b(2)\u53f0\u7063\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u5efa\u8b70HbA1c\u7cd6\u5316\u8840\u8272\u7d20\u7684\u63a7\u5236\u76ee\u6a19\u70ba 7.0 %\u4ee5\u4e0b\uff1b(3)\u5bb9\u6613\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u60a3\u8005\uff0c\u61c9\u8003\u616e\u907f\u514d\u4f7f\u7528\u80f0\u5cf6\u7d20\uff1b(4)Glucagon-like peptide-1 (GLP-1)\u985e\u7684\u91dd\u5291\u7cd6\u5c3f\u75c5\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u6bd4\u80f0\u5cf6\u7d20\u91dd\u5291\u70ba\u4f4e\uff1b(5)SGLT-2\u6291\u5236\u5291\u9020\u6210\u6ccc\u5c3f\u9053\u611f\u67d3\u7684\u6a5f\u6703\u8f03\u9ad8\nA. (1)+(4)\nB. (3)+(5)\nC. (2)+(5)\nD. (1)+(3)\nE. (3)+(4)\n": "(D)", "106-10.\n\u7cd6\u5c3f\u75c5\u6cbb\u7642\u85e5\u7269\u4e2d\uff0cGlucagon-like peptide-1\u91dd\u5291\u85e5\u7269\u53caDPP-4 inhibitor\u5747\u5c6c\u65bc\u8178\u6ccc\u7d20 (Incretin)\u985e\u85e5\u7269\uff0c\u4e0b\u5217\u6709\u95dc\u8178\u6ccc\u7d20\u53ca\u76f8\u95dc\u85e5\u7269\u7684\u6558\u8ff0\uff0c\u54ea\u4e00\u500b\u662f\u932f\u8aa4\u7684?\nA. \u4eba\u9ad4\u751f\u7406\u5b78\u4e0a\u5206\u6ccc\u7684GLP-1\u4f86\u81ea\u8178\u9053\u7684L-\u7d30\u80de\nB. DPP-4 inhibitor \u7684\u7814\u7a76\u4e2d\u767c\u73fe\uff0cDPP-4 ihbibitor \u53ef\u80fd\u6709\u9020\u6210\u75c5\u60a3\u5fc3\u81df\u8870\u7aed\u7684\u98a8\u96aa\nC. \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u4e5f\u9069\u5408\u4f7f\u7528GLP-1\u985e\u7684\u91dd\u5291\u85e5\u7269\nD. \u8178\u6ccc\u7d20\u985e\u7684\u85e5\u7269\u767c\u751f\u4f4e\u8840\u7cd6\u7684\u6a5f\u6703\u6bd4\u786b\u80fa\u985e (Sulfonylurea)\u985e\u85e5\u7269\u70ba\u4f4e\nE. \u7814\u7a76\u986f\u793a\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4f7f\u7528GLP-1\u985e\u85e5\u7269\u6642\uff0c\u53ef\u4ee5\u6e1b\u8f15\u75c5\u60a3\u9ad4\u91cd\n": "(C)", "107-1.\n\u4e00\u4f4d56\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a\u3002\u4ed6\u6709\u591a\u5e74\u9ad8\u8840\u58d3\u3001\u7cd6\u5c3f\u75c5\u53f2\uff0c\u4f7f\u7528\u85e5\u7269\u63a7\u5236\u4e2d\u3002\u5bb6\u5c6c\u63d0\u53ca\u75c5\u4eba\u4f5c\u606f\u53ca\u98f2\u98df\u6b63\u5e38\uff0c\u5728\u610f\u8b58\u6539\u8b8a\u524d\uff0c\u75c5\u4eba\u8868\u793a\u6709\u6025\u6027\u5287\u70c8\u982d\u75db\u53ca\u8996\u91ce\u6a21\u7cca\uff0c\u5176\u4ed6\u4e26\u7121\u7570\u72c0\u3002\u75c5\u4eba\u5916\u89c0\u6709\u80a2\u7aef\u80a5\u5927\u75c7\u7279\u5fb5\uff0c\u5176\u8840\u58d3\u70ba90/60 mmHg\u3001\u8840\u7cd6\u503c\u70ba65 mg/dL\u3001\u8840\u9209\u70ba125 mmol/L\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba\uff1f (1). \u75c5\u4eba\u7684\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u53ef\u80fd\u767c\u73fe\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u5167\u51fa\u8840 (2).\t\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u7532\u72c0\u817a\u7d20\u6cbb\u7642 (3).\t\u61c9\u7acb\u5373\u4f7f\u7528\u9ad8\u5291\u91cf\u985e\u56fa\u9187\u6cbb\u7642 (4).\t\u61c9\u5118\u901f\u5b89\u6392\u624b\u8853\u6e1b\u58d3 (5). \u75c5\u4eba\u672a\u4f86\u53ef\u80fd\u7522\u751f\u7a7a\u8776\u978d\u75c7 (empty sella)\nA. (1)+(3)+(4)\nB. (2)+(3)+(5)\nC. (2)+(4)+(5)\nD. (1)+(3)+(4)+(5)\nE. (1)+(2)+(3)+(4)+(5)\n": "(D)", "107-2.\n\u7121\u75c7\u72c0\u7684\u539f\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u75c7(asymptomatic primary hyperparathyroidism)\u6709\u4e0b\u5217\u54ea\u4e9b\u73fe\u8c61\u61c9\u8a72\u5efa\u8b70\u958b\u5200?\u8acb\u9078\u64c7\u6700\u9069\u7576\u7684\u7b54\u6848\u3002(1). \u8840\u6e05\u4e2d\u9223\u6fc3\u5ea6\u9ad8\u65bc\u6b63\u5e38\u503c 1.2 mg/dL (2). 24\u5c0f\u6642\u5c3f\u9223\u70ba 200 mg (3). \u808c\u9150\u6e05\u9664\u7387 (creatinine clearance) \u70ba 50 mL/min (4). \u810a\u690e (spine)\u4e4b\u9aa8\u5bc6\u5ea6\u6aa2\u67e5 T score < - 2.5 (5). \u75c5\u4eba\u5e74\u7d00 \u70ba55 \u6b72\nA. (1)+(2)+(3)+(4)\nB. (1)+(2)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "107-3.\n\u6709\u95dc\u7532\u72c0\u817a\u75be\u75c5\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba\uff1f(1). \u4f7f\u7528 Amiodarone \u6cbb\u7642\u5fc3\u5f8b\u4e0d\u6574\u53ef\u80fd\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6216\u4f4e\u4e0b (2).\t34\u6b72\u7537\u6027\u75c5\u4eba\u5ffd\u7136\u6709\u7532\u72c0\u817a\u816b\u5927\uff0c\u61c9\u8a72\u7acb\u5373\u4f7f\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269\u6cbb\u7642 (3).\t\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6642\u7d55\u5c0d\u7981\u6b62\u4f7f\u7528\u542b\u7898\u85e5\u7269 (4).\t\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u4e4b\u5973\u6027\u75c5\u4eba\u82e5\u61f7\u5b55\u6642\u61c9\u8a72\u7acb\u5373\u505c\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 (5).\t\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\u4e4b\u5973\u6027\u75c5\u4eba\u5982\u679c\u61f7\u5b55\u53ef\u80fd\u9700\u8981\u589e\u52a0\u7532\u72c0\u817a\u7d20\u5291\u91cf\nA. (1)+(3)\nB. (2)+(4)\nC. (1)+(5)\nD. (1)+(4)\nE. (1)+(3)+(5)\n": "(C)", "107-4.\n\u4e0b\u5217\u6709\u95dc\u8178\u80c3\u9053\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624(gastrointestinal neuroendocrine tumor, GI-NETs)\u53ca\u80f0\u81df\u795e\u7d93\u5167\u5206\u6ccc\u816b\u7624 (pancreatic neuroendocrine tumor, pNETs)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. GI-NETs\u5c6c\u65bcAPUDomas (amine precursor uptake and decarboxylation tumor)\uff0c\u4f46 pNETs\u4e0d\u5c6c\u65bcAPUDomas\nB. \u8840\u6e05\u4e2d chromogranin A \u6fc3\u5ea6\u53ef\u4ee5\u505a\u70baGI-NETs\u53ca pNETs\u4e4b\u816b\u7624\u6a19\u8a8c (tumor marker)\nC. GI-NETs \u5c11\u6709\u9ad4\u6291\u7d20\u63a5\u53d7\u9ad4(somatostatin receptor)\uff0c\u800cpNETs\u5247\u5e38\u898b\u6709\u9ad4\u6291\u7d20\u63a5\u53d7\u9ad4\nD. \u514d\u75ab\u7d30\u80de\u5316\u5b78\u6aa2\u67e5(immunocytochemical studies) \u53ef\u4ee5\u9810\u6e2cGI-NETs\u53ca pNETs\u4e4b\u81e8\u5e8a\u8868\u5fb5\nE. GI-NETs\u5927\u591a\u6578\u9032\u5c55\u7de9\u6162\uff0cpNETs\u7d55\u5927\u591a\u6578\u9032\u5c55\u6975\u70ba\u5feb\u901f\n": "(B)", "107-5.\n\u4e0b\u5217\u6709\u95dc\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u55dc\u927b\u7d30\u80de\u7624\u7684\u75c5\u4eba\u5e38\u4ee5\u5fc3\u60b8\u3001\u982d\u75db\u3001\u5192\u6c57\u7b49\u75c7\u72c0\u8868\u73fe\uff0c\u4f46\u4e5f\u6709\u75c5\u4eba\u53ef\u80fd\u591a\u5e74\u6beb\u7121\u75c7\u72c0\nB. \u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c5\u4eba\uff0c\u70ba\u907f\u514d\u8a98\u767c\u9ad8\u8840\u58d3\uff0c\u4ee5\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u505a\u5f71\u50cf\u6aa2\u67e5\u6642\u61c9\u8a72\u7981\u7528\u986f\u5f71\u5291\nC. \u4e00\u4f4d28\u6b72\u5973\u6027\u75c5\u4eba\u5728\u61f7\u5b55\u521d\u671f\u88ab\u8a3a\u65b7\u6709\u55dc\u927b\u7d30\u80de\u7624\uff0c\u70ba\u5b55\u5a66\u53ca\u53ca\u80ce\u5152\u5b89\u5168\u8003\u91cf\uff0c\u6700\u597d\u5728\u751f\u7522\u5f8c\u624d\u5b89\u6392\u986f\u5fae\u624b\u8853\u5207\u9664\nD. \u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624\u7b2c\u4e8c\u578b(multiple endocrine neoplasia type 2, MEN 2)\u7684\u75c5\u4eba\uff0c\u5176\u55dc\u927b\u7d30\u80de\u7624\u901a\u5e38\u70ba\u5169\u5074\u814e\u4e0a\u817a\u7684\u60e1\u6027\u816b\u7624\nE. \u55dc\u927b\u7d30\u80de\u7624\u75c5\u4eba\u5982\u679c\u6709\u8ddf\u907a\u50b3\u6709\u95dc\u7684\u57fa\u56e0\u7a81\u8b8a\uff0c\u5176\u767c\u75c5\u5e74\u9f61\u5e73\u5747\u8f03\u5076\u767c\u578b(sporadic type)\u75c5\u4eba\u665a10\u6b72\n": "(A)", "107-6.\n\u4e0b\u5217\u6709\u95dc\u65bc\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7(primary aldosteronism)\u7684\u63cf\u8ff0\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u70ba\u589e\u52a0\u6aa2\u67e5\u4e4b\u6b63\u78ba\u6027\uff0c\u5df2\u4f7f\u7528spironolactine\u6cbb\u7642\u7684\u75c5\u4eba\uff0c\u61c9\u8a72\u5148\u505c\u85e5\u4e00\u9031\u624d\u6aa2\u67e5\u8840\u6e05\u919b\u56fa\u916e\u6fc3\u5ea6\u8207\u814e\u7d20\u6d3b\u6027\u4e4b\u6bd4\u503c(aldosterone-renin ratio, ARR)\nB. \u4e59\u578b\u4ea4\u611f\u795e\u7d93\u7d20\u963b\u65b7\u5291(\u03b2-blockers)\u6703\u4f7fARR\u4e0a\u5347\nC. \u57284\u5c0f\u6642\u5167\u704c\u6ce8\u751f\u7406\u98df\u9e7d\u6c342\u516c\u5347 (saline infusion test)\u5f8c\uff0c\u8840\u6e05\u919b\u56fa\u916e (aldosterone)\u6fc3\u5ea6\u70ba10 ng/dL \u53ef\u4ee5\u6392\u9664\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7\nD. \u70ba\u78ba\u4fdd\u8a3a\u65b7\u53ca\u6cbb\u7642\u6b63\u78ba\uff0c\u6240\u6709\u61f7\u7591\u70ba\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7\u7684\u75c5\u4eba\u90fd\u61c9\u8a72\u63a5\u53d7\u5169\u5074\u814e\u4e0a\u975c\u8108\u53d6\u6a23\u6aa2\u67e5(selective adrenal vein sampling, AVS)\nE. \u505aAVS\u6aa2\u67e5\u6642\uff0c\u55ae\u5074\u814e\u4e0a\u817a\u975c\u8108\u7684aldosterone/cortisol\u6bd4\u503c\u81f3\u5c11\u9700\u70ba\u5c0d\u5074\u76844\u500d\u4ee5\u4e0a\u624d\u80fd\u505a\u70ba\u8a3a\u65b7\u8a72\u5074\u816b\u7624\u7684\u4f9d\u64da\n": "(B)", "107-7.\n\u4e00\u4f4d32\u6b72\u672a\u5a5a\u5973\u6027\u4e3b\u8a34\u6700\u8fd14\u500b\u6708\u6c92\u6709\u6708\u7d93\uff0c\u5979\u6c92\u6709\u6027\u884c\u70ba\u4e5f\u6c92\u6709\u670d\u7528\u4efb\u4f55\u85e5\u7269\u3002\u8eab\u9ad4\u8a3a\u5bdf\u9664\u4e86\u6709\u4e73\u6c41\u5206\u6ccc\u53ca\u7532\u72c0\u817a\u7565\u70ba\u816b\u5927\u5916\uff0c\u5176\u9918\u7686\u6b63\u5e38\u3002\u8377\u723e\u8499\u6aa2\u67e5\u986f\u793a\u6ccc\u4e73\u6fc0\u7d20(prolactin\uff0960 ng/mL; \u751f\u9577\u6fc0\u7d20\uff08growth hormone, GH\uff096 ng/mL; \u76ae\u8cea\u9187(cortisol) 8 am \u70ba16 \u03bcg/dL\u3001 4 pm\u70ba9 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20\uff08ACTH\uff0946 pg/mL\uff1b\u6e38\u96e2\u578b\u7532\u72c0\u817a\u7d20 (fT4) 0.9 ng/dL\uff1b\u7532\u72c0\u817a\u523a\u6fc0\u7d20 (TSH) 0.6 \u03bcIU/mL\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u6aa2\u67e5\u5c0d\u65bc\u8a3a\u65b7\u6216\u6cbb\u7642\u6700\u53ef\u80fd\u6709\u5e6b\u52a9?\r (\u53c3\u8003\u503c: Prolactin 1.9~25 ng/m\uff2c\uff1bGH < 8 ng/mL\uff1bcortisol 8 am 5~25 \u03bcg/dL\u30014 pm 2.5~12.5 \u03bcg/dL\uff1bACTH 7.4~57.3 pg/mL; fT4 0.89~1.76 ng/dL\uff1bTSH 0.4~4 \u03bcIU/mL)\nA. Insulin hypoglycemia test\nB. Oral glucose tolerance test\nC. TRH stimulation test\nD. Bromocriptine test\nE. ACTH stimulation test\n": "(D)", "107-8.\n\u4e00\u4f4d50\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u4f11\u514b\u88ab\u9001\u81f3\u6025\u8a3a\uff0c\u5979\u7684\u610f\u8b58\u4e0d\u6e05\uff0c\u8840\u58d3\u3001\u8840\u9209\u3001\u8840\u7cd6\u7686\u504f\u4f4e\u3002\u8377\u723e\u8499\u6aa2\u67e5\u5df2\u62bd\u8840\u9001\u6aa2\uff0c\u4f46\u5c1a\u7121\u5831\u544a\u3002\u6709\u95dc\u9451\u5225\u8a3a\u65b7\u4ee5\u53ca\u8655\u7f6e\u7684\u63cf\u8ff0\u54ea\u4e00\u9805\u6700\u6b63\u78ba?\nA. \u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u6c34\u725b\u80a9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\uff0c\u5979\u6700\u53ef\u80fd\u7684\u6aa2\u67e5\u7d50\u679c\u70ba ACTH\u9ad8\u3001cortisol\u9ad8\nB. \u5148\u4ee55% G/W\u5efa\u7acb\u975c\u8108\u8f38\u6db2\uff0c\u7b49\u5019\u8377\u723e\u8499\u6aa2\u67e5\u5831\u544a\u5f8c\u518d\u9032\u4e00\u6b65\u6cbb\u7642\nC. \u4ee53% Nacl \u6821\u6b63\u5176\u4f4e\u8840\u9209\nD. \u75c5\u4eba\u5916\u8868\u70ba\u9ed1\u4e7e\u7626\uff0c\u61c9\u8a72\u5b89\u6392\u8166\u4e0b\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\nE. \u75c5\u4eba\u4e73\u6688\u984f\u8272\u6de1\u3001\u7121\u814b\u6bdb\uff0c\u5979\u6700\u53ef\u80fd\u7684\u6aa2\u67e5\u7d50\u679c\u70ba ACTH\u4f4e\u3001cortisol\u4f4e\n": "(E)", "107-9.\n\u4e0b\u5217\u6709\u95dc\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba?\nA. \u7f79\u60a3\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\u7684\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba1:1; \u800c\u7f79\u60a3\u7570\u4f4d\u6027\u4fc3\u814e\u4e0a\u817a\u76ae\u8cea\u7d20\u75c7\u4faf\u7fa4(ectopic ACTH syndrome)\u7684\u7537\u5973\u6bd4\u7d04\u70ba4:1\nB. \u5c0d\u65bc\u5916\u8868\u6709\u6708\u4eae\u81c9\u3001\u6c34\u725b\u80a9\u3001\u7d2b\u8272\u82b1\u7d0b\u7b49\u7279\u5fb5\u7684\u75c5\u4eba\uff0c\u5982\u679c\u517624\u5c0f\u6642\u5c3f\u6db2\u4e2d\u7684free cortisol \u70ba\u53c3\u8003\u503c\u76841.5\u500d\uff0c\u5c31\u53ef\u4ee5\u78ba\u8a8d\u6b64\u75c5\u4eba\u6709\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\nC. \u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c5\u56e0\u7684\u9451\u5225\u8a3a\u65b7\u6d41\u7a0b\u4e2d\uff0c\u5982\u679c\u8840\u6e05\u4e2d\u7684ACTH\u6fc3\u5ea6<5 pg/mL\u5247\u61c9\u8a72\u9032\u4e00\u6b65\u5b89\u6392\u76ae\u8cea\u91cb\u7d20\u8a66\u9a57(corticotropin-releasing hormone (CRH) test)\nD. \u4e0b\u5ca9\u6a23\u7ac7\u63a1\u6a23(inferior petrosal sinus sampling)\u53ef\u4ee5\u5e6b\u52a9\u5206\u8fa8\u662f\u5426\u70ba\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\uff0c\u4f46\u5c0d\u65bc\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u7684\u5b9a\u4f4d(lateralization)\u5247\u4e0d\u4e00\u5b9a\u53ef\u9760\nE. \u6cbb\u7642\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u85e5\u7269\uff0cmetyrapone \u7684\u4f5c\u7528\u6a5f\u8f49\u70ba\u6291\u5236cortisol\u8207\u5176\u63a5\u53d7\u5668\u7684\u7d50\u5408\uff0c\u800cketoconazole \u5247\u6703\u6291\u5236cortisol \u7684\u5408\u6210\n": "(D)", "107-10.\n\u4e00\u4f4d54\u6b72\u7532\u72c0\u817a\u4e73\u7a81\u764c\u7537\u6027\u75c5\u4eba\uff0c\u7d93\u904e\u96d9\u8449\u5168\u7532\u72c0\u817a\u5207\u9664(bilateral total thyroidectomy)\u53ca\u591a\u6b21\u653e\u5c04\u6027\u7898 (I-131\uff0c\u7e3d\u91cf\u70ba 600 mCi)\u6cbb\u7642\uff0c\u6bcf\u65e5\u88dc\u5145100 \u03bcg levothyroxine sodium\uff0c\u5176\u7532\u72c0\u817a\u529f\u80fd\u70ba fT4 1.0 dL (\u53c3\u8003\u503c 0.89~1.76 ng/dL)\u3001 TSH 0.1 \u03bcIU/mL (\u53c3\u8003\u503c 0.4~4 \u03bcIU/mL)\uff0c\u8840\u6e05thyroglobulin 50 ng/mL (\u6b63\u5e38\u53c3\u8003\u503c < 55 ng/mL)\uff0canti-thyroglobulin antibody 156.7 IU/mL (\u53c3\u8003\u503c <14.4 IU/mL)\u3002\u75c5\u4eba\u6c92\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\uff0c\u4e5f\u6c92\u6709\u4efb\u4f55\u4e0d\u9069\uff0c\u75c5\u4eba\u6700\u8fd1\u4e00\u6b21\u4ee5 I-131 150 mCi\u6cbb\u7642\u5f8c\u7684\u6383\u63cf\u6c92\u6709\u986f\u793a\u6709\u4efb\u4f55uptake\u3002\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba?\nA. \u75c5\u4eba\u6709\u81e8\u5e8a\u524d\u671f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032(subclinical hyperthyroidism)\uff0c\u61c9\u8a72\u7acb\u5373\u505c\u7528\u7532\u72c0\u817a\u7d20\u3002\nB. \u75c5\u4eba\u7684anti-thyroglobulin antibody \u8f03\u53c3\u8003\u503c\u9ad8\uff0c\u53ef\u4ee5\u589e\u52a0thyroglobulin \u7576\u4f5ctumor marker\u7684\u81e8\u5e8a\u6307\u6a19\u610f\u7fa9\nC. \u61c9\u8a72\u5b89\u6392\u6b63\u5b50\u6383\u63cf\u6aa2\u67e5 (positron emission tomography, PET)\nD. \u518d\u5b89\u6392\u4e00\u6b21\u9ad8\u5291\u91cf\u7684 I-131 \u6cbb\u7642\nE. \u7acb\u5373\u4f7f\u7528\u6a19\u9776\u6cbb\u7642\n": "(C)", "107-1.\n\u9673\u5c0f\u59d0\uff0c36\u6b72 \uff0c\u8eab\u9ad8160\u516c\u5206\uff0c\u9ad4\u91cd73\u516c\u65a4\uff0c\u6700\u8fd1\u5169\u5e74\uff0c\u9ad4\u91cd\u81ea58\u516c\u65a4\u589e\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd\u3002\u7121\u500b\u4eba\u6216\u5bb6\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2\u3002\u6700\u8fd1\u5169\u5e74\uff0c\u6578\u6b21\u5728\u5bb6\u4e2d\u6216\u5de5\u4f5c\u5834\u6240\uff0c\u56e0\u660f\u5012\u610f\u8b58\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u66fe\u65bc\u6025\u8a3a\u767c\u73fe\u8840\u7cd6\u503c\u70ba32mg/dL\uff0c\u5728\u6ce8\u5c0450%\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58\u3002\u4e4b\u5f8c\uff0c\u66fe\u65bc\u795e\u7d93\u5167\u79d1\u53ca\u5bb6\u5ead\u91ab\u5b78\u79d1\u5c31\u91ab\u8907\u67e5\uff0c\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5\u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab\uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba28 mg/dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58\uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\u7570\u5e38\u75c7\u72c0\uff0c\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0\u3002\u5728\u75c5\u623f\u4f4f\u9662\u6642\uff0c\u7a7a\u81798\u5c0f\u6642\uff0c\u4e26\u7121\u8f38\u6db2\u4e0b\uff0c\u7a7a\u8179\u8840\u7cd6\u70ba86mg/dL\uff0cACTH 36.5pg/mL,\rCortisol 16.8 ug/dL, Insulin 1.6 mIU/mL, C-peptide 2.2 ng/mL, TSH 1.62 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5?\nA. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\nB. Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\nC. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\nD. 72 \u5c0f\u6642\u4e4b Prolonged fasting test\nE. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\n": "(D)", "107-2.\n\u5728\u53f0\u7063\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u773e\u591a\uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b\u3001\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u9810\u9632\u4e4b\u5916\uff0c\u4e00\u65e6\u78ba\u8a3a\u70ba\u7cd6\u5c3f\u75c5\u4e4b\u5f8c\uff0c\u85e5\u7269\u6cbb\u7642\u4e5f\u662f\u975e\u5e38\u91cd\u8981\u7684\u4e00\u74b0\u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u6558\u8ff0\uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684\uff1f(1). Biguanide\u4e4bMetformin\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u539f\u5247\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\uff0c\u4f46\u662f\u82f1\u570b\u4e4b\u6cbb\u7642\u6307\u5f15\u5efa\u8b70\uff0c\u7576eGFR < 45 \u6642\uff0c\u5373\u4e0d\u61c9\u4f7f\u7528Metformin (2). \u76ee\u524d\u570b\u5167\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\uff0cHbA1c (\u7cd6\u5316\u8840\u7d05\u7d20)\u4e4b\u63a7\u5236\u76ee\u6a19\u70ba 7% \u4ee5\u4e0b (3). Sulphonylurea\u985e\u85e5\u7269\uff0c\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 (4). \u80f0\u5cf6\u7d20\u96d6\u7136\u53ef\u4ee5\u8fc5\u901f\u964d\u4f4e\u8840\u7cd6\uff0c\u4f46\u9577\u671f\u4f7f\u7528\u6642\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 (5). \u65b0\u578b\u4e4b\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269\uff0c\u5982DPP-4\rinhibitor\u53caSGLT-2 inhibitor\uff0c\u4e0d\u4f46\u53ef\u4ee5\u964d\u4f4e\u8840\u7cd6\uff0c\u4e5f\u90fd\u6709\u6e1b\u8f15\u7cd6\u5c3f\u75c5\u60a3\u9ad4\u91cd\u7684\u6548\u679c\nA. (1)+(3)\nB. (3)+(5)\nC. (2)+(5)\nD. (1)+(5)\nE. (3)+(4)\n": "(D)", "107-3.\n\u80f0\u5cf6\u7d20\u662f\u6cbb\u7642\u7cd6\u5c3f\u75c5\uff0c\u63a7\u5236\u8840\u7cd6\u7684\u91cd\u8981\u91dd\u5291\u85e5\u7269\uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u6cbb\u7642\u7684\u8aaa\u660e\u53ca\u5176\u751f\u7406\u6a5f\u8f49\uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684?\nA. \u8eab\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u76f4\u63a5\u5206\u6ccc\u9032\u5165\u9580\u975c\u8108\u7cfb\u7d71\uff0c\u4f46\u662f\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u5247\u5728\u6ce8\u5c04\u5f8c\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0\uff0c\u56e0\u6b64\u6ce8\u5c04\u4e4b\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u6642\uff0c\u8f03\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\u4f4e\uff0c\u5c6c\u65bcsubphysiologic insulin level\u3002\nB. \u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00\uff0c\u6bd4\u8f03\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u57fa\u790e\u80f0\u5cf6\u7d20(basal insulin)\nC. \u5982\u679c\u9700\u8981\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u591a\u6b21\u80f0\u5cf6\u7d20\u6ce8\u5c04\uff0c\u662f\u9054\u6210\u63a7\u5236\u6a19\u7684\u7684\u91cd\u8981\u65b9\u6cd5\uff0c\u4f46\u662f\u9700\u8981\u914d\u5408\u66f4\u983b\u7e41\u4e4b\u81ea\u6211\u8840\u7cd6\u76e3\u6e2c\nD. \u5c31\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u800c\u8a00\uff0c\u6bcf\u5929\u9700\u8981\u4e4b\u80f0\u5cf6\u7d20\u6ce8\u5c04\u7e3d\u91cf\u5927\u7d04\u5728 0.5-1 \u55ae\u4f4d/\u6bcf\u516c\u65a4/\u6bcf\u5929\nE. \u7576\u4e00\u5929\u5167\u9700\u591a\u6b21\u6ce8\u5c04\u80f0\u5cf6\u7d20\u6642\uff0c\u80f0\u5cf6\u7d20\u7e3d\u5291\u91cf\u768450%\uff0c\u61c9\u4ee5\u57fa\u790e\u80f0\u5cf6\u7d20(basal insulin) \u7684\u65b9\u5f0f\u7d66\u85e5\n": "(B)", "107-4.\n\u6839\u64da\u4e16\u754c\u885b\u751f\u7d44\u7e54(WHO)\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u81e8\u5e8a\u5efa\u8b70\uff0c\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u4e4b\u6a19\u6e96\uff0c\u4ee5\u4e0b\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u7a7a\u8179\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc 126 mg/dL\nB. \u7cd6\u5316\u8840\u8272\u7d20\u503c\u5728NGSP (National Glycohemoglobin Standardization Program)\u6aa2\u6e2c\u6a19\u6e96\u4e0b\uff0c\u5927\u65bc\u6216\u7b49\u65bc6.5%\nC. \u7a7a\u8179\u8840\u7cd6\u4e4b\u57fa\u672c\u5b9a\u7fa9\u70ba\u81f3\u5c118\u5c0f\u6642\u672a\u9032\u98df\nD. \u96a8\u6a5f\u8840\u7cd6\u6aa2\u9a57 (random blood glucose)\u5927\u65bc\u6216\u7b49\u65bc140 mg/dL\uff0c\u540c\u6642\u4f75\u6709\u7cd6\u5c3f\u75c5\u4e4b\u5178\u578b\u75c7\u72c0\nE. \u53e3\u670d\u8461\u8404\u7cd6\u8a66\u9a57 (oral glucose tolerance test) \u4e4b\u5f8c\u7684\u5169\u5c0f\u6642\u8840\u7cd6\u5927\u65bc\u6216\u7b49\u65bc200 mg/dL\n": "(D)", "107-5.\n\u7d71\u8a08\u4e0a\u986f\u793a\u81f3\u5c117%\u4e4b\u61f7\u5b55\u5a66\u5973\u70ba\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\uff0c\u96d6\u7136\u7522\u5f8c\u5927\u591a\u6578\u4e4b\u5a66\u5973\uff0c\u8840\u7cd6\u90fd\u53ef\u4ee5\u6062\u5fa9\u5230\u6b63\u5e38\u7bc4\u570d\u4e4b\u5167\uff0c\u4f46\u4ecd\u670935-60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\u76f8\u95dc\u6558\u8ff0\uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684\uff1f (1). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\uff0c\u5bc6\u5207\u76f8\u95dc (2). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe\uff0c\u4e3b\u8981\u8207\u60a3\u8005\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3\u76f8\u95dc (3). \u5728\u61f7\u5b55\u671f\u9593\uff0c\u521d\u6b21\u767c\u73fe\u4e4b\u8840\u7cd6\u7570\u5e38\uff0c\u5982\u679c\u7b26\u5408\u7cd6\u5c3f\u75c5\u4e4b\u8a3a\u65b7\uff0c\u61c9\u6b78\u985e\u65bc\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5 (overt diabetes) (4). \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5728\u61f7\u5b55\u4e4b\u5f8c\u671f\u5b55\u671f\u6642 (late\rpregnancy)\uff0c\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6703\u660e\u986f\u964d\u4f4e\uff0c\u8840\u7cd6\u6bd4\u8f03\u5bb9\u6613\u63a7\u5236\u3002\nA. (1)+(2)\nB. (2)+(3)\nC. (3)+(4)\nD. (1)+(4)\nE. (2)+(4)\n": "(E)", "107-6.\n\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u6839\u6e90\u5728\u65bc\u8102\u86cb\u767d (lipoprotein)\u7684\u4ee3\u8b1d\u7570\u5e38\uff0c\u4e00\u822c\u5e38\u898b\u7684\u75be\u75c5\u72c0\u614b\u8207\u81bd\u56fa\u9187/\u4e09\u9178\u7518\u6cb9\u916f(TG)\u589e\u52a0\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d (HDL)\u6e1b\u5c11\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. \u5927\u591a\u6578\u75c5\u60a3\u7f79\u75c5\u6642\u7684\u8840\u8102\u7570\u5e38\uff0c\u540c\u6642\u53d7\u5230\u907a\u50b3\u56e0\u5b50(genetic predisposition)\u53ca\u74b0\u5883\u56e0\u7d20(environmental contribution)\u7684\u5f71\u97ff\nB. \u8840\u8102\u7570\u5e38\u6642\uff0c\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d(LDL & VLDL)\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50\uff0c\u591a\u6578\u8207\u80a5\u80d6\u3001\u80f0\u5cf6\u7d20\u963b\u6297\u53ca\u907a\u50b3\u76f8\u95dc\nC. \u9577\u671f\u651d\u53d6\u9ad8\u71b1\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152\uff0c\u5176\u8840\u8102\u7570\u5e38\u53ef\u767c\u73fe\u589e\u52a0VLDL\u53caTG\uff0c\u4e26\u964d\u4f4eHDL\u4e4b\u8840\u4e2d\u6fc3\u5ea6\nD. \u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u7d93\u5e38\u662fTG\u589e\u52a0\uff0c\u4f46\u662fHDL \u964d\u4f4e\nE. \u5167\u5206\u6ccc\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u7d93\u5e38\u5c0e\u81f4LDL\u589e\u52a0\uff0c\u56e0\u70ba\u7532\u72c0\u817a\u7d20\u53ef\u589e\u52a0\u809d\u81df\u4e4bLDL\u53d7\u5668\uff0c\u964d\u4f4e\u8840\u4e2d\u4e4bLDL\uff0c\u4f46\u7532\u72c0\u817a\u7d20\u4e0d\u8db3\u6642\uff0c\u8840\u4e2d\u4e4bLDL\u4e4b\u6e05\u9664\u6548\u7387\u4e5f\u6703\u660e\u986f\u4e0b\u964d\n": "(C)", "107-7.\n\u9673\u5148\u751f\uff0c72\u6b72\uff0c\u7cd6\u5c3f\u75c5\u53f220\u5e74\uff0c\u76ee\u524d\u63a5\u53d7\u53e3\u670d\u7cd6\u5c3f\u75c5\u85e5\u7269\u53ca\u57fa\u790e\u80f0\u5cf6\u7d20\u6cbb\u7642\uff0c\u6700\u8fd1\u4e00\u6b21\u4e4bHbA1c\u70ba7.5%\uff0c\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u4e4b\u65e9\u6668\u7a7a\u8179\u8840\u7cd6\u5728140-160 mg/dL\u5de6\u53f3\u3002\u75c5\u60a3\u4e5f\u56e0\u5fc3\u81df\u8870\u7aed\u75c5\u53f2\u65bc\u5fc3\u81df\u5167\u79d1\u898f\u5f8b\u6cbb\u7642\u3002\u672c\u6b21\u56e0\u547c\u5438\u5598\u53ca\u4e0b\u80a2\u6c34\u816b\uff0c\u81f3\u6025\u8a3a\u5c31\u91ab\u3002\u6025\u8a3a\u4e4b\u96a8\u6a5f\u8840\u7cd6\u70ba226 mg/dL\uff0c\u9209\u96e2\u5b50\u70ba146mEq/dL\uff0c\u9240\u96e2\u5b50\u70ba3.2 mEq/dL\uff0c\u808c\u9178\u9150\u70ba1.8 mg/dL\uff0c\u8840\u58d3\u70ba98/62 mmHg\uff0c\u8108\u640f\u70ba108 bpm\u3002\u5728\u8003\u91cf\u672c\u75c5\u60a3\u4e4b\u60c5\u6cc1\u4e0b\uff0c\u8003\u616e\u8f38\u6db2\u53ca\u76e3\u8996\u5c3f\u6392\u51fa\u91cf (urine output)\uff0c\u8acb\u554f\u4e0b\u5217\u4e4b\u8f38\u6db2\uff0c\u4f55\u8005\u70ba\u6700\u662f\u7576\u4e4b\u9078\u9805?\nA. Lactate Ringer solution\nB. 0.45% Half Saline solution\nC. 0.9% Normal Saline solution\nD. 5% Dextrose solution plus regular insulin with intravenous infusion\nE. Lactate Ringer solution plus regular insulin with intravenous infusion\n": "(C)", "107-8.\n\u5c31\u7cd6\u5c3f\u75c5\u4e4b\u8840\u7cd6\u63a7\u5236\u800c\u8a00\uff0c\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance)\u662f\u91cd\u8981\u7684\u81f4\u75c5\u6a5f\u8f49\uff0cThiazolidinedione (TZD)\u662f\u589e\u52a0\u80f0\u5cf6\u7d20\u654f\u611f\u5ea6\u7684\u91cd\u8981\u85e5\u7269\uff0c\u4f46\u662f\u85e5\u7269\u5fc5\u9808\u7559\u610f\u5176\u526f\u4f5c\u7528\uff0c\u76ee\u524d\u570b\u5167TZD\u985e\u85e5\u7269\uff0c\u50c5\u6709pioglitazone\uff0c\u4e0b\u5217\u4e4b\u9078\u9805\u4e2d\uff0c\u90a3\u4e9b\u662f\u5fc5\u9808\u7559\u610f\u7684\u85e5\u7269\u526f\u4f5c\u7528\uff1f (1). \u9aa8\u8cea\u758f\u9b06 (2). \u6c34\u816b (3). \u9ad4\u91cd\u589e\u52a0 (4). \u5c3f\u9053\u611f\u67d3 (5). \u8166\u4e2d\u98a8\nA. (1)+(3)+(5)\nB. (2)+(3)+(4)\nC. (1)+(4)+(5)\nD. (2)+(3)+(4)\nE. (1)+(2)+(3)\n": "(E)", "107-9.\n\u7cd6\u5c3f\u75c5\u6cbb\u7642\u4e2d\uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u7684\u4f75\u767c\u75c7\u4e4b\u4e00\uff0c\u9810\u9632\u53ca\u6cbb\u7642\u7cd6\u5c3f\u75c5\u7684\u4f75\u767c\u75c7\uff0c\u662f\u4e00\u822c\u91ab\u5b78\u4e2d\u7684\u91cd\u8981\u8ab2\u984c\uff0c\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4f4e\u8840\u7cd6\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u4e00\u822c\u7d71\u8a08\u4e0a\uff0c\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u7684\u4f4e\u8840\u7cd6\u767c\u751f\u7387\u4f4e\u65bc\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\nB. \u904e\u53bb\u7684\u7814\u7a76\u986f\u793a6-10%\u7684\u7684\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u7684\u6b7b\u4ea1\u539f\u56e0\u662f\u4f4e\u8840\u7cd6\nC. \u96d6\u7136sulphonylurea\u53cainsulin\u985e\u7684\u85e5\u7269\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\uff0c\u4f46\u662f\u7576\u4e0a\u8ff0\u5169\u985e\u85e5\u7269\u5408\u4f75\u65b0\u578b\u85e5\u7269\uff0c\u5982\u53e3\u670d\u4e4bDPP-4 inhibitor \u6216 \u6ce8\u5c04\u4e4bGLP-1 receptor agonist\u85e5\u7269\u6642\uff0c\u53ef\u4ee5\u6709\u6548\u7684\u964d\u4f4e\u4f4e\u8840\u7cd6\u7684\u767c\u751f\nD. \u6839\u64daACCORD\u53caADVANCE\u7684\u7814\u7a76\u767c\u73fe\uff0c\u4f7f\u7528\u85e5\u7269\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u662f\u9020\u6210\u4f4e\u8840\u7cd6\u767c\u751f\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\nE. \u7d71\u8a08\u4e0a\uff0c\u7576\u75c5\u60a3\u4f7f\u7528\u4e00\u5929\u4e00\u6b21\u4e4b\u57fa\u790e\u80f0\u5cf6\u7d20\u63a7\u5236\u8840\u7cd6\u6642\uff0c\u767c\u751f\u4f4e\u8840\u7cd6\u4e4b\u6a5f\u6703\uff0c\u4f4e\u65bc\u4e00\u5929\u9700\u591a\u6b21\u6ce8\u5c04\u9910\u524d\u80f0\u5cf6\u7d20\u4f86\u63a7\u5236\u8840\u7cd6\u7684\u75c5\u4eba\n": "(C)", "107-10.\n\u674e\u5973\u58eb\uff0c62\u6b72\uff0c\u53ef\u81ea\u7531\u6d3b\u52d5\uff0c\u8207\u5bb6\u4eba\u540c\u4f4f\uff0c\u6578\u6b21\u56e0\u80ba\u708e\u6216\u6ccc\u5c3f\u9053\u611f\u67d3\u4f4f\u9662\u6cbb\u7642\uff0c\u8840\u7cd6\u7570\u5e38\u75c5\u53f22\u5e74\u3002\u76ee\u524d\u4e26\u672a\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u63a7\u5236\u8840\u7cd6\u3002\u672c\u6b21\u56e0\u80ba\u708e\u4f4f\u9662\uff0c\u6297\u751f\u7d20\u4f7f\u75285\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a\uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662\u3002\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a\uff0c\u5165\u9662\u96a8\u6a5f\u4e4bHbA1c \u70ba8.2 %\uff0c\u4f4f\u9662\u4e4b\u7b2c\u4e94\u5929\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba168 mg/dL\uff0c\u7576\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u62bd\u8840\u6aa2\u67e5\u4e4b\u8840\u7cd6\u70ba223 mg/dL\uff0c\u808c\u9178\u9150\u70ba 0.6 mg/dL\u3002\u96d6\u7136\u76ee\u524d\u7121\u660e\u986f\u7cd6\u5c3f\u75c5\u75c7\u72c0\uff0c\u4f46\u4ecd\u61c9\u591a\u52a0\u6ce8\u610f\u75c5\u7a0b\u767c\u5c55\u3002\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u5b89\u6392\u6558\u8ff0\uff0c\u4f55\u8005\u932f\u8aa4\uff1f\nA. \u61c9\u5efa\u8b70\u5728\u51fa\u9662\u75c5\u6cc1\u7a69\u5b9a\u4e4b\u5f8c\uff0c\u7d66\u4e88Metformin\u85e5\u7269\u6cbb\u7642\nB. \u5efa\u8b70\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\nC. \u5efa\u8b70\u5b89\u6392\u53e3\u670d\u8461\u8404\u7cd6\u6e2c\u8a66 (OGTT)\u9032\u4e00\u6b65\u78ba\u8a3a\u5176\u7cd6\u5c3f\u75c5\nD. \u5efa\u8b70\u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u53ca\u904b\u52d5\u885b\u6559\nE. \u5efa\u8b70\u75c5\u60a3\u53ef\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\n": "(C)", "108-1.\n\u4ee5Amiodarone\u6cbb\u7642\u5fc3\u5f8b\u4e0d\u6574\u53ef\u80fd\u5f71\u97ff\u7532\u72c0\u817a\u529f\u80fd\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba? (1)\u56e0\u70ba\u4f7f\u7528amiodarone\u800c\u4e0a\u5347\u7684\u7898\u542b\u91cf\uff0c\u5728\u505c\u7528amiodarone\u5169\u9031\u5f8c\u53ef\u4ee5\u4e0b\u964d\u81f3\u6b63\u5e38 (2)\u4f7f\u7528\u6bcf\u5929\u4e00\u6b21 200 mg amiodarone\u5c31\u53ef\u80fd\u4f7f\u8840\u7898\u53ca\u5c3f\u7898\u4e0a\u534740\u500d (3)\u8207\u7898\u7f3a\u4e4f\u5730\u5340\u6bd4\u8f03\uff0c\u7898\u5145\u8db3\u5730\u5340\u56e0\u70ba\u4f7f\u7528amiodarone \u800c\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b(hypothyroidism)\u7684\u767c\u751f\u7387\u6bd4\u8f03\u9ad8 (4)\u4f7f\u7528 amiodarone \u5f8c\u9020\u6210\u7684\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 ( amiodarone-induced thyrotoxicosis (AIT) )\u7b2c\u4e8c\u578b\u5176\u767c\u751f\u7387\u8207amidarone \u7684\u7d2f\u7a4d\u5291\u91cf\u7121\u95dc (5)\u4f7f\u7528amiodarone\u9020\u6210\u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b\uff0c\u4e0d\u9700\u8981\u505c\u7528amiodarone\u3002\nA. (1)+(3)\nB. (2)+(4)\nC. (2)+(3)+(5)\nD. (1)+(2)+(4)\nE. (1)+(3)+(5)\n": "(C)", "108-2.\n\u4e00\u4f4d28\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u5df2\u61f7\u5b558\u9031\uff0c\u6709\u5fc3\u60b8\u3001\u6015\u71b1\u3001\u9ad4\u91cd\u4e0b\u964d\u7b49\u75c7\u72c0\uff0c\u8eab\u9ad4\u8a3a\u5bdf\u986f\u793a\u6709\u51f8\u773c\u3001\u7532\u72c0\u817a\u7030\u6f2b\u6027\u816b\u5927\uff0c\u62bd\u8840\u6aa2\u67e5\u986f\u793a free thyroxine (fT4) 2.92 ng/ dL\u3001thyroid stimulating hormone (TSH) <0.001 \u03bcIU/mL (\u53c3\u8003\u503c: fT4 0.70~1.48 ng/dL\u3001hsTSH 0.35~4.94 \u03bcIU/mL)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u9078\u64c7\u6700\u6b63\u78ba? (1)\u61f7\u5b55\u524d\u671f\u4f7f\u7528methimazole \u6216carbimazole\u53ef\u80fd\u5f71\u97ff\u80da\u80ce\u767c\u80b2\uff0c\u56e0\u6b64\u6700\u597d\u9078\u64c7\u4f7f\u7528 propylthiouracil \u6cbb\u7642 (2)propylthiouracil \u53ef\u80fd\u6709\u809d\u6bd2\u6027\uff0c\u56e0\u6b64\u61f7\u5b55\u4e2d\u671f\u4ee5\u5f8c\u82e5\u4ecd\u9700\u8981\u6297\u7532\u72c0\u817a\u85e5\u7269\uff0c\u6700\u597d\u6539\u7528methimazole \u6216 carbimazole (3)\u6297\u7532\u72c0\u817a\u85e5\u7269\u4e0d\u6703\u7a7f\u900f\u80ce\u76e4\u5f71\u97ff\u80ce\u5152\r(4)\u6388\u4e73\u671f\u7981\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269\u4ee5\u514d\u5f71\u97ff\u5b30\u5152 (5)\u70ba\u907f\u514d\u6297\u7532\u72c0\u817a\u85e5\u7269\u4e4b\u526f\u4f5c\u7528\uff0c\u5efa\u8b70\u5b89\u6392\u7532\u72c0\u817a\u5207\u9664\u624b\u8853\nA. (1)+(2)\nB. (3)+(4)\nC. (2)+(3)+(4)\nD. (1)+(2)+(5)\nE. (1)+(3)+(5)\n": "(A)", "108-3.\n\u85e5\u7269\u53ef\u80fd\u5f71\u97ffrenin\u3001aldosterone\u7684\u5b9a\u91cf\u4ee5\u53caAldosterone-renin ratio (ARR)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?? (1)\u03b2-blocker \u53ef\u80fd\u4f7f renin \u4e0b\u964d\u3001aldosterone \u4e0a\u5347\u3001ARR\u4e0a\u5347 (2)\u03b1-blocker \u4e0d\u6703\u5f71\u97ff renin\u3001aldosterone\u3001ARR (3)Angiotensin-converting enzyme inhibitors (ACEI) \u53ef\u80fd\u4f7f renin \u4e0b\u964d\u3001aldosterone \u4e0a\u5347\u3001ARR\u4e0a\u5347 (4)Calcium antagonists\u61c9\u8a72\u5148\u505c\u7528\u4e00\u9031\uff0c\u4ee5\u907f\u514d\u5f71\u97ffrenin\u3001aldosterone\u7684\u5b9a\u91cf (5)Saline infusion test\u6642\uff0c\u5982\u679c aldosterone \u70ba10 ng/dL\uff0c\u53ef\u4ee5\u6392\u9664\u539f\u767c\u6027\u9ad8\u919b\u56fa\u916e\u75c7 (primary aldosteronism)\nA. (1)+(3)+(5)\nB. (2)+(4)\nC. (1)+(2)\nD. (3)+(5)\nE. (1)+(2)+(4)\n": "(C)", "108-4.\n\u4e00\u4f4d58\u6b72\u7537\u6027\u75c5\u4eba\u6709\u9ad4\u91cd\u4e0b\u964d\u3001\u5026\u6020\u3001\u59ff\u614b\u6027\u4f4e\u8840\u58d3\u7b49\u75c7\u72c0\uff0c\u4ed6\u7684\u8840\u9209\u662f125 mmol/L\uff0c\u8840\u7cd6\u662f60 mg/dL\uff0c\u61f7\u7591\u6709\u814e\u4e0a\u817a\u529f\u80fd\u4e0d\u5168\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba?\nA. \u5982\u679c\u75c5\u4eba\u5916\u8868\u9ed1\u3001\u4e7e\u3001\u7626\uff0c\u5247\u5176ACTH\u3001cortisol \u90fd\u61c9\u8a72\u6bd4\u6b63\u5e38\u503c\u4f4e\nB. \u5982\u679c\u75c5\u4eba\u7684\u4e73\u982d\u984f\u8272\u8f03\u6de1\uff0c\u61c9\u8a72\u540c\u6642\u4f7f\u7528glucocorticoid \u53ca mineralocorticoid \u6cbb\u7642\nC. \u5982\u679c\u75c5\u4eba\u6709\u6708\u4eae\u81c9\u3001\u4e2d\u6a1e\u6027\u80a5\u80d6\u3001\u7d2b\u6591\u3001\u8179\u90e8\u7d2b\u8272\u6591\u7d0b\u7b49\u5916\u8868\u7279\u5fb5\uff0c\u5247\u5176ACTH\u3001cortisol \u90fd\u61c9\u8a72\u6bd4\u6b63\u5e38\u503c\u9ad8\nD. \u5982\u679c\u75c5\u4eba\u7684 fT4\u53caTSH\u90fd\u504f\u4f4e\uff0c\u61c9\u8a72\u512a\u5148\u4f7f\u7528\u7532\u72c0\u817a\u7d20\u6cbb\u7642\nE. \u4e0d\u7ba1\u662f\u539f\u767c\u6027\u6216\u6b21\u767c\u6027\u814e\u4e0a\u817a\u529f\u80fd\u4e0d\u5168\uff0c\u814e\u4e0a\u817a\u96c4\u6027\u7d20( adrenal androgen) \u7684\u5206\u6ccc\u90fd\u6709\u53ef\u80fd\u53d7\u5230\u5f71\u97ff\n": "(E)", "108-5.\n\u4e00\u4f4d38\u6b72\u5973\u6027\u75c5\u4eba\uff0c\u56e0\u70ba\u9663\u767c\u6027\u9ad8\u8840\u58d3\u3001\u982d\u75db\u3001\u5fc3\u60b8\u4f86\u8a3a\uff0c\u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624 (pheochromocytoma)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u9069\u7576?\nA. \u56e0\u70ba\u8840\u58d3\u592a\u9ad8\uff0c\u4e0b\u80a2\u6709\u8f15\u5fae\u6c34\u816b\uff0c\u61c9\u8a72\u9650\u5236\u6c34\u5206\u651d\u53d6\nB. \u6aa2\u67e5\u5c3f\u6db2\u4e2d\u7684fractionated metanephrines \u53ca catecholamine \u5c0d\u65bc\u55dc\u927b\u7d30\u80de\u7624\u7684\u8a3a\u65b7\u6709\u6700\u9ad8\u7684\u7279\u7570\u6027( specificity)\nC. \u75c5\u4eba\u66fe\u7d93\u4f7f\u7528\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ca\u5229\u5c3f\u5291\uff0c\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ef\u80fd\u9020\u6210\u507d\u967d\u6027(false positive)\u7684catecholamine\u6aa2\u9a57\u7d50\u679c\uff0c\u4f46\u5229\u5c3f\u5291\u5247\u4e0d\u6703\u5f71\u97ff\u6aa2\u9a57\u7d50\u679c\nD. \u70ba\u6e1b\u5c11\u58d3\u529b\uff0c\u505a\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u7b49\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642\u61c9\u8a72\u907f\u514d\u4f7f\u7528\u986f\u5f71\u5291\nE. \u55dc\u927b\u7d30\u80de\u7624\u6216\u526f\u795e\u7d93\u7bc0\u7d30\u80de\u7624 ( paragangliomas) \u5927\u7d04\u67095-10% \u662f\u60e1\u6027\u7684\n": "(E)", "108-6.\n\u4e00\u4f4d50\u6b72\u7537\u6027\u75c5\u4eba\uff0c\u6709\u80a2\u7aef\u80a5\u5927\u3001\u95dc\u7bc0\u708e\u3001\u7761\u7720\u547c\u5438\u4e2d\u6b62\u7b49\u75c7\u72c0\uff0c\u4ed6\u7684\u751f\u9577\u6fc0\u7d20\uff08Growth hormone, GH\uff09\u70ba10 ng/mL (\u53c3\u8003\u503c < 8 ng/mL)\u3001insulin-like growth factor-1 (IGF-1) \u70ba 300 ng/mL (\u53c3\u8003\u503c48.1~209 ng/mL)\uff0c\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u9752\u6625\u671f\u6642IGF-1 \u7684\u53c3\u8003\u503c\u901a\u5e38\u8f03\u5e74\u7d00\u5927\u6642\u70ba\u9ad8\nB. \u55ae\u6b21\u96a8\u610f(single random) \u7684\u8840\u6e05GH\u503c\u8207\u80a2\u7aef\u80a5\u5927\u75c7\u75be\u75c5\u56b4\u91cd\u5ea6\u6709\u6b63\u76f8\u95dc\nC. \u7d66\u4e88\u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd6\u5f8cGH\u7684\u6700\u4f4e\u503c\u70ba4 ng/mL\uff0c\u53ef\u4ee5\u6392\u9664\u80a2\u7aef\u80a5\u5927\u75c7\nD. \u751f\u9577\u6fc0\u7d20\u7624\u7684\u9996\u9078\u6cbb\u7642\u70ba\u624b\u8853\u5207\u9664\uff0c\u8853\u524d\u7981\u5fcc\u7d66\u4e88somatostatin analogues\nE. \u751f\u9577\u6fc0\u7d20\u7624\u7684\u653e\u5c04\u6027\u6cbb\u7642(radiotherapy)\uff0c\u901a\u5e38\u5728\u4e00\u5e74\u5de6\u53f3\u53ef\u4ee5\u770b\u5230\u751f\u5316\u6307\u6a19(biochemical parameter)\u6b63\u5e38\u5316\n": "(A)", "108-7.\n\u4e0b\u5217\u54ea\u4e00\u9805\u53ef\u80fd\u4f7f\u526f\u7532\u72c0\u817a\u8377\u723e\u8499\u6fc3\u5ea6(parathyroid hormone, PTH)\u4e0a\u5347?\nA. Calcium-sensing receptor (CaSR) agonists such as cinacalcet\nB. Vitamin D\nC. Fibroblast growth factor 23 (FGF23)\nD. Phosphates\nE. Severe intracellular magnesium deficiency\n": "(D)", "108-8.\n\u4e00\u4f4d25\u6b72\u7537\u6027\u75c5\u4eba\u56e0\u70ba\u7b2c\u4e8c\u6027\u5fb5\u4e0d\u660e\u986f\u4f86\u6c42\u8a3a\uff0c\u7d93\u75c5\u53f2\u8a62\u554f\u53ca\u8eab\u9ad4\u8a3a\u5bdf\u5f8c\u78ba\u8a8d\u6709\u6027\u817a\u529f\u80fd\u4f4e\u4e0b(hypogonadism)\u3001\u55c5\u89ba\u7570\u5e38\u3001\u8272\u76f2\u3001\u984e\u88c2\uff0c\u8acb\u554f\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6b63\u78ba?\nA. \u6b64\u75c5\u4eba\u4e4b\u776a\u4e38\u5c0f\u800c\u786c\nB. \u6b64\u75c5\u4eba\u4e4b\u6ffe\u6ce1\u523a\u6fc0\u7d20\uff08follicle-stimulating hormone, FSH\uff09\u53ca\u9ec3\u9ad4\u5316\u6fc0\u7d20 (luteinizing hormone, LH) \u8f03\u53c3\u8003\u503c\u9ad8\nC. \u6b64\u75c5\u4eba\u53ef\u80fd\u6709X-linked KAL gene \u7a81\u8b8a\nD. \u82e5\u6b64\u75c5\u4eba\u6025\u65bc\u7d50\u5a5a\u751f\u5b50\uff0c\u61c9\u8a72\u8d95\u5feb\u7d66\u4e88testosterone \u6cbb\u7642\nE. \u6838\u78c1\u5171\u632f\u6aa2\u67e5\u767c\u73fe\u6709\u8166\u4e0b\u5782\u9ad4\u5fae\u5c0f\u816b\u7624(microadenoma)\n": "(C)", "108-9.\n\u4e0b\u5217\u6709\u95dc\u6ccc\u4e73\u6fc0\u7d20\u7624(prolactinoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f\nA. \u4e00\u516c\u5206\u4ee5\u4e0a\u7684prolactinoma,\u7537\u5973\u6bd4\u7d04\u70ba1:3\nB. \u5973\u6027\u75c5\u4eba\u6709prolactin microadenoma (< 1 cm) \u4f46\u7121\u75c7\u72c0\uff0c\u4e0d\u9808\u6cbb\u7642\uff0c\u8ffd\u8e64\u5373\u53ef\nC. \u8840\u6db2\u4e2d\u6ccc\u4e73\u6fc0\u7d20(Prolactin)\u6fc3\u5ea6\u8207\u816b\u7624\u5927\u5c0f\u7121\u95dc\nD. Prolactinoma\u75c5\u4eba\u5982\u679c\u4ee5dopamine agonists\u6cbb\u7642\uff0c\u6700\u597d\u7dad\u6301\u5176prolactin \u6fc3\u5ea6\u65bc\u53c3\u8003\u503c\u4e4b1\u81f31.5\u500d\nE. \u5973\u6027\u75c5\u4eba\u6709\u5c0f\u65bc1\u516c\u5206\u7684prolactinoma\uff0c\u5982\u679c\u4ee5dopamine agonists\u6cbb\u7642\u5f8c\u61f7\u5b55\uff0c\u4e0d\u53ef\u4ee5\u505c\u85e5\uff0c\u61c9\u8a72\u6301\u7e8c\u4f7f\u7528dopamine agonists\n": "(B)", "108-10.\n\u81ea\u9ad4\u514d\u75ab\u591a\u767c\u6027\u5167\u5206\u6ccc\u75c7\u5019\u7fa4\u7b2c\u4e00\u578b(Autoimmune Polyendocrine Syndromes type 1, APS-1) \u6709\u4e0b\u5217\u7279\u5fb5\uff0c\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?\nA. Candidiasis\nB. \u7259\u91c9\u8cea\u589e\u751f (Hyperplasia of the dental enamel)\nC. Hypoparathyroidism\nD. Addison's disease\nE. \u70baAIRE gene \u7684\u9ad4\u67d3\u8272\u9ad4\u96b1\u6027\u7a81\u8b8a\n": "(B)", "108-1.\n\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u7d44\u6210\u7cd6\u80d6\u75c7(Diabesity)\uff0c\u5728\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u7684\u7bc4\u7587\u5167\uff0c\u5f7c\u6b64\u5bc6\u5207\u76f8\u95dc\uff0c\u4e0b\u5217\u4e4b\u6709\u95dc\u6b64\u5169\u985e\u75be\u75c5\u6558\u8ff0\u4e2d\uff0c\u4f55\u8005\u6709\u8aa4?\nA. \u9577\u671f\u7684\u7814\u7a76\u4e2d\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u898f\u5f8b\u4e4b\u8db3\u91cf\u904b\u52d5\uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u4e4b\u6a5f\u7387\uff0c\u5176\u95dc\u9375\u6a5f\u8f49\u70ba\u63a7\u5236\u9ad4\u91cd\nB. \u904b\u52d5\u5c0d\u65bc\u9ad4\u91cd\u4e4b\u63a7\u5236\u975e\u5e38\u91cd\u8981\uff0c\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\uff0c\u7814\u7a76\u4e4b\u8cc7\u6599\u986f\u793a\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u7387\uff0c\u4e5f\u53ef\u4ee5\u964d\u4f4e\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387\nC. \u9664\u4e86\u8eab\u9ad4\u8cea\u91cf(body mass index, BMI)\u4e4b\u5916\uff0c\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u5bc6\u5207\u76f8\u95dc\u7684\u80a5\u80d6\u578b\u614b\u662f\u4e2d\u5fc3\u6027\u8179\u90e8\u80a5\u80d6 (central abdominal obesity)\nD. \u4f9d\u7167\u7cd6\u5c3f\u75c5\u98f2\u98df\u63a7\u5236\u539f\u5247\uff0c\u9810\u9632\u75be\u75c5\u9032\u5c55\u6642\uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u964d\u4f4e\u7684\u9ad4\u91cd\uff0c\u4e3b\u8981\u662f\u8102\u80aa\u7d44\u7e54\nE. \u7f8e\u570b\u570b\u885b\u9662\u9032\u884c\u4e4b\u751f\u6d3b\u578b\u614b\u7814\u7a76LOOKAHEAD\uff0c\u91dd\u5c0d\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005\u5b89\u6392\u71df\u990a\u8aee\u8a62\u53ca\u9ad4\u91cd\u7ba1\u7406\uff0c\u96d6\u7136\u53ef\u4ee5\u6539\u5584\u8840\u7cd6\u53caHbA1c\u4e4b\u63a7\u5236\uff0c\u4f46\u662f\u7814\u7a76\u7d50\u679c\u986f\u793a\u4e26\u7121\u6cd5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u5fc3\u81df\u8840\u7ba1\u75be\u75c5 \u6b7b\u4ea1\u7387\n": "(B)", "108-2.\n\u7cd6\u5c3f\u75c5\u7528\u85e5\u7684\u6a5f\u8f49\uff0c\u8207\u75c5\u60a3\u7a7a\u8179\u6216\u98ef\u5f8c\u8840\u7cd6\u63a7\u5236\u5bc6\u5207\u76f8\u95dc\uff0c\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\uff0c\u6709\u4e9b\u8207\u80f0\u5cf6\u7d20\u5206\u6ccc\u6216\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6709\u95dc\uff0c\u6709\u4e9b\u5247\u7121\u76f4\u63a5\u95dc\u806f(non-insulin dependent)\uff0c\u4ee5\u4e0b\u964d\u8840\u7cd6\u85e5\u7269\u4e2d\uff0c\u4f55\u9805\u85e5\u7269\u70ba\u975e\u80f0\u5cf6\u7d20\u76f8\u95dc(non-insulin dependent)\u4e4b\u6a5f\u8f49?\nA. Sulfonylurea\nB. Biguanide\nC. Dipeptidyl dipeptidase 4 inhibitor (DPP4 inhibitor)\nD. Sodium-glucose co-transporter 2 inhibitor (SGLT 2 inhibitor)\nE. Glucagon like peptide 1 receptor agonist (GLP 1 RA)\n": "(D)", "108-3.\n\u7cd6\u5c3f\u75c5\u7684\u6cbb\u7642\uff0c\u751f\u6d3b\u578b\u614b\u7ba1\u63a7\u98f2\u98df\u53ca\u904b\u52d5\u4e4b\u5916\uff0c\u53e3\u670d\u6216\u6ce8\u5c04\u578b\u85e5\u7269\u4e5f\u662f\u95dc\u9375\u63a7\u5236\u56e0\u5b50\uff0c\u4e0b\u5217\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u4e4b\u63cf\u8ff0? (1) Metformin\u53ef\u4ee5\u5b89\u5168\u5730\u4f7f\u7528\u65bceGFR < 30\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005 (2)Sulfobnylurea\u985e\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5bb9\u6613\u9020\u6210\u75c5\u60a3\u4e4b\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 (3) \u570b\u5167\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70\u4e2d\uff0cHbA1c\u7cd6\u5316\u8840\u8272\u7d20\u61c9\u63a7\u5236\u65bc < 6% (4) Sodium glucose co-transporter 2 inhibitor (SGLT2 inhibitor) \u5728\u964d\u4f4e\u8840\u7cd6\u4e4b\u6642\uff0c\u901a\u5e38\u4e5f\u6703\u4f34\u96a8\u6e1b\u8f15\u75c5\u60a3\u4e4b\u9ad4\u91cd (5) \u814e\u529f\u80fd\u4e0d\u4f73\uff0ceGFR < 60\u6642\uff0c\u61c9\u907f\u514d\u4f7f\u7528\u80f0\u5cf6\u7d20\u53caGLP-1 receptor agonist\u4e4b\u91dd\u5291\u85e5\u7269\u3002\nA. (2)+(4)+(5)\nB. (1)+(3)+(4)\nC. (1)+(4)+(5)\nD. (1)+(3)+(5)\nE. (3)+(4)+(5)\n": "(D)", "108-4.\nSodium glucose co-transporter 2 inhibitor (SGLT 2 inhibitor) \u662f\u8fd1\u5e7e\u5e74\u4f86\u4f7f\u7528\u65bc\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u65b0\u578b\u53e3\u670d\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u964d\u8840\u7cd6\u4e4b\u6a5f\u8f49\u662f\u7d93\u7531\u5c3f\u6db2\u5c07\u8461\u8404\u7cd6\u6392\u51fa\u9ad4\u5916\uff0c\u4ee5\u4e0b\u6709\u95dc\u672c\u9805\u85e5\u54c1\u4e4b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. SGLT 2 inhibitor \u6240\u5f62\u6210\u4e4b\u9ad8\u5c3f\u7cd6\uff0c \u589e\u52a0\u6ccc\u5c3f\u9053\u53ca\u751f\u6b96\u5668\u611f\u67d3\u4e4b\u98a8\u96aa\nB. \u81e8\u5e8a\u8a66\u9a57\u7814\u7a76\u986f\u793aSGLT 2 inhibitor \u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u56e0\u5fc3\u81df\u8870\u7aed\u4f4f\u9662\u7684\u6a5f\u7387\nC. SGLT 2 inhibitor \u5c0d\u7cd6\u5c3f\u75c5\u60a3\u8005\u800c\u8a00\uff0c\u5728\u964d\u4f4e\u8840\u7cd6\u4e4b\u969b\uff0c\u4e5f\u540c\u6642\u964d\u4f4e\u4e86\u75c5\u60a3\u7522\u751f\u916e\u9178\u4e2d\u6bd2(diabetic ketoacidosis) \u7684\u6a5f\u7387\nD. \u76ee\u524d\u4e4b\u7814\u7a76\u986f\u793aSGLT 2 inhibitor\u53ef\u4ee5\u8207\u80f0\u5cf6\u7d20\u540c\u6642\u5408\u4f75\u4f7f\u7528\u4f86\u63a7\u5236\u8840\u7cd6\nE. eGFR > 60 \u4ee5\u4e0a\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u90fd\u53ef\u4ee5\u4f7f\u7528SGLT 2 inhibitor\n": "(C)", "108-5.\n\u5728\u5167\u79d1\u7cd6\u5c3f\u75c5\u8840\u7cd6\u4e4b\u63a7\u5236\u4e2d\uff0c\u80f0\u5cf6\u7d20(lnsulin)\u53caGLP-1 receptor agonist  (GLP-1 RA)\u6ce8\u5c04\u578b\u88fd\u5291\u662f\u91cd\u8981\u7684\u63a7\u5236\u85e5\u7269\uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u53caGLP-1 RA\u6cbb\u7642\u4e4b\u63cf\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?\nA. Basal insulin (\u57fa\u790e\u80f0\u5cf6\u7d20) \u4f7f\u7528\u4e4b\u8d77\u59cb\u5291\u91cf(initial dose) \u7684\u539f\u5247\u70ba 0.2 unit/kg/day\nB. Basal insulin \u53ef\u4ee5\u5408\u4f75GLP-1 RA\uff0c\u5354\u540c\u63a7\u5236\u75c5\u60a3\u4e4b\u8840\u7cd6\nC. GLP-1 RA \u5e38\u898b\u7684\u526f\u4f5c\u7528\u70ba\u8179\u8139\u5641\u5fc3\u611f\uff0c\u80f0\u5cf6\u7d20\u6700\u5e38\u898b\u4e4b\u526f\u4f5c\u7528\u70ba\u4f4e\u8840\u7cd6\nD. GLP-1 RA \u53ef\u4ee5\u5408\u4f75\u80f0\u5cf6\u7d20\u6cbb\u7642\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\uff0c\u4e26\u53ef\u6e1b\u5c11\u80f0\u5cf6\u7d20\u4f7f\u7528\u4e4b\u5291\u91cf\nE. \u81e8\u5e8a\u8a66\u9a57\u7814\u7a76\u4e4b\u7d50\u679c\u986f\u793a\uff0cGLP-1 RA  \u4e4b\u4f7f\u7528\uff0c\u5728\u964d\u4f4e\u8840\u7cd6\u6642\uff0c\u4e5f\u6703\u540c\u6642\u6e1b\u8f15\u75c5\u60a3\u4e4b\u9ad4\u91cd\n": "(D)", "108-6.\n\u9673\u5148\u751f\uff0c40 \u6b72\uff0c\u8eab\u9ad8173\u516c\u5206\uff0c\u9ad4\u91cd 84 \u516c\u65a4\uff0c\u8fd1\u4e00\u5e74\u4f86\uff0c\u9ad4\u91cd\u589e\u52a0\u4e866 \u516c\u65a4\u3002\u4e26\u7121\u7cd6\u5c3f\u75c5\u4e4b\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2\uff0c\u534a\u5e74\u4f86\uff0c\u66fe\u7d93\u6709\u6578\u6b21\u4e0d\u660e\u539f\u56e0\u7684\u660f\u5012\uff0c\u90fd\u572830 \u5206\u9418\u5167\u7526\u9192\u904e\u4f86\u3002\u9580\u8a3a\u75c5\u7121\u5fc3\u5f8b\u4e0d\u6574\u6216\u7570\u5e38\u795e\u7d93\u8840\u7ba1\u4e4b\u7570\u5e38\u72c0\u6cc1\u3002\u672c\u6b21\u56e0\u518d\u5ea6\u65bc\u5de5\u4f5c\u6642\u660f\u5012\uff0c\u4f46\u662f\u610f\u8b58\u6301\u7e8c\u4e0d\u6e05\uff0c\u56e0\u6b64\u9001\u5230\u6025\u8a3a\u3002\u6025\u8a3a\u4e4b\u8840\u58d3\u70ba110/68 mmHg\uff0c\u8108\u640f\u70ba\u898f\u5f8b\u768472 bpm\uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u986f\u793a\u70ba35 mg/dL\uff0c\u7d66\u4e8850%\u4e4b\u8461\u8404\u7cd6\u8f38\u6db2\u5f8c\uff0c\u6062\u5fa9\u610f\u8b58\u3002\u5efa\u8b70\u4f4f\u9662\u8a3a\u5bdf\uff0c\u5728\u75c5\u623f\u7121\u9ede\u6ef4\u8f38\u6db2\u7684\u524d\u63d0\u4e0b\uff0c\u7a7a\u81798 \u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u5831\u544a\u70ba: \u7a7a\u8179\u8840\u7cd6 84 mg/dL\uff0c Insulin 3.6 mIU/mL \uff0cC-peptide 2.6 ng/mL\uff0cACTH 62.2 pg/mL\uff0cCortisol\r24.3 ug/dL\uff0cIGF-1 198 ng/mL\uff0cTSH 1.2 mIU/mL\uff0c\u6b64\u6642\u61c9\u8003\u616e\u4e4b\u512a\u5148\u6aa2\u67e5\u9805\u76ee\u70ba\u4f55?\nA. 24\u5c0f\u6642\u5fc3\u96fb\u5716\nB. \u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71(MRI)\nC. \u8179\u90e8\u96fb\u8166\u65b7\u5c64\nD. 75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (Oral glucose tolerance test)\nE. 72\u5c0f\u6642\u4e4b Prolonged fasting test\n": "(E)", "108-7.\nGlitazone(TZD)\u985e\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\uff0c\u5c6c\u65bc\u80f0\u5cf6\u7d20\u589e\u654f\u5291\uff0c\u53ef\u4ee5\u6539\u5584\u80f0\u5cf6\u7d20\u5728\u4eba\u9ad4\u5167\u4e4b\u654f\u611f\u5ea6\uff0c\u4f46\u662f\u4e5f\u6709\u4e9b\u85e5\u7269\u4e4b\u526f\u4f5c\u7528\uff0c\u4ee5Pioglitazone\u70ba\u4f8b\uff0c\u4f7f\u7528\u76f8\u95dc\u85e5\u7269\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u4f55\u8005?  (1)\u9aa8\u8cea\u758f\u9b06 (2)\u8a8d\u77e5\u969c\u7919 (cognitive dysfunction) (3)\u6c34\u816b (4)\u8166\u4e2d\u98a8 (Storke) (5)\u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0\u3002\nA. (1)+(2)+(3)\nB. (1)+(3)+(5)\nC. (3)+(4)+(5)\nD. (1)+(2)+(5)\nE. (2)+(3)+(5)\n": "(B)", "108-8.\n\u674e\u5148\u751f\uff0c56\u6b72\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\u70ba10\u5e74\uff0c\u5169\u5e74\u524d\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5\u9032\u884c\u5fc3\u5c0e\u7ba1\u7f6e\u653e\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u85e5\u7269\u5305\u62ec: \u9810\u6df7\u578b\u80f0\u5cf6\u7d20 (Premix insulin)\uff0c\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\u65e5valsatan 160mg \u53caamlodipine 5mg \uff0c\u81bd\u56fa\u9187\u85e5\u7269\u70ba rosuvastatin \u6bcf\u65e520mg\u3002\u76ee\u524dHbA1c \u70ba 6.8%\uff0cLDL cholesterol \u70ba 50 mg/dL\uff0cHDL cholesterol 31 mg/dL\uff0cTriglyceride \u70ba 828 mg/dL\uff0c\u5c3f\u6db2\u6aa2\u67e5\u6b63\u5e38\uff0c\u7121\u5fae\u91cf\u767d\u86cb\u767d\u5c3f\uff0c\u8f15\u5fae\u80cc\u666f\u578b\u8996\u7db2\u819c\u75c5\u8b8a (Background retinopathy)\uff0c\u76ee\u524d\u61c9\u8a72\u589e\u52a0\u4f7f\u7528\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269?\nA. Pioglitazone\nB. Nicotic acid\nC. Fenofibrate\nD. Acarbose\nE. Cholestyramine\n": "(C)", "108-9.\n\u4f4e\u8840\u7cd6\u7684\u767c\u751f\uff0c\u6709\u6642\u8207\u7cd6\u5c3f\u75c5\u4e4b\u6cbb\u7642\u5bc6\u5207\u76f8\u95dc\uff0c\u4f46\u975e\u7cd6\u5c3f\u75c5\u4e4b\u75be\u75c5\u4e5f\u53ef\u80fd\u767c\u751f\u4f4e\u8840\u7cd6\uff0c\u4e0b\u5217\u6558\u8ff0\u7684\u75c5\u75c7\u4e2d\uff0c\u4f55\u8005\u70ba\u4f4e\u8840\u7cd6\u767c\u751f\u7684\u539f\u56e0? (1)\u4f7f\u7528\u80f0\u5cf6\u7d20\u6216sulfonylurea \u985e\u964d\u8840\u7cd6\u85e5\u7269 (2)\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (Cushing's Syndrome) (3)\u80c3\u5207\u9664\u624b\u8853\u5f8c (Post-gastric bypass survey) (4)\u814e\u4e0a\u817a\u6a5f\u80fd\u4e0d\u8db3 (Adrenal insufficiency) (5) \u80a2\u7aef\u80a5\u5927\u75c7 (Acromegaly)\u3002\nA. (1)+(2)+(3)\nB. (3)+(4)+(5)\nC. (1)+(3)+(5)\nD. (2)+(3)+(4)\nE. (1)+(3)+(4)\n": "(E)", "108-10.\n\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u3001\u9ad8\u8840\u58d3\u53ca\u9ad8\u8840\u8102\u6cbb\u7642\u85e5\u7269\u7684\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?  (1)\u96a8\u8457\u5e74\u9f61\u7684\u8001\u5316\uff0c\u8840\u7cd6\u63a7\u5236\u7684HbA1c\u53ca\u8840\u58d3\u63a7\u5236\u7bc4\u570d\uff0c\u9ad8\u9f61\u7684\u7cd6\u5c3f\u75c5\u75c5\u60a3\u6703\u8f03\u5e74\u8f15\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\u5bec\u9b06\u4e9b (2)\u76ee\u524d\u7cd6\u5c3f\u75c5\u9ad8\u8840\u58d3\u6cbb\u7642\u7684\u9996\u9078\u85e5\u7269\u70ba Angiotensin converting enzyme inhibitor (ACEI)\u6216 angiotension receptor blocker (ARB) (3)\u7cd6\u5c3f\u75c5\u60a3\u8005\u5982\u9700\u85e5\u7269\u63a7\u5236\u6cbb\u7642\u9ad8\u8840\u8102\uff0c\u5176\u4f4e\u5bc6\u5ea6\u81bd\u56fa\u9187(LDL-cholestrol) \u4e4b\u6cbb\u7642\u6a19\u7684\u70ba\u4f4e\u65bc130 mg/mL (4)\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e4b\u9ad8\u8840\u58d3\u63a7\u5236\u76ee\u6a19\uff0c\u57fa\u672c\u4e0a\u5b9a\u5728\u4f4e\u65bc120/80 mmHg\uff0c\u5982\u679c\u5408\u4f75\u86cb\u767d\u5c3f\u6642\uff0c\u8840\u58d3\u63a7\u5236\u5efa\u8b70\u70ba\u4f4e\u65bc110/70 mmHg\r(5)\u7576HbA1c\u3001\u8840\u58d3\u53ca\u8840\u8102\u5747\u9054\u5230\u63a7\u5236\u6a19\u6e96\u6642\uff0c\u6212\u83f8\u5df2\u7121\u52a9\u65bc\u9032\u4e00\u6b65\u964d\u4f4e\u7cd6\u5c3f\u75c5\u8840\u7ba1\u4f75\u767c\u75c7\u4e4b\u98a8\u96aa\u3002\nA. (3)+(4)+(5)\nB. (1)+(3)+(5)\nC. (1)+(2)+(3)\nD. (1)+(4)+(5)\nE. (2)+(4)+(5)\n": "(A)", "109-120.58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u56e0\u70ba\u8840\u58d3\u4f4e\u53ca\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a \u3002\u5979\u7684\u5167\u5206\u6ccc\u6aa2\u67e5\u986f\u793a fT4 0 .65 ng/dL, hsTSH 0.32 \nuIU/mL, cortisol (8 am) 5 ug /dL, ACTH 40 pg /mL, GH 2.5 ng/mL, prolactin 6 ng /mL\u3002\u4e0b\u5217\u54ea\u4e00\u500b\u9078\u9805\uff0c \n\u6700\u652f\u6301\u8166\u5782\u9ad4\u529f\u80fd\u4e0d\u5168 (hypopituitarism) \u8a3a\u65b7 \uff1f(\u53c3\u8003\u503c: fT4 0 .70~1.48 ng/dL; hsTSH 0.35~4.94 uIU/mL; \ncortisol (8am) 5~25 ug/dL; cortisol (4pm) 2.5~12.5 ug/dL; ACTH 7.4~57.3 pg/mL; GH <8 ng/dL; \nprolactin 5~23 ng/mL)\n(1) insulin hyoglycemia test, \u7576 glucose <40 mg/dL\u6642, GH \u70ba 6 ng /mL.\n(2) Insulin hypoglycemia test, \u7576 glucose < 40 mg /dL\u6642, cortisol \u70ba 9 ug /dL.\n(3) TRH stimulation test, peak TSH 4.25 uIU/mL.\n(4) TRH stimulation test, peak prolactin 19 ng /mL.\n(5) CRH stimulation test, peak ACTH 90 pg /mL.   \nA.(1)+(2)\nB.(2)+(3)\nC.(3)+(4)\nD.(1)+(2)+(3)\nE.(2)+(3)+(5)\n": "[B]", "109-121.\u4e00\u4f4d65\u6b72\u7537\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u6709\u591a\u5c3f\u591c\u5c3f \uff0c\u4ed6\u6c92\u6709\u7cd6\u5c3f\u75c5 \uff0c\u8003\u616e\u6b64\u75c5\u4eba\u662f\u5426\u6709\u5c3f\u5d29\u75c7 (diabetes insipidus, \nDI)\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u601d\u8003\u6700\u6b63\u78ba \uff1f\n(1) \u8b93\u75c5\u4eba\u96a8\u610f\u559d\u6c34\u7684\u60c5\u6cc1\u4e0b, \u5982\u679c24\u5c0f\u6642\u5c3f\u91cf , < 40 mL /kg,  \u5c3f\u6ef2\u900f\u58d3 > 300 mosm /L, \u61c9\u8a72\u5148\u6aa2\u67e5\u6ccc\u5c3f\u7cfb\n\u7d71\u662f\u5426\u6709\u7570\u5e38 \u3002\n(2) \u5982\u679c24\u5c0f\u6642\u5c3f\u91cf > 40 mL /kg,  \u5c3f\u6ef2\u900f\u58d3 < 300 mosm /L, basal plasma arginine vasopressin (AVP) < 1 \npg/mL, \u61c9\u8a72\u8003\u616e central DI \u6216 primary polydipsia \u3002\n(3) \u5982\u679c\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5\u986f\u793a\u5f8c\u8449\u6c92\u6709\u4eae\u9ede, \u53ef\u4ee5\u6392\u9664 central DI \u3002\n(4) \u75c5\u4eba\u7684\u5c3f\u6ef2\u900f\u58d3\u5728\u9650\u6c34 4\u5c0f\u6642\u5f8c, \u7531 250 mOsm /L \u4e0a\u5347\u70ba 400 mOsm /L, \u75c5\u4eba\u53ef\u80fd\u662f central DI \u3002\n(5) \u75c5\u4eba\u5728\u9650\u6c34 4\u5c0f\u6642\u4ee5\u5f8c, \u7d66\u4e88 desmopressin (DDAVP), \u5176\u5c3f\u6ef2\u900f\u58d3\u70ba 250 mOsm /L, \u75c5\u4eba\u53ef\u80fd\u662f \nnephrogenic DI \u3002   \nA.(1)+(2)+(4)\nB.(2)+(3)+(5)\nC.(1)+(2)+(5)\nD.(3)+(4)+(5)\nE.(2)+(4)\n": "[C]", "109-122.\u4e00\u4f4d35\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u70ba\u61f7\u7591\u6709\u5eab\u6b23\u6c0f\u75c7\u800c\u63a5\u53d7\u8166\u5782\u9ad4\u624b\u8853 \uff0c\u4f46\u958b\u5200\u4e09\u500b\u6708\u5f8c \uff0c\u6708\u4eae\u81c9\uff0c\u8179\u90e8\u7d2b\u8272\u6591\u7d0b \uff0c\u5026\n\u6020\uff0c\u4e0a\u80a2\u7121\u529b\u7b49\u75c7\u72c0\u5747\u672a\u6539\u5584 \uff0c\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u672a\u898b\u660e\u986f\u816b\u7624 \uff0c\u5979\u7684\u6aa2\u9a57\u7d50\u679c\u70ba cortisol (8am) 28 ug /dL, \n4pm 26 ug /dL, ACTH 96 pg /mL, K 2.8 mmol/L, LDH 864 U/L\u3002\u8acb\u554f\u54ea\u4e00\u9805\u6aa2\u67e5\u6216\u8655\u7f6e\u6700\u6070\u7576 \uff1f(\u53c3\u8003\u503c \ncortisol (8sm) 5 ~25 ug/dL, cortisol (4pm) 2.5 ~12.5 ug/dL, ACTH 7.4 ~ 57.3 pg/mL, K 3.5 ~5.1 mmol/L, \nLDH 140 ~271 U/L)   \nA.High dose dexamethasone suppression test\nB.\u8ffd\u8e64, \u4e09\u500b\u6708\u5f8c\u518d\u505a\u4e00\u6b21\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\nC.\u96d9\u5074infeiror petrosal sinus sampling\nD.\u80f8\u8179\u9aa8\u76c6\u8154\u96fb\u8166\u65b7\u5c64\nE.\u7533\u8acb\u5065\u4fdd\u7d66\u4ed8\uff0c \u4ee5 pasireotide \u6cbb\u7642   \n": "[D]", "109-123.\u4e00\u4f4d49\u6b72\u5973\u6027\u75c5\u4eba\u56e0\u70ba B\u578b\u809d\u708e\u5e36\u539f\u8ffd\u8e64\u8179\u90e8\u8d85\u97f3\u6ce2\u767c\u73fe\u6709\u53f3\u5074\u814e\u4e0a\u817a\u816b\u7624 \uff0c\u814e\u4e0a\u817a\u96fb\u8166\u65b7\u5c64\u986f\u793a\u816b\u7624\u5927\n\u5c0f\u70ba4\u516c\u5206\uff0c CT density \u70ba10 HU\u3002\u5979\u7684\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b \uff1acortisol (8am) 16.0 ug/dL, cortisol (4pm) 12.2 \nug/dL, ACTH 13 .7 pg/mL, aldosterone 18 ng /dL, plasma renin activity 0.95 ng/mL/hr, urine VMA 4.7 \nmg/24hr, urine dopamine 254 .5 ug/24 hr, urine epinephrine 9.3 ug/24hr, urine norepinephrine 83 .5 \nug/24hr\u3002\u8acb\u554f\u4ee5\u4e0b\u54ea\u4e00\u9805\u6558\u8ff0\u6b63\u78ba \uff1f(\u53c3\u8003\u503c; cortisol (8am) 5.0~25.0 ug/dL, cortisol (4pm) 2.5~12.5 \nug/dL, ACTH 7.4~57.3 pg/mL, plasma renin activity 1~5 ng/mL/hr, aldosterone 5~30 ng/dL, urine \ndopamine 50 ~450 ug/24 hr, urine epinephrine < 22 .4 ug/24hr, urine norepinephrine 12 .1~85.5 ug/24hr, \nurine VMA 1~7 mg/24hr)   \nA.\u7d55\u5927\u591a\u6578\u55ae\u5074\u814e\u4e0a\u817a\u816b\u7624\u70ba\u5206\u6ccccortisol\u7684\u826f\u6027\u816b\u7624\nB.\u6b64\u75c5\u4eba\u61c9\u8a72\u512a\u5148\u8003\u616eprimary aldosteronism\nC.\u4f7f\u7528\u5229\u5c3f\u5291\u6216\u4e09\u74b0\u6297\u6182\u9b31\u85e5\u7269\u53ef\u80fd\u5f15\u8d77urine catecholamine \u5047\u6027\u504f\u4f4e\nD.\u61c9\u8a72\u52a0\u6e2c17-hydroxyprogesterone \u53caDHEAS\nE.\u5efa\u8b70\u624b\u8853\u5207\u9664\u6b64\u814e\u4e0a\u817a\u816b\u7624\n": "[D]", "109-124.\u67d0\u4e9b\u975e\u7532\u72c0\u817a\u75be\u75c5 (nonthyroidal illness )\u53ef\u80fd\u9020\u6210\u7532\u4fc3\u7d20 (TSH)\u6216\u7532\u72c0\u817a\u8377\u723e\u8499\u6fc3\u5ea6\u7570\u5e38\u7684sick euthyroid \nsyndrome \u3002\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u4e0d\u6b63\u78ba \uff1f   \nA.\u7981\u98df\u53ef\u80fd\u5f71\u97ff5-deiodinase\u7684\u4f5c\u7528\uff0c\u4f7f T4 \u8b8a\u6210 rT3, \u9020\u6210 low T3 syndrome\nB.\u5982\u679c\u75c5\u4eba\u6709low T4, low T3, \u4ee3\u8868\u75c5\u60c5\u6975\u70ba\u56b4\u91cd\uff0c\u9810\u5f8c\u4e0d\u4f73\nC.\u6025\u6027\u809d\u75c5\u8b8a (acute liver disease) \u53ef\u80fd\u91cb\u653ethyroxine -binding globulin (TBG)\u800c\u4f7ftotal T 3\u53caT4 \u589e\n\u52a0\uff0c\u4f46unbound T 3\u53ca T4\u5247\u4e0d\u6703\u589e\u52a0\nD.\u4f7f\u7528dopamine \u6216 glucocorticoid \u6cbb\u7642\u53ef\u80fd\u4f7fTSH \u504f\u4f4e\nE.\u5728HIV\u611f\u67d3\u521d\u671f\uff0c\u5373\u4f7f\u75c5\u4eba\u6709\u9ad4\u91cd\u4e0b\u964d\uff0cT3 \u53caT4\u4ecd\u7136\u53ef\u80fd\u589e\u9ad8\n": "[A]", "109-125.\u4e00\u4f4d28\u6b72\u7537\u6027\u75c5\u4eba\u63a5\u53d7\u96d9\u5074\u7532\u72c0\u817a\u5168\u5207\u9664\u624b\u8853\uff0c \u5176\u75c5\u7406\u5831\u544a\u5982\u4e0b \uff1a\u5de6\u5074\u7532\u72c0\u817a\u6709 4*2.2*1.8 \u516c\u5206\u7532\u72c0\u817a\u4e73\n\u7a81\u764c\uff0c\u53f3\u5074\u7532\u72c0\u817a\u7121\u764c\u75c5\u8b8a \u3002\u5de6\u5074level II, III, IV\u6dcb\u5df4\u7d50\u5171\u5207\u966411 \u500b\uff0c\u5176\u4e2d5\u500b\u6709\u7532\u72c0\u817a\u4e73\u7a81\u764c\u8f49\u79fb \u3002\u8acb\u554f\n\u6709\u95dc\u9019\u4f4d\u75c5\u4eba\u7684\u8a3a\u65b7\u8207\u8655\u7f6e \uff0c\u54ea\u4e00\u9805\u6b63\u78ba \uff1f   \nA.\u4f9d\u64da\u7f8e\u570b\u806f\u5408\u764c\u75c7\u59d4\u54e1\u6703 (American Joint Commiottee on Cancer staging ), \u6b64\u75c5\u4eba\u70ba T2N1bMx, \nstage IVA\nB.\u75c5\u4eba\u7684\u518d\u767c\u98a8\u96aa\u9ad8\uff0c\u624b\u8853\u5f8c\u4e8c\u9031\u5167\u61c9\u8a72\u7d66\u4e88\u653e\u5c04\u6027\u7898(I -131)\u6cbb\u7642\nC.\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u524d \uff0c\u61c9\u8a72\u5148\u4ee5\u4f4e\u5291\u91cf (3mCi)\u653e\u5c04\u6027\u7898\u6383\u63cf \uff0c\u4ee5\u4e86\u89e3\u6b98\u9918\u7532\u72c0\u817a\u7d44\u7e54\u6709\u591a\u5c11\u4e26\u4f30\u7b97\u9069\n\u7576\u7684\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5291\u91cf\nD.\u75c5\u4eba\u5728\u63a5\u53d7\u653e\u5c04\u6027\u7898\u6cbb\u7642\u5f8c \uff0c\u61c9\u8a72\u88dc\u5145\u7532\u72c0\u817a\u7d20 \u4ee5\u7dad\u6301\u5176\u7532\u72c0\u817a\u529f\u80fd\u5728subclinical \nhyperthyroidism\u7684\u7bc4\u570d\nE.\u8840\u6e05\u4e2dthyroglobulin\u53ef\u505a\u70ba\u7532\u72c0\u817a\u764c\u8ffd\u8e64\u6307\u6a19\uff0c\u6700\u597d\u7dad\u6301\u572810 ng/ML \u4ee5\u4e0b (\u6b63\u5e38\u53c3\u8003\u503c< 55 ng/mL)\n": "[D]", "109-126.\u9ad8\u8840\u9223(hypercalcemia)\u7684\u9451\u5225\u8a3a\u65b7\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba\uff1f    \nA.Vitamin A intoxication\u53ef\u80fd\u9020\u6210\u526f\u7532\u72c0\u817a\u8377\u723e\u8499(PTH)\u4f4e\u7684\u9ad8\u8840\u9223\u75c7\nB.\u5982\u679c\u77ed\u671f\u6025\u6027\u51fa\u73fe\u9ad8\u8840\u9223\u75c7\u4e14PTH\u503c\u504f\u4f4e\uff0c\u61c9\u8a72\u5148\u8003\u616e\u60e1\u6027\u816b\u7624\nC.\u7d04\u6709 10% \u4ee5lithium \u6cbb\u7642 bipolar depression \u7684\u75c5\u4eba\u53ef\u80fd\u7522\u751f\u9ad8\u8840\u9223\u75c7\nD.Calcimimetics\u53ef\u4ee5\u4e0b\u964dPTH\u7684\u5206\u6ccc\uff0c\u964d\u4f4e\u8840\u9223, \u589e\u52a0\u9aa8\u5bc6\u5ea6\nE.\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u6216\u814e\u4e0a\u817a\u529f\u80fd\u4f4e\u4e0b\u90fd\u53ef\u80fd\u5f15\u8d77\u9ad8\u8840\u9223\u75c7\n": "[D]", "109-127.\u4e0b\u5217\u6709\u95dc\u9aa8\u8cea\u758f\u9b06(osteroporosis)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f       \nA.\u4ee5DXA\u6e2c\u91cf\u9aa8\u5bc6\u5ea6 (bone minearal density, BMD ), T-score\u662f\u8207\u76f8\u540c\u6027\u5225 \u3001\u76f8\u540c\u7a2e\u65cf \u3001\u76f8\u540c\u5e74\u7d00\u7684\u4eba\n\u505a\u6bd4\u8f03\nB.Klinefelter's syndrome\u6703\u589e\u52a0\u9aa8\u8cea\u758f\u9b06\u98a8\u96aa\nC.\u5982\u679c\u5176\u4ed6\u689d\u4ef6\u90fd\u76f8\u540c, \u9aa8\u5bc6\u5ea6 T-score <-2.5\u7684\u4eba\u767c\u751f\u9aa8\u6298\u7684\u98a8\u96aa \uff13\u500d\u65bcT-score \u4ecb\u65bc -1.0 \u53ca -2.5\u4e4b\u9593\n\u7684\u4eba\nD.\u4ee5 Fracture risk assessment tool (FRAX)\u4f30\u7b97\uff0c\u5982\u679c\u7236\u6bcd\u6709\u8170\u690e\u9aa8\u6298\u75c5\u53f2\uff0c\u5247\u9aa8\u6298\u98a8\u96aa\u6703\u589e\u52a0\nE.Denosumab\u53ef\u80fd\u589e\u52a0osteonecrosis of the jaw (ONJ)\u7684\u98a8\u96aa\uff0c\u4f46\u4e0d\u6703\u589e\u52a0atypical femur fracture\u7684\u98a8\n\u96aa\n": "[B]", "109-128.\u4e0b\u5217\u6709\u95dc\u7537\u6027\u5065\u5eb7\u7684\u8ad6\u8ff0\uff0c\u54ea\u4e00\u9805\u6b63\u78ba\uff1f    \nA.\u6210\u4eba\u7537\u6027\u8377\u723e\u8499testosterone \u6fc3\u5ea6\u96a8\u5e74\u7d00\u589e\u52a0\u800c\u4e0b\u964d\u7684\u901f\u5ea6\u8207\u9ad4\u91cd\u76f8\u95dc\uff0c\u80a5\u80d6\u8005\u4e0b\u964d\u901f\u5ea6\u8f03\u6162\nB.\u5e74\u8001\u8005\u7684 sex-hormone binding globulin (SHBG) \u6bd4\u5e74\u8f15\u4eba\u9ad8\nC.Total testosterone \u6fc3\u5ea6\u8207\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance )\u7121\u95dc\uff0c\u4f46bioavailable testosterone\u6fc3\u5ea6\u8d8a\u4f4e\n\u5247insulin resistance \u8d8a\u9ad8\nD.Testosterone \u6cbb\u7642\u53ef\u4ee5\u589e\u52a0\u8170\u690e\u53ca\u80a1\u9aa8\u7684\u9aa8\u5bc6\u5ea6\nE.\u524d\u5217\u817a\u764c(Prostate cancer)\u7684\u75c5\u4eba\u63a5\u53d7 androgen deprivation therapy \u53ef\u4ee5\u6e1b\u5c11\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\n": "[B]", "109-129.Medullary thyroid cancer (MTC) \u53ef\u4ee5\u8868\u73fe\u65bc\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia, MEN )\uff0c\u4ee5\n\u4e0b\u54ea\u4e00\u9805\u6b63\u78ba \uff1f   \nA.\u6709MTC\u5bb6\u65cf\u75c5\u53f2\u7684\u5e7c\u5152\uff0c\u6700\u597d\u57285\u6b72\u4ee5\u524d\u63a5\u53d7\u9810\u9632\u6027\u7684\u7532\u72c0\u817a\u5207\u9664\u624b\u8853\nB.MEN2A \u4e2d\u7684 MTC \u6bd4 MEN2B\u4e2d\u7684MTC \u66f4\u5177\u4fb5\u8972\u6027 (more aggressive)\nC.Calcitonin\u53ef\u4ee5\u7576\u4f5c MTC \u8853\u524d\u8a3a\u65b7\u53ca\u8853\u5f8c\u8ffd\u8e64\u7684tumor marker\nD.MTC\u8853\u5f8c\u518d\u767c\u9838\u90e8\u6dcb\u5df4\u817a\u8f49\u79fb\u61c9\u8a72\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\nE.MTC\u82e5\u6709\u9060\u90e8\u8f49\u79fb\uff0c\u517610\u5e74\u5b58\u6d3b\u7387\u7d04\u70ba 50%\n": "[C]", "109-130.\u8fd1\u5e74\u4f86\uff0c\u7cd6\u5c3f\u75c5\u4e4b\u65b0\u85e5\u767c\u5c55\u8fc5\u901f \uff0c\u5176\u4e2dSGLT2 inhibitor (\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\uff0csodium \nglucose co -transporter 2 inhibitor )\u5c6c\u65bc\u65b0\u6a5f\u8f49\u4e4b\u85e5\u7269 \u3002\u4e0b\u5217\u7684\u6709\u95dcSGLT2 inhibitor\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u4e4b\u57fa\u672c\u6a5f\u8f49\uff0c\u8207\u80f0\u5cf6\u7d20\u4e4b\u4f5c\u7528\u7121\u95dc\nB.\u5927\u578b\u7cd6\u5c3f\u75c5\u4e4b\u9810\u5f8c\u7814\u7a76\u7d50\u679c\u986f\u793a \uff0c\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u53ef\u4ee5\u6e1b\u5c11\u7cd6\u5c3f\u75c5\u60a3\u8005\u767c\u751f\u8166\u4e2d\n\u98a8\nC.\u76ee\u524d\u7684\u7814\u7a76\u7d50\u679c\u986f\u793a \uff0c\u6b64\u985e\u85e5\u7269\u81e8\u5e8a\u4e0a\u6700\u4ee4\u4eba\u64d4\u5fc3\u7684\u7cfb\u7d71\u6027\u526f\u4f5c\u7528\u70ba\u916e\u9178\u4e2d\u6bd2 (Ketoacidosis )\uff0c\u5176\u81f4\n\u75c5\u6a5f\u8f49\u63a8\u8ad6\u8207\u672c\u9805\u85e5\u7269\u4f7f\u7528\u4e4b\u5f8c \uff0c\u6703\u589e\u52a0\u75c5\u60a3\u8840\u4e2d\u6607\u7cd6\u6fc0\u7d20 (glucagon )\u4e4b\u6fc3\u5ea6\nD.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u4f7f\u7528\u5f8c\u4e4b\u9ad4\u91cd\u6e1b\u8f15\u73fe\u8c61 \uff0c\u4e3b\u8981\u7684\u539f\u56e0\u4f86\u81ea\u65bc\u672c\u9805\u85e5\u54c1\u53ef\u5c07\u8840\u4e2d\u8461\n\u8404\u7cd6\u6392\u9664\u65bc\u5c3f\u6db2\u4e2d\nE.\u9209-\u8461\u8404\u7cd6\u5354\u540c\u8f49\u904b\u86cb\u767d\u8cea 2\u6291\u5236\u5291\u7684\u7814\u7a76\u767c\u73fe \uff0c\u672c\u9805\u85e5\u7269\u53ef\u4ee5\u6539\u5584\u86cb\u767d\u5c3f\u7684\u73fe\u8c61 \uff0c\u5177\u6709\u5ef6\u7de9\u7cd6\u5c3f\u75c5\n\u814e\u75c5\u8b8a\u7684\u85e5\u7406\u6548\u61c9\n": "[B]", "109-131.\u53f0\u7063\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u4eba\u53e3 \uff0c\u96a8\u8457\u5e73\u5747\u58fd\u547d\u4e4b\u5ef6\u9577 \uff0c\u5448\u73fe\u5feb\u901f\u589e\u52a0\u7684\u73fe\u8c61 \uff0c\u5176\u4e2d\u7cd6\u5c3f\u75c5\u814e\u81df\u7167\u8b77 \uff0c\u5fc5\u9808\u91cd\n\u8996\uff0c\u4e0b\u5217\u6709\u95dc\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u814e\u81df\u7167\u8b77\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4 \uff1f   \nA.\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u814e\u81df\u75c5\u8b8a\u6642 \uff0c\u75c5\u60a3\u8ca7\u8840\u7684\u7a0b\u5ea6 \u3001\u5de6\u5fc3\u5ba4\u80a5\u5927\u73fe\u8c61 \u3001\u5fc3\u8840\u7ba1\u75be\u75c5\u767c\u751f\u7387\u53ca\u6b7b\u4ea1\u7387\u4e4b\u9593 \uff0c\u5448\n\u73fe\u7d71\u8a08\u5b78\u4e0a\u986f\u8457\u7684\u76f8\u95dc\u6027\nB.\u96d6\u7136\u7cd6\u5c3f\u63a7\u5236\u6307\u6a19\u7cd6\u5316\u8840\u8272\u7d20 (HbA1c) \u4e00\u822c\u5efa\u8b70\u7684\u6a19\u7684\u662f 7%\uff0c\u4f46\u662f\u91dd\u5c0d\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5 \uff0c\u5408\u4f75\u814e\u75c5\u8b8a\n\u6642\uff0c\u9700\u8003\u616e\u75c5\u60a3\u4e4b\u8eab\u9ad4\u5065\u5eb7\u72c0\u6cc1\u53ca\u6d3b\u52d5\u80fd\u529b \uff0c\u76ee\u524d\u8001\u5e74\u7cd6\u5c3f\u75c5\u7167\u8b77\u4e4b\u5efa\u8b70 \uff0c\u91dd\u5c0d\u6d3b\u52d5\u529b\u8f03\u5dee\u4e4b\u60a3\n\u8005\uff0c\u63a7\u5236\u6a19\u7684\u70baHbA 1c < 8 %   \nC.\u8001\u5e74\u6027\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u63a5\u53d7\u5fc3\u5c0e\u7ba1\u6216\u5176\u4ed6\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642 \uff0c\u986f\u5f71\u5291\u53ef\u80fd\u662f\u9020\u6210\u814e\u81df\u529f\u80fd\u6025\u901f\u60e1\u5316\u7684\u539f\u56e0\u4e4b\n\u4e00\nD.\u76ee\u524d\u5df2\u77e5\u7684\u5927\u578b\u81e8\u5e8a\u7814\u7a76\u5747\u986f\u793a \uff0c\u70ba\u4e86\u964d\u4f4e\u5fc3\u8840\u7ba1\u6b7b\u4ea1 \uff0c\u4ee5\u53ca\u9810\u9632\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u767c\u751f \uff0c\u5728\u75c5\u60a3\u814e\u529f\u80fd\u7121\n\u865e\u7684\u524d\u63d0\u4e0b \uff0c\u5e74\u7d00\u6108\u9577\u7684\u7cd6\u5c3f\u75c5\u60a3 \uff0c\u61c9\u5c07HbA 1c\u63a7\u5236< 6.5%\u4ee5\u4e0b\uff0c\u624d\u662f\u9577\u671f\u7684\u91ab\u7642\u6a21\u5f0f\nE.\u8001\u5e74\u7cd6\u5c3f\u75c5, \u60a3\u814e\u529f\u80fd\u4e0d\u4f73\u6642, \u78fa\u8132\u985e\u85e5\u7269(Sulfonylureas)\u4e4b\u4f7f\u7528, \u53ef\u80fd\u662f\u4f4e\u8840\u7cd6\u7684\u91cd\u8981\u539f\u56e0\u4e4b\u4e00\n": "[D]", "109-132.\u5f35\u8001\u5e2b\uff0c48\u6b72 \uff0c\u8eab\u9ad8173\u516c\u5206 \uff0c\u9ad4\u91cd90\u516c\u65a4 \uff0c\u6700\u8fd1\u5169\u5e74 \uff0c\u9ad4\u91cd\u81ea75\u516c\u65a4\u589e\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd \u3002\u7121\u500b\u4eba\u6216\u5bb6\n\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2 \u3002\u6700\u8fd1\u5e7e\u5e74 \uff0c\u597d\u5e7e\u6b21\u5728\u6e05\u6668\u4e0a\u73ed\u6216\u4e0a\u8ab2\u4e2d\u660f\u5012 \uff0c\u660f\u5012\u6642\u610f\u8b58\u4e0d\u6e05 \uff0c\u66fe\u65bc\u8f49\u9001\u6025\u8a3a\u5f8c \uff0c\u767c\u73fe\u8840\n\u7cd6\u503c\u70ba28mg /dL\uff0c\u5728\u6ce8\u5c0450 %\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \u3002\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5 \u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\n\u4e0d\u6e05\uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba38 mg /dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\n\u7570\u5e38\u75c7\u72c0 \uff0c\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0 \u3002\u56de\u9580\u8a3a\u8ffd\u8e64\u6642 \uff0c\u5728\u63a5\u53d7\u4efb\u4f55\u8f38\u6db2\u4e0b \uff0c\u7a7a\u8179\u8840\u7cd6\u70ba 98 \nmg/dL\uff0c\u6e05\u66688\u9ede\u6642\u4e4bACTH  42 .2 pg/mL, Cortisol 21 .8 ug/dL, \u7a7a\u8179\u4e4bInsulin \u70ba  2.12  mIU/mL, \nC-peptide\u70ba 1.40 ng/mL, \u7532\u72c0\u817a\u529f\u80fd\u7be9\u6aa2TSH\u70ba 4.20 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5 \uff1f   \nA.\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\nB.72 \u5c0f\u6642\u4e4b Prolonged fasting test (\u5ef6\u9577\u98e2\u9913\u6e2c\u8a66)\nC.75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57 (Oral glucose tolerance test)\nD.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\nE.Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\n": "[B]", "109-133.\u7d71\u8a08\u4e0a\uff0c\u53f0\u7063\u76ee\u524d\u7b2c\u4e8c\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u9054230\u842c\u4eba \uff0c\u9664\u4e86\u751f\u6d3b\u578b\u614b \u3001\u98f2\u98df\u53ca\u904b\u52d5\u4f86\u9810\u9632\u4e4b\u5916 \uff0c\u4e00\u65e6\u78ba\u8a3a\u70ba\u7cd6\n\u5c3f\u75c5\u4e4b\u5f8c \uff0c\u85e5\u7269\u6cbb\u7642\u4e5f\u662f\u975e\u5e38\u91cd\u8981\u7684\u4e00\u74b0 \u3002\u4ee5\u4e0b\u6709\u95dc\u7cd6\u5c3f\u75c5\u4e4b\u6558\u8ff0 \uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684 \uff1f\n(1) Biguanide \u4e4bMetformin\u662f\u53f0\u7063\u53ca\u7f8e\u570b\u5efa\u8b70\u7cd6\u5c3f\u75c5\u6cbb\u7642\u7684\u7b2c\u4e00\u7dda\u7528\u85e5\n(2) \u76ee\u524d\u570b\u5167\u53ca\u7f8e\u570b\u7cd6\u5c3f\u75c5\u5b78\u6703\u4e4b\u5efa\u8b70 \uff0cHbA1c (\u7cd6\u5316\u8840\u7d05\u7d20 )\u4e4b\u63a7\u5236\u76ee\u6a19\u61c9\u8a72\u70ba 6 % \u4ee5\u4e0b \n(3) Sulphonylurea\u985e\u85e5\u7269 \uff0c\u5bb9\u6613\u9020\u6210\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 \n(4) \u80f0\u5cf6\u7d20\u96d6\u7136\u53ef\u4ee5\u8fc5\u901f\u964d\u4f4e\u8840\u7cd6 \uff0c\u4f46\u9577\u671f\u4f7f\u7528\u6642 \uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 \n(5) \u65b0\u578b\u4e4b\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269 \uff0c\u5982DPP-4 inhibitor \u53caSGLT-2 inhibitor \uff0c\u9664\u4e86\u964d\u4f4e\u8840\u7cd6\u4e4b\u5916 \uff0c\u4e5f\u6709\u6e1b\u8f15\u7cd6\u5c3f\u75c5\n\u60a3\u9ad4\u91cd\u7684\u85e5\u7406\u6548\u61c9   \nA.(1)+(2)\nB.(2)+(5)\nC.(3)+(4)\nD.(2)+(4)\nE.(4)+(5)\n": "[B]", "109-134.2020\u5e74\u4e4bCovid -19 \u65b0\u578b\u51a0\u72c0\u75c5\u6bd2\u7684\u8086\u8650 \uff0c\u5c0d\u65bc\u7cd6\u5c3f\u75c5\u60a3\u800c\u8a00 \uff0c\u5728\u7d71\u8a08\u5b78\u4e0a \uff0c\u986f\u7136\u662f\u91cd\u5927\u7684\u96b1\u6182 \uff0c\u56e0\u70ba\u7cd6\n\u5c3f\u75c5\u60a3\u7f79\u60a3\u65b0\u51a0\u80ba\u708e \uff0c\u7522\u751f\u4f75\u767c\u75c7\u5f8c\u4e4b\u6b7b\u4ea1\u7387 \uff0c\u660e\u986f\u9ad8\u65bc\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005 \u3002\u4f9d\u71672020\u4e0a\u534a\u5e74\u4e4b\u7814\u7a76\u5831\n\u544a\uff0c\u4e0b\u5217\u6709\u95dc\u4e4b\u56e0\u5b50\u4e2d\u4f55\u8005 \uff0c\u4e26\u975e\u78ba\u8a8d\u4e4b\u75be\u75c5\u60e1\u5316\u98a8\u96aa\u56e0\u5b50 \uff1f   \nA.\u5e74\u9f61\u6108\u5927\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005 (Aging)\nB.\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u5408\u4f75\u9ad8\u8840\u58d3 \uff0c\u5728\u7f79\u60a3\u65b0\u51a0\u80ba\u708e\u524d \uff0c\u5373\u5df2\u4f7f\u7528angiotensin -converting enzyme inhibitor \n(ACEI) \u6216 Angiotnensin receptor blocker (ARB)\uff0c\u63a7\u5236\u9ad8\u8840\u58d3\u8005\nC.\u539f\u672c\u5373\u5df2\u7f79\u60a3\u78ba\u8a3a\u4e4b\u5fc3\u81df\u8840\u7ba1\u75be\u75c5(ASCVD, atherosclerotic cardiovascular disease) \u8005\nD.Body mass index (BMI) \u504f\u9ad8\u4e4b\u80a5\u80d6\u7cd6\u5c3f\u75c5\u60a3\u8005 (Obesity)\nE.\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005 (Type 1 diabetes mellitus)   \n": "[B]", "109-135.\u8fd1\u5e74\u4e4b\u7814\u7a76\u986f\u793a\u61f7\u5b55\u8207\u7cd6\u5c3f\u75c5\u4e4b\u95dc\u4fc2\u91d0\u6e05 \uff0c\u662f\u5b89\u5168\u6210\u529f\u751f\u80b2\u7684\u95dc\u9375\u56e0\u5b50\u4e4b\u4e00 \u3002\u5b55\u524d\u672a\u8a3a\u65b7\u7cd6\u5c3f\u4e4b\u5a66\u5973 \uff0c\u61f7\n\u5b55\u6642\u7522\u751f\u4e4b\u8840\u7cd6\u7570\u5e38\u70ba\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5 \uff0c\u96d6\u7136\u7522\u5f8c\u5927\u591a\u6578\u4e4b\u5a66\u5973 \uff0c\u8840\u7cd6\u90fd\u53ef\u4ee5\u6062\u5fa9\u5230\u6b63\u5e38\u7bc4\u570d\u4e4b\u5167 \uff0c\u4f46\u4ecd\n\u670935-60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973 \uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\u60a3 \u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\n\u76f8\u95dc\u6558\u8ff0 \uff0c\u90a3\u4e00\u4e9b\u662f\u932f\u8aa4\u7684 \uff1f\n(1) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe \uff0c\u4e3b\u8981\u8207\u60a3\u8005\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3 (insulin deficiency) \u76f8\u95dc\n(2) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2 \uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\u5bc6\u5207\u76f8\u95dc \n(3) \u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5728\u61f7\u5b55\u4e4b\u5f8c\u671f\u5b55\u671f\u6642 (late pregnancy )\uff0c\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u6703\u660e\u986f\u964d\u4f4e \uff0c\u8840\u7cd6\u6bd4\u8f03\u5bb9\u6613\u63a7\u5236 \n(4) \u5728\u61f7\u5b55\u671f\u9593 \uff0c\u521d\u6b21\u767c\u73fe\u4e4b\u8840\u7cd6\u7570\u5e38 \uff0c\u5982\u679c\u7b26\u5408\u7cd6\u5c3f\u75c5\u4e4b\u8a3a\u65b7 \uff0c\u61c9\u6b78\u985e\u65bc\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5 (overt diabetes )   \nA.(1)+(2)\nB.(2)+(4)\nC.(2)+(3)\nD.(1)+(4)\nE.(1)+(3)\n": "[E]", "109-136.\u9673\u5976\u5976\uff0c78\u6b72\uff0c\u53ef\u81ea\u7531\u6d3b\u52d5 \uff0c\u4e3b\u8981\u7167\u8b77\u8005\u70ba\u5bb6\u4eba \uff0c\u540c\u4f4f\u3002\u6578\u6b21\u56e0\u80ba\u708e\u6216\u6ccc\u5c3f\u9053\u611f\u67d3\u4f4f\u9662\u6cbb\u7642 \uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\n\u5df210\u5e74\u3002\u76ee\u524d\u63a5\u53d7\u53e3\u670d\u85e5\u7269\u63a7\u5236\u8840\u7cd6 \uff0c\u4f46\u672a\u898f\u5f8b\u56de\u8a3a\u8ffd\u8e64\u6025\u7be9\u6aa2\u4f75\u767c\u75c7 \u3002\u672c\u6b21\u56e0\u80ba\u708e\u4f4f\u9662 \uff0c\u6297\u751f\u7d20\u4f7f\n\u75285\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a \uff0c\u9810\u8a082\u5929\u5f8c\u51fa\u9662 \u3002\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a \uff0c\u5165\u9662\u96a8\u6a5f\u4e4bHbA 1c \u70ba 9.5 %\uff0c\u4f4f\u9662\u4e4b\u7b2c\n\u4e94\u5929\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba220 mg /dL\uff0c\u7576\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u4e4b\u8840\u7cd6\u70ba268 mg /dL\uff0c\u808c\u9178\u9150\u70ba 0.9 mg/dL\u3002\u96d6\u7136\u76ee\n\u524d\u7121\u660e\u986f\u591a\u5c3f\u6216\u5176\u4ed6\u4e0d\u9069\u75c7\u72c0 \u3002\u5c31\u75c5\u7a0b\u767c\u5c55\u800c\u8a00 \uff0c\u4e0b\u5217\u6709\u95dc\u6cbb\u7642\u5b89\u6392\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u5c31\u4f4f\u9662\u8840\u7cd6\u8b8a\u5316\uff0c\u61c9\u5efa\u8b70\u81f3\u5c11\u52a0\u5165basal Insulin\u91dd\u5291\u985e(\u57fa\u790e\u80f0\u5cf6\u7d20)\u85e5\u7269\u6cbb\u7642\nB.\u5efa\u8b70\u5118\u65e9\u5b89\u6392\u7cd6\u5c3f\u75c5\u8996\u7db2\u819c\u53ca\u8db3\u90e8\u795e\u7d93\u5b78\u6aa2\u67e5\nC.\u5efa\u8b70\u61c9\u5b89\u6392\u7cd6\u5c3f\u75c5\u98f2\u98df\u53ca\u904b\u52d5\u885b\u6559\nD.\u672a\u4f86\u7cd6\u5c3f\u75c5HbA1c\u6307\u6a19\uff0c\u63a7\u5236\u6a19\u7684\u70ba < 6.5 % \u4ee5\u4e0b\nE.\u5efa\u8b70\u75c5\u60a3\u672a\u4f86\u61c9\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\n": "[D]", "109-137.\u4e0d\u8ad6\u7cd6\u5c3f\u75c5\u6216\u975e\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u6839\u6e90\u5728\u65bc\u80f0\u5cf6\u7d20\u963b\u6297\u6027 (Insulin resistance) \u53ca \u8102\u86cb\u767d \n(lipoprotein )\u7684\u4ee3\u8b1d\u7570\u5e38 \uff0c\u4e00\u822c\u5e38\u898b\u7684\u75be\u75c5\u72c0\u614b\u70ba\u81bd\u56fa\u9187 /\u4e09\u9178\u7518\u6cb9\u916f (TG)\u589e\u52a0\uff0c\u9ad8\u5bc6\u5ea6\u8102\u86cb\u767d (HDL)\u6e1b\u5c11\n\u76f8\u95dc\uff0c\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684 \uff1f   \nA.\u8840\u8102\u7570\u5e38\u6642 \uff0c\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL & VLDL )\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50 \uff0c\u591a\u8207\u80a5\u80d6 \u3001\u80f0\u5cf6\u7d20\n\u963b\u6297\u53ca\u907a\u50b3\u76f8\u95dc \uff0c\u56e0\u6b64\u80a5\u80d6\u60a3\u8005 \uff0c\u5728\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u5f8c \uff0c\u76f8\u95dc\u6aa2\u67e5\u6578\u503c\u90fd\u6703\u6539\u5584\nB.\u907a\u50b3\u56e0\u5b50(genetic predisposition)\u53ca\u74b0\u5883\u56e0\u7d20(environmental contribution)\u6703\u540c\u6642\u5f71\u97ff\u75c5\u60a3\u8840\u8102\u4e4b\u8b8a\u5316\nC.\u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u7d93\u5e38\u662fTG\u589e\u52a0\uff0c\u4f46\u662fHDL \u964d\u4f4e\nD.\u9577\u671f\u651d\u53d6\u9ad8\u71b1\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152 \uff0c\u5176\u8840\u8102\u7570\u5e38\u53ef\u767c\u73fe\u70ba\u589e\u52a0VLDL \u53caTG\uff0c\u4f46\u662f\u964d\u4f4eHDL\u4e4b\u8840\n\u4e2d\u6fc3\u5ea6\nE.\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u6642\uff0c\u75c5\u60a3\u4e4bLDL\u589e\u52a0 \uff0c\u56e0\u70ba\u539f\u672c\u7532\u72c0\u817a\u7d20\u53ef\u589e\u52a0\u809d\u81df\u4e4bLDL \u53d7\n\u5668\uff0c\u964d\u4f4e\u8840\u4e2d\u4e4bLDL \uff0c\u4f46\u7532\u72c0\u817a\u7d20\u4e0d\u8db3\u6642 \uff0c\u8840\u4e2d\u4e4bLDL\u4e4b\u6e05\u9664\u6548\u7387\u4e5f\u6703\u660e\u986f\u4e0b\u964d\n": "[D]", "109-138.\u80f0\u5cf6\u7d20\u662f\u6cbb\u7642\u7cd6\u5c3f\u75c5 \uff0c\u63a7\u5236\u8840\u7cd6\u7684\u91cd\u8981\u91dd\u5291\u85e5\u7269 \uff0c\u4ee5\u4e0b\u6709\u95dc\u80f0\u5cf6\u7d20\u6cbb\u7642\u7684\u8aaa\u660e\u53ca\u5176\u751f\u7406\u6a5f\u8f49 \uff0c\u4f55\u8005\u662f\u6b63\u78ba\n\u7684\uff1f   \nA.\u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00 \uff0c\u6bd4\u8f03\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u57fa\u790e\u80f0\u5cf6\u7d20 (basal \ninsulin)\nB.\u5982\u679c\u9700\u8981\u7a4d\u6975\u63a7\u5236\u8840\u7cd6\u6642 \uff0c\u591a\u6b21\u80f0\u5cf6\u7d20\u6ce8\u5c04 \uff0c\u662f\u9054\u6210\u63a7\u5236\u6a19\u7684\u7684\u91cd\u8981\u65b9\u6cd5 \uff0c\u4f46\u662f\u9700\u8981\u914d\u5408\u66f4\u983b\u7e41\u4e4b\u81ea\n\u6211\u8840\u7cd6\u76e3\u6e2c \uff0c\u672a\u4f86\u7684\u8da8\u52e2\u662f\u9023\u7e8c\u8840\u7cd6\u5075\u6e2c\u6a21\u5f0f (continuous glucose monitoring )   \nC.\u8eab\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u76f4\u63a5\u5206\u6ccc\u9032\u5165\u809d\u975c\u8108\u7cfb\u7d71 \uff0c\u4f46\u662f\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u5247\u5728\u6ce8\u5c04\u5f8c\n\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0 \uff0c\u56e0\u6b64\u6ce8\u5c04\u4e4b\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u6642 \uff0c\u8f03\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\u9ad8 \uff0c\u5c6c\n\u65bcsupraphysiologic insulin level \u3002\nD.\u5c31\u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u4e4b\u60a3\u8005\u800c\u8a00 \uff0c\u6bcf\u5929\u9700\u8981\u4e4b\u80f0\u5cf6\u7d20\u6ce8\u5c04\u7e3d\u91cf \uff0c\u4e00\u822c\u5728 1.5 - 2.0 \u55ae\u4f4d/\u6bcf\u516c\u65a4/\u6bcf\u5929 \n(unit/kg/day) \u5de6\u53f3\nE.GLP-1 RA (Glucgon like peptide -1 receptor agonist) \u662f\u4e00\u7a2e\u57fa\u790e\u80f0\u5cf6\u7d20 \uff0c\u4f46\u662f\u537b\u6c92\u6709\u50b3\u7d71\u80f0\u5cf6\u7d20\u6703\n\u589e\u52a0\u75c5\u60a3\u9ad4\u91cd\u7684\u526f\u4f5c\u7528\n": "[B]", "109-139.\u4f9d\u7167 2017\u53f0\u7063\u9ad8\u5371\u96aa\u75c5\u60a3\u8840\u8102\u6cbb\u7642\u6307\u5f15 \uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u4ee5\u751f\u6d3b\u578b\u614b\u53ca\u85e5\u7269\u6cbb\u7642\u70ba\u57fa\u672c\u6a19\u7684 \uff0c\u4e0b\u5217\u6558\u8ff0 \uff0c\u4f55\n\u8005\u70ba\u932f\u8aa4\u7684 \uff1f   \nA.\u7cd6\u5c3f\u75c5\u60a3\u8005\u5408\u4f75\u6025\u6027\u51a0\u72c0\u52d5\u8108\u75c7\u5019\u7fa4 (acute coronary syndrome )\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\n\u7684\u70ba < 55 mg /dL\nB.\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad8\u81bd\u56fa\u9187\u8840\u75c7\u63a7\u5236\u4e4b\u5efa\u8b70\u9996\u9078\u85e5\u7269\u70baStatins\nC.\u7cd6\u5c3f\u75c5\u60a3\u8005\u5408\u4f75\u5fc3\u8840\u7ba1\u75be\u75c5\u98a8\u96aa\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\u7684\u70ba < 70 mg/dL\nD.40\u6b72\u4ee5\u4e0a\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0c\u5728\u7121\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2\u6642\uff0c\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\u7684\u63a7\u5236\u6a19\u7684\u70ba < 100 mg/dL\nE.\u4e00\u822c\u63a7\u5236\u539f\u5247 \uff0c40\u6b72\u4ee5\u4e0b\u4e4b\u7cd6\u5c3f\u75c5\u60a3\u8005 \uff0c\u7121\u8ad6\u662f\u5426\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2 \uff0c\u5747\u4e0d\u5b9c\u4f7f\u7528Statins\u985e\u85e5\u7269\u63a7\n\u5236\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d (LDL-C)\n": "[E]", "110-97.81\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u6709\u9ad8\u8840\u58d3\u53ca\u7cd6\u5c3f\u75c5\u75c5\u53f2 \u3002\u56e0\u610f\u8b58\u4e0d\u6e05\u88ab\u9001\u81f3\u6025\u8a3a \uff0c\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u986f\u793a\u6709\u8166\u4e0b\u5782\u9ad4\u816b\u7624 \uff0c\u62bd\n\u8840\u6aa2\u67e5\u986f\u793a: \u8840\u9209126 mmol /L\u3001\u8840\u92404.1 mmol/L\u3001\u8840\u7cd6126 mg /dL\u3001fT4 0.78 ng/dL\u3001hsTSH 4.59 \n\u00b5IU/mL\u3001cortisol (8 am) 18 .9 \u03bcg/dL\u3001ACTH 7.5 pg/mL\u3001LH 0.67 mIU/mL\u3001FSH 7.2 mIU/mL\u3001GH 0.19 \nng/mL\u3001IGF-1 60.3 ng/mL\u3001prolactin 56 .3 ng/mL \u3002\u4e0b\u5217\u54ea\u4e00\u500b\u63cf\u8ff0\u6700\u6b63\u78ba ?\n\uff08\u53c3\u8003\u503c\uff1afT4 0.93~1.70 ng/dL\u3001hsTSH 0.27~4.20 \u00b5IU/mL\u3001cortisol: 8 am 5.27~22.45 \u03bcg/dL\u3001ACTH: \n7.9~47.1 pg/mL\u3001GH 0.01-3.61 ng/mL\u3001prolactin 1.8-20.3 ng/mL\u3001LH (\u505c\u7d93\u5f8c)15.9-54.0 mIU/mL\u3001FSH \n(\u505c\u7d93\u5f8c) 23 .0-116.3 mIU/mL\u3001IGF-1 30.6-208 ng/mL\uff09\u3002\n(1)\u75c5\u4eba\u7684TSH \u8f03\u53c3\u8003\u503c\u9ad8 \uff0c\u61c9\u8a72\u8003\u616eTSHoma\u3002 \n(2)\u75c5\u4eba\u7684prolactin \u8f03\u53c3\u8003\u503c\u9ad8 \uff0c\u61c9\u8a72\u8a3a\u65b7\u70baprolactinoma .\n(3)\u75c5\u4eba\u7684LH \u53caFSH \u8f03\u53c3\u8003\u503c\u4f4e \uff0c\u61c9\u8a72\u8003\u616e\u6709hypopituitarism \u3002\n(4)\u61c9\u8a72\u5148\u7d66\u4e88\u985e\u56fa\u9187\u6cbb\u7642 \u3002\n(5)\u61c9\u8a72\u5148\u7d66\u4e88\u7532\u72c0\u817a\u7d20\u6cbb\u7642 \u3002   \nA.1\u3002\nB.2\u3002\nC.3\u3002\nD.(3)+(4)\u3002\nE.(2)+(5)\u3002\n": "[D]", "110-98.\u4e0b\u5217\u54ea\u4e00\u9805\u6709\u95dc\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u7684\u63cf\u8ff0\u6700\u6b63\u78ba \uff1f\n(1)\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u662f\u6700\u5e38\u898b\u7684\u8166\u4e0b\u5782\u9ad4\u816b\u7624 \uff0c\u7d04\u4f54\u6709\u529f\u80fd\u7684\u8166\u4e0b\u5782\u9ad4\u816b\u7624 (functioning pituitary \ntumor)\u768470%\u4ee5\u4e0a\u3002 \n(2)\u8166\u4e0b\u5782\u9ad4\u816b\u7624\u53ef\u80fd\u540c\u6642\u5206\u6ccc\u5169\u7a2e\u4ee5\u4e0a\u7684\u8377\u723e\u8499 \uff0c\u4f8b\u5982: GH\u53ca prolactin (PRL), ACTH\u53ca PRL, TSH\u53ca \nPRL\u7b49\u3002\n(3)\u5c0f\u65bc1\u516c\u5206\u7684\u6ccc\u4e73\u6fc0\u7d20\u7624 \uff0c\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba 1:20\uff1b\u5927\u65bc1\u516c\u5206\u7684\u6ccc\u4e73\u6fc0\u7d20\u7624\u7537\u5973\u6bd4\u4f8b\u7d04\u70ba 2:1\u3002\n(4)\u8840\u4e2d\u6ccc\u4e73\u6fc0\u7d20\u6fc3\u5ea6\u901a\u5e38\u8207\u6ccc\u4e73\u6fc0\u7d20\u816b\u7624\u5927\u5c0f\u6210\u6b63\u76f8\u95dc \uff0cPRL> 250 \u03bcg/L \u901a\u5e38\u5176\u816b\u7624\u5927\u65bc 1\u516c\u5206 \u3002\n(5)\u6709\u6ccc\u4e73\u6fc0\u7d20\u7624\u7684\u5a66\u5973\u82e5\u8003\u616e\u61f7\u5b55 \uff0c\u61c9\u4f7f\u7528cabergoline\u6cbb\u7642 \u3002   \nA.(1)+(2)+(4)\u3002\nB.(2)+(3)+(5)\u3002\nC.(1)+(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(2)+(4)\u3002   \n": "[E]", "110-99.\u6709\u95dc\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u7684\u8a3a\u65b7\u53ca\u6cbb\u7642 \uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba ?\n(1)\u6297\u7532\u72c0\u817a\u85e5\u7269\u53ef\u80fd\u901a\u904e\u80ce\u76e4\u5f71\u97ff\u80ce\u5152\u767c\u80b2 \u3002\n(2)\u54fa\u4e73\u671f\u7d55\u5c0d\u7981\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 \u3002\n(3)\u4ee5carbimazole \u6cbb\u7642\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032 \uff0c\u82e5\u6b32\u7d66\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642 \uff0c\u5728\u7d66\u4e88\u653e\u5c04\u6027\u7898\u524d 2-3\u5929\u61c9\u5148\u66ab\n\u505ccarbimazole \uff0c\u82e5\u6709\u9700\u8981 \uff0c\u5728\u7d66\u4e88\u653e\u5c04\u6027\u7898 3-7\u5929\u5f8c\u518d\u7d66\u4e88carbimazole \u3002\u4f7f\u7528propylthiouracil \u5f8c\u82e5\u8981\u7d66\n\u4e88\u653e\u5c04\u6027\u7898\u6cbb\u7642 \uff0c\u5247\u53ef\u4ee5\u4e0d\u9700\u8981\u505c\u7528propylthiouracil \u3002\n(4)\u75c5\u4eba\u5982\u679c\u6709\u7532\u72c0\u817a\u6bd2\u75c7 (thyrotoxicosis )\u7684\u81e8\u5e8a\u8868\u73fe \uff0c\u5176TSH\u504f\u4f4e\u4f46fT 4\u6b63\u5e38\uff0c\u61c9\u8a72\u6aa2\u6e2cfT 3\u4ee5\u78ba\u5b9a\u662f\u5426\u70ba \nT3 toxicosis \u3002\n(5)fT4 \u9ad8\u3001TSH \u6b63\u5e38\u6216\u9ad8 \uff0c\u9808\u8003\u616eTSH -secreting pituitary adenoma \u6216\u7532\u72c0\u817a\u8377\u723e\u8499\u62ee\u6297\u75c7\u5019\u7fa4 (thyroid \nhormone resistance syndrome )\u3002   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(2)+(3)+(4)\u3002\n": "[D]", "110-100.\u4e00\u4f4d58\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u6709\u7cd6\u5c3f\u75c5 \u3001\u9ad8\u8840\u58d3\u53ca\u9aa8\u8cea\u758f\u9b06\u75c5\u53f2 \u3002\u5979\u6709\u76ae\u4e0b\u7600\u9752 \u3001\u8179\u90e8\u7d2b\u8272\u6591\u7d0b \u3002\u6aa2\u9a57\u767c\u73fe\u76ae\u8cea\n\u9187\uff08cortisol\uff098 am 20.86 \u03bcg/dL\u30014 pm 20.97 \u03bcg/dL\uff1b\u814e\u4e0a\u817a\u76ae\u8cea\u6fc0\u7d20 \uff08ACTH\uff098 am <5 pg/mL\uff0c\u96fb\u8166\n\u65b7\u5c64\u986f\u793a\u5de6\u5074\u814e\u4e0a\u817a\u6709 3.3\u516c\u5206\u7684\u816b\u7624 \uff0c\u5982\u679c\u5b89\u6392\u5de6\u5074\u814e\u4e0a\u817a\u5207\u9664 \uff0c\u4e0b\u5217\u54ea\u4e00\u500b\u63cf\u8ff0\u6700\u9069\u7576 \uff1f\n(\u53c3\u8003\u503c: cortisol: 8 am 5.77~22.45 \u03bcg/dL\u30014 pm 3.44-16.9 \u03bcg/dL ; ACTH; 7.9~47.1 pg/mL )   \nA.\u6b64\u75c5\u4eba\u8853\u524d\u7684cortisol\u6c92\u6709\u589e\u9ad8\uff0c\u56e0\u6b64\u5de6\u5074\u814e\u4e0a\u817a\u5207\u9664\u8853\u5f8c\u4e0d\u9808\u7d66\u4e88hydrocortisone\u3002\nB.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u53ef\u80fd\u589e\u52a0\u6df1\u90e8\u975c\u8108\u6813\u585e\u6216\u80ba\u6813\u585e\u7684\u98a8\u96aa\u3002\nC.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u5728\u7d66\u4e88\u9069\u7576\u7684\u6cbb\u7642\u5f8c \uff0chypothalamus -pituitary-adrenal (HPA) axis\u6062\u5fa9\u6b63\u5e38\u7684\u6a5f\u6703\u56e0\u70ba\n\u75c5\u56e0\u4e0d\u540c\u6703\u6709\u5dee\u5225 \u3002\u4e00\u822c\u800c\u8a00 \uff0c\u814e\u4e0a\u817a\u816b\u7624\u9020\u6210\u7684\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u5728\u814e\u4e0a\u817a\u816b\u7624\u5207\u9664\u5f8c \uff0c\u5176HPA \naxis\u6062\u5fa9\u6b63\u5e38\u7684\u6bd4\u7387\u70ba80 %\uff0c\u9060\u9ad8\u65bcectopic ACTH syndrome \u6216Cushing\u2019s disease\u6cbb\u7642\u5f8c HPA axis \n\u6062\u5fa9\u6b63\u5e38\u7684\u6bd4\u7387 \u3002\nD.\u75c5\u4eba\u63a5\u53d7\u814e\u4e0a\u817a\u816b\u7624\u5207\u9664\u8853\u5f8c\uff0c\u9808\u589e\u52a0\u964d\u8840\u58d3\u53ca\u964d\u8840\u7cd6\u85e5\u7269\u5291\u91cf\u3002\nE.\u5eab\u6b23\u6c0f\u75c7\u4faf\u7fa4\u7684\u75c5\u4eba\u5982\u679c\u4e0d\u9069\u5408\u624b\u8853 \uff0c\u53ef\u4ee5\u8003\u616e\u4f7f\u7528metyraponec \u6216ketoconazole \u3002Mitotane \u53ef\u4ee5\u7528\n\u65bc\u6cbb\u7642\u814e\u4e0a\u817a\u76ae\u8cea\u764c \uff0c\u4f46\u4e0d\u5efa\u8b70\u7528\u65bc\u826f\u6027\u814e\u4e0a\u817a\u816b\u7624\u7684\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 \u3002\n": "[B]", "110-101.\u4e00\u4f4d53\u6b72\u7537\u6027\u56e0\u70ba\u524d\u9838\u90e8\u816b\u5927\u7d04\u4e00\u500b\u6708 \u3002\u4ed6\u9664\u4e86\u56e0\u70ba\u814e\u7d50\u77f3\u63a5\u53d7\u904e\u591a\u6b21\u9ad4\u5916\u9707\u6ce2\u788e\u77f3\u8853\u6cbb\u7642\u5916\u7121\u5176\u4ed6\u75c5\n\u53f2\u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u5176\u524d\u9838\u90e8\u6709\u7d04 3\u516c\u5206\u7684\u816b\u5927 \uff0c\u53ef\u96a8\u541e\u56a5\u6ed1\u52d5 \uff0c\u8868\u9762\u76ae\u819a\u6b63\u5e38 \u3002\u4ed6\u7684\u6aa2\u9a57\u7d50\u679c\u5982\u4e0b: fT4 \n1.13 ng/dL\u3001TSH 0.31 \u03bcIU/mL\u3001PTH 125 .3 pg/mL\u3001\u8840\u922311.9 mg/dL\u3001creatinine 1.2 mg/dL\u3002\u8d85\u97f3\u6ce2\u986f\n\u793a\u7532\u72c0\u817a\u56ca\u816b\u6027\u7d50\u7bc0 \u3002\u7d30\u91dd\u7a7f\u523a\u7d30\u80de\u5b78\u6aa2\u67e5\u986f\u793asheet of follicular cells with macrophages and \ncolloid\u3002\u7d30\u91dd\u7a7f\u523a\u62bd\u5230\u768417 ml\u6db2\u9ad4\u4e2d \uff0cPTH\u6fc3\u5ea6> 3000 pg /mL\uff0cthyroglobulin \u6fc3\u5ea6\u70ba211 ng /mL\u3002Tc99m \nsestamibi scintigraphy \u986f\u793alocal hot spots at left upper and left lower thyroid beds, and a large cold area \nat right lobe of thyroid \u3002\n(\u8840\u4e2d\u6fc3\u5ea6\u53c3\u8003\u503c: fT4 0 .93-1.70 ng/dL\u3001TSH 0.27-4.20 \u03bcIU/mL\u3001PTH 18.4-80.1 pg/mL\u3001Ca 8.6-10.2 \nmg/dL\u3001thyroglobulin <55 ng/mL\u3001creatinine 0.7-1.2 mg/dL)\n\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u662f\u6700\u53ef\u80fd\u7684\u6b63\u78ba\u8a3a\u65b7 ?   \nA.\u7532\u72c0\u817a\u56ca\u816b\u6027\u7d50\u7bc0\u3002\nB.\u7532\u72c0\u817a\u764c\u3002\nC.\u55ae\u4e00\u526f\u7532\u72c0\u817a\u816b\u7624\u3002\nD.\u591a\u767c\u6027\u5167\u5206\u6ccc\u816b\u7624 (multiple endocrine neoplasia)\u3002\nE.\u6b21\u767c\u6027\u526f\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\n": "[D]", "110-102.\u4e0b\u5217\u6709\u95dc\u55dc\u927b\u7d30\u80de\u7624(pheochromocytoma)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?       \nA.\u4e09\u74b0\u6297\u6182\u616e\u85e5\u7269(tricyclic antidepressants) \u53caopiates\u90fd\u53ef\u80fd\u8a98\u767c\u9ad8\u8840\u58d3\u3001\u5fc3\u60b8\u3001\u5192\u6c57\u7b49\u75c7\u72c0\u3002\nB.\u55dc\u927b\u7d30\u80de\u7624\u7d04\u67095-10%\u662f\u60e1\u6027\u7684\u3002\u5982\u679c\u6709SDHC\u7a81\u8b8a\uff0c\u6700\u5bb9\u6613\u6709\u8f49\u79fb\u3002\nC.\u55dc\u927b\u7d30\u80de\u7624\u7684\u8a3a\u65b7 \uff0c\u6aa2\u9a57\u8840\u4e2d\u7684free metanephrines \u6bd4\u6aa2\u9a57\u8840\u4e2d\u7684catecholamines \u6709\u66f4\u9ad8\u7684\u654f\u611f\u6027\n\u53ca\u7279\u7570\u6027 \u3002\nD.\u55dc\u927b\u7d30\u80de\u7624\u7684\u624b\u8853\u6aa2\u9ad4\u4ee5\u514d\u75ab\u7d44\u7e54\u5316\u5b78\u67d3\u8272 (immunohistochemistry )\u53ef\u4ee5\u770b\u5230\n\u6709chromogranin \u3001synaptophysin \u7684\u967d\u6027\u53cd\u61c9 \u3002\nE.\u60e1\u6027\u55dc\u927b\u7d30\u80de\u7624\u5408\u4f75\u8f49\u79fb\u53ef\u4ee5\u8003\u616e\u7528\u653e\u5c04\u6027\u6838\u7a2e(radionuclide)\u6cbb\u7642\uff0c\u4f8b\u5982 \u00b9\u00b3\u00b9I-MIBG \u3002\n": "[B]", "110-103.\u6709\u95dc\u539f\u767c\u6027\u76ae\u8cea\u919b\u916e\u75c7(primary aldosteronism, PA) \u7684\u63cf\u8ff0\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u4e0d\u6b63\u78ba?    \nA.Primary aldosteronism\u75c5\u4eba\u5e38\u8868\u73fe\u9ad8\u8840\u58d3\u53ca\u4f4e\u8840\u9240 \uff0c\u6703\u589e\u52a0\u7cd6\u5c3f\u75c5\u7f79\u60a3\u7387 \uff0c\u4f46\u53ef\u4ee5\u6e1b\u5c11\u9aa8\u8cea\u758f\u9b06\u98a8\n\u96aa\u3002\nB.\u5927\u591a\u6578\u7684\u826f\u6027aldosterone -producing adenoma \u901a\u5e38\u5c0f\u65bc 2\u516c\u5206\uff0c\u5e74\u8f15\u4eba\u6709\u8f03\u5927\u7684\u816b\u7624\u61c9\u8a72\u8981\u5c0f\u5fc3\u662f\n\u5426\u6709\u60e1\u6027\u8b8a\u5316 \u3002\nC.Glucocorticoid -remediable aldosteronsim (GRA)\u6709\u5bb6\u65cf\u907a\u50b3 \uff0c\u53ef\u80fd\u6703\u6709\u65e9\u767c\u6027\u7684\u9ad8\u8840\u58d3\u53ca\u4e2d\u98a8 \u3002\u4f7f\n\u7528glucocorticoid \u53ef\u4ee5\u6e1b\u5c11aldosterone\u7684\u7522\u751f \u3002\nD.\u6aa2\u6e2caldosterone \u53carenin \u6fc3\u5ea6\u524d \uff0c\u61c9\u8a72\u5148\u5c07\u8840\u9240\u8abf\u81f3\u6b63\u5e38\u7bc4\u570d \uff0c\u4e26\u505c\u7528 minerocorticoid receptor \nantagonist \u81f3\u5c11 4\u9031\u3002\nE.\u4f7f\u7528thiazide\u6cbb\u7642\u5176\u9ad8\u8840\u58d3\u53ef\u80fd\u5c0e\u81f4\u4f4e\u8840\u9240\u60e1\u5316\u3002\n": "[A]", "110-104.\u4e00\u4f4d50\u6b72\u5973\u6027\u75c5\u4eba \uff0c\u4e3b\u8a34\u56db\u6708\u521d\u56e0\u70ba\u5de6\u5074\u524d\u9838\u90e8\u816b\u75db\u5728\u5916\u5c31\u8a3a \uff0c\u7576\u6642\u7684\u7532\u72c0\u817a\u529f\u80fd\u6aa2\u67e5\u70ba: T4 10.85 \n\u03bcg/dL\u3001TSH 0.153 \u03bcIU/mL\uff0c\u672a\u505a\u5176\u4ed6\u6aa2\u67e5\u53ca\u6cbb\u7642 \u3002\u4e94\u6708\u521d\u75c5\u4eba\u4f86\u8a3a \uff0c\u8868\u793a\u5de6\u5074\u524d\u9838\u90e8\u75bc\u75db\u7a0d\u6e1b \uff0c\u4f46\u53f3\u5074\n\u524d\u9838\u90e8\u958b\u59cb\u75bc\u75db \u3002\u8eab\u9ad4\u8a3a\u5bdf\u767c\u73fe\u7532\u72c0\u817a\u816b\u5927 \uff0c\u53f3\u5074\u5c40\u90e8\u58d3\u75db\u6bd4\u5de6\u5074\u660e\u986f \uff0c\u8868\u9762\u76ae\u819a\u6b63\u5e38 \u3002\u6aa2\u67e5\u7d50\u679c\u986f\u793a \nfT4 3.01 ng/dL\u3001 TSH \u2266 0.005\u03bcIU/mL\u3001anti-thyroglobulin antibody 292 IU /mL\u3001anti-TPO 414 \nIU/mL\u3001ESR 36 mm /hr\u3001CRP 7.0 mg/L\u3001WBC 4.58*10\u00b3/\u03bcL\uff1b\u8acb\u554f\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\u78ba ?\n(\u53c3\u8003\u503c: T4: 5.1-14.1\u03bcg/dL\u3001fT4 0.93~1.70 ng/dL\u3001TSH 0.270 ~ 4.200 \u00b5IU/mL\u3001anti-thyroglobulin \nantibody <60 IU/mL\u3001anti-TPO <60 IU/mL\u3001ESR 0-20 mm/hr\u3001CRP <5 mg/L\u3001WBC 4.00-10.80*10\u00b3/\u03bcL \n)   \nA.\u75c5\u4eba\u6709\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\uff0c\u61c9\u8a72\u7d66\u4e88\u6297\u7532\u72c0\u817a\u85e5\u7269\u3002\nB.\u75c5\u4eba\u6709\u81ea\u9ad4\u514d\u75ab\u7532\u72c0\u817a\u75be\u75c5\uff0c\u61c9\u8a72\u7d66\u4e88\u985e\u56fa\u9187\u3002\nC.\u75c5\u4eba\u6709\u4e9e\u6025\u6027\u7532\u72c0\u817a\u708e\uff0c\u53ef\u4ee5\u7d66\u4e88non-steroid anti-inflammatory drug\u3002\nD.\u75c5\u4eba\u6709\u6025\u6027\u7532\u72c0\u817a\u708e\uff0c\u61c9\u8a72\u7d66\u4e88\u6297\u751f\u7d20\u3002\nE.\u7532\u72c0\u817a\u8d85\u97f3\u6ce2\u6bd4\u653e\u5c04\u6027\u7898\u6383\u63cf\u66f4\u6709\u52a9\u65bc\u9451\u5225fT4\u9ad8\u7684\u539f\u56e0\u3002\n": "[C]", "110-105.\u7cd6\u5c3f\u75c5\u7684\u8840\u7cd6\u63a7\u5236 \uff0c\u80f0\u5cf6\u7d20\u963b\u6297 (insulin resistance )\u662f\u91cd\u8981\u7684\u81f4\u75c5\u6a5f\u8f49 \uff0cThiazolidinedione (TZD)\u53ef\u4ee5\u6539\n\u5584\u589e\u52a0\u589e\u52a0\u80f0\u5cf6\u7d20\u654f\u611f\u5ea6 \uff0c\u76ee\u524d\u570b\u5167TZD\u985e\u85e5\u7269 \uff0c\u50c5\u6709Pioglitazone \uff0c\u4e0b\u5217\u4e4b\u9078\u9805\u4e2d \uff0c\u4f55\u8005\u70ba\u5fc5\u9808\u7559\u610f\u7684\n\u85e5\u7269\u526f\u4f5c\u7528\uff1f (1)\u9aa8\u6298 (2)\u5c3f\u9053\u611f\u67d3  (3)\u5fc3\u81df\u8870\u7aed (4)\u8166\u4e2d\u98a8 (5)\u773c\u775b\u9ec3\u6591\u90e8\u6c34\u816b \u3002   \nA.(1)+(2)+(3)\u3002\nB.(3)+(4)+(5)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(2)+(5)\u3002   \n": "[C]", "110-106.\u9673\u5148\u751f\uff0c70\u6b72\uff0c\u9ad4\u91cd76\u516c\u65a4 \uff0c\u8eab\u9ad8160\u516c\u5206 \uff0cBMI \u70ba29.7\uff0c\u7cd6\u5c3f\u75c5\u8a3a\u65b7\u903e\u5341\u5e74 \uff0c\u672c\u6b21\u4f4f\u9662\u524d\u534a\u5e74 \uff0c\u66fe\u56e0\u5fc3\n\u808c\u6897\u585e\uff0c\u4f4f\u9662\u9032\u884c\u5fc3\u5c0e\u7ba1\u53ca\u7f6e\u653e\u652f\u67b6\u6cbb\u7642 \uff0c\u76ee\u524d\u751f\u6d3b\u4f5c\u606f\u53ef\u81ea\u7406 \uff0c\u4e3b\u8981\u7167\u9867\u8005\u70ba\u540c\u4f4f\u4e4b\u5152\u5b50 \u3002\u4f4f\u9662\u524d\u50c5\u63a5\n\u53d7\u6bcf\u5929\u65e9 \u3001\u665a\u9910\u5f8c\u53e3\u670d\u4e00\u9846Metformin (500mg/tab) \u6cbb\u7642 \uff0c\u4f4f\u9662\u4e2d\u63a5\u53d7\u80f0\u5cf6\u7d20\u6ce8\u5c04\u6cbb\u7642 \u3002\u672c\u6b21\u56e0\u793e\u5340\u578b\u80ba\n\u708e\u4f4f\u9662\u6cbb\u7642 \uff0c\u6297\u751f\u7d20\u4f7f\u7528 7\u5929\u5f8c\uff0c\u8a55\u4f30\u60c5\u6cc1\u7a69\u5b9a \uff0c\u76ee\u524d\u751f\u547d\u5fb5\u8c61\u7a69\u5b9a \uff0c\u4e26\u9810\u5099\u51fa\u9662 \u3002\u4f4f\u9662\u4e2d\u4e4bHbA 1c \n\u70ba7.6 %\uff0c\u808c\u9178\u9150\u70ba 2.3 mg/dL (eGFR\u70ba 28mL /min/1.73m\u00b2)\u3002\u9810\u51fa\u9662\u524d\u4e4b\u6668\u9593\u7a7a\u8179\u8840\u7cd6\u70ba122 mg /dL\uff0c\u7576\n\u65e5\u65e9\u9910\u5f8c\u5169\u5c0f\u6642\u6307\u5c16\u624e\u91dd\u8840\u4e4b\u8840\u7cd6\u70ba166 mg /dL\u3002\u4e0b\u5217\u6709\u95dc\u51fa\u9662\u5f8c\u7cd6\u5c3f\u75c5\u6cbb\u7642\u5b89\u6392\u6558\u8ff0 \uff0c\u4f55\u8005\u932f\u8aa4 \uff1f   \nA.\u4f9d\u7167\u75c5\u60a3\u4e4beGFR\u8b8a\u5316\uff0cMetfromin\u5df2\u4e0d\u5b9c\u4f7f\u7528\u3002\nB.\u70ba\u9810\u9632\u7cd6\u5c3f\u75c5\u814e\u529f\u80fd\u7e7c\u7e8c\u60e1\u5316\u53ca\u75c5\u60a3\u66fe\u6709\u5fc3\u8840\u7ba1\u75be\u75c5\u75c5\u53f2\uff0c\u61c9\u52a0\u4e0aDPP-4 inhibitor \u985e\u85e5\u7269\u6cbb\u7642\u3002\nC.\u4f9d\u64da\u76ee\u524d\u814e\u529f\u80fd\u4e4b\u8b8a\u5316\uff0c\u51fa\u9662\u5f8c\u4e0d\u5b9c\u4f7f\u7528SGLT-2 inhibitor\u3002\nD.\u5efa\u8b70\u51fa\u9662\u5f8c\u4e4bHbA1c\u63a7\u5236\u61c9\u4ee57.0 %\u4ee5\u4e0b\u70ba\u76ee\u6a19\u3002\nE.\u5efa\u8b70\u75c5\u60a3\u61c9\u65bc\u5c45\u5bb6\u81ea\u6211\u76e3\u6e2c\u8840\u7cd6 (Self Monitoring of Blood Glucose)\u3002\n": "[B]", "110-107.\u6709\u95dc\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2 (Diabetic ketoacidosis)\u8a3a\u65b7\u53ca\u8655\u7f6e\uff0c\u4e0b\u5217\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?    \nA.\u75c5\u60a3\u591a\u6703\u5408\u4f75\u9ad8\u8840\u7cd6\u53ca\u4ee3\u8b1d\u9178\u4e2d\u6bd2 (Metabolic acidosis)\u3002\nB.\u75c5\u60a3\u8840\u4e2d\u51fa\u73fe\u916e\u9ad4 (serum ketone)\u662f\u8a3a\u65b7\u7cd6\u5c3f\u75c5\u916e\u9178\u4e2d\u6bd2\u7684\u91cd\u8981\u95dc\u9375\u3002\nC.\u88dc\u5145\u6b64\u985e\u75c5\u60a3\u4e4b\u9ad4\u6db2\uff0c\u61c9\u540c\u6642\u78ba\u8a8d\u96fb\u89e3\u8cea\u5e73\u8861\uff0c\u4e00\u822c\u6703\u4f7f\u7528 0.9% Normal saline \u53ca 0.45% Saline\u3002\nD.\u898f\u5f8b\u6ce8\u5c04\u57fa\u790e\u80f0\u5cf6\u7d20\u662f\u6821\u6b63\u53ca\u907f\u514d\u75c5\u60a3\u916e\u9178\u4e2d\u6bd2\u60e1\u5316\u7684\u91cd\u8981\u6b65\u9a5f\u3002\nE.\u7576\u4f7f\u7528\u80f0\u5cf6\u7d20\u6821\u6b63\u8840\u7cd6\u81f3250 mg /dL \u6642\uff0c\u9664\u7e7c\u7e8c\u6ce8\u610f\u9ad4\u6db2\u91cf\u4e4b\u5e73\u8861\u4e4b\u5916 \uff0c\u61c9\u540c\u6b65\u52a0\u4e0a 5% Glucose \u4e4b\n\u8f38\u6db2\u3002\n": "[D]", "110-108.\u6709\u95dc\u7cd6\u5c3f\u75c5\u85e5\u7269\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\u70ba\u662f\u932f\u8aa4\u7684 \uff1f\n(1)Metformin\u662f\u7cd6\u5c3f\u75c5\u6cbb\u7642\u539f\u5247\u7684\u7b2c\u4e00\u7dda\u7528\u85e5 \uff0c\u4f46\u7576eGFR < 45 \u6642\uff0c\u5373\u4e0d\u61c9\u4f7f\u7528Metformin \n(2)\u7814\u7a76\u986f\u793a \uff0cGLP-1 receptor agonist\u985e\u4e4b\u85e5\u7269\uff0c \u5177\u6709\u7cd6\u5c3f\u75c5\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u4fdd\u8b77\u7642\u6548\n(3)\u4f7f\u7528 Sulphonylurea\u985e\u85e5\u7269\u53ca\u80f0\u5cf6\u7d20 \uff0c\u5bb9\u6613\u51fa\u73fe\u4f4e\u8840\u7cd6\u53ca\u9ad4\u91cd\u4e0a\u5347 \n(4)Thiazolidinediones (TZD)\u9577\u671f\u4f7f\u7528\u6642 \uff0c\u4f4e\u8840\u7cd6\u662f\u5e38\u898b\u4e4b\u85e5\u7269\u526f\u4f5c\u7528 \n(5)\u7cd6\u5c3f\u75c5\u53e3\u670d\u85e5\u7269\u4e2d \uff0cDPP-4 inhibitor \u53caSGLT-2 inhibitor \uff0c\u5177\u6709\u7cd6\u5c3f\u75c5\u5fc3\u8840\u7ba1\u75be\u75c5\u4e4b\u4fdd\u8b77\u7642\u6548   \nA.(1)+(2)+(5)\u3002\nB.(1)+(3)+(4)\u3002\nC.(2)+(3)+(5)\u3002\nD.(2)+(3)+(4)\u3002\nE.(1)+(4)+(5)\u3002\n": "[E]", "110-109.\u4e00\u4f4d48\u6b72 \u7684\u5973\u6027 \uff0c\u8eab\u9ad8155\u516c\u5206 \uff0c\u9ad4\u91cd70\u516c\u65a4 \uff0c\u7121\u500b\u4eba\u6216\u5bb6\u65cf\u4e4b\u7cd6\u5c3f\u75c5\u53f2 \u3002\u6700\u8fd1\u5169\u5e74 \uff0c\u9ad4\u91cd\u81ea58\u516c\u65a4\u589e\n\u52a0\u81f3\u76ee\u524d\u4e4b\u9ad4\u91cd \u3002\u6700\u8fd1\u5169\u5e74 \uff0c\u6578\u6b21\u56e0\u660f\u5012\u610f\u8b58\u4e0d\u6e05 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u4e26\u66fe\u65bc\u6025\u8a3a\u767c\u73fe\u6307\u5c16\u624e\u8840\u4e4b\u8840\u7cd6\n\u503c40mg/dL\uff0c\u5728\u6ce8\u5c0450 %\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\u5fa9\u610f\u8b58 \u3002\u75c5\u60a3\u65bc\u795e\u7d93\u5167\u79d1\u53ca\u5bb6\u5ead\u91ab\u5b78\u79d1\u5c31\u91ab\u8907\u67e5 \uff0c\u4e26\u672a\u767c\u73fe\u795e\u7d93\u5b78\n\u7570\u5e38\u6216\u7cd6\u5c3f\u75c5 \u3002\u672c\u6b21\u518d\u5ea6\u56e0\u610f\u8b58\u72c0\u614b\u4e0d\u6e05 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \uff0c\u6025\u8a3a\u8840\u7cd6\u503c\u70ba 36mg /dL\uff0c\u6ce8\u5c04\u8461\u8404\u7cd6\u6db2\u5f8c\u6062\n\u5fa9\u610f\u8b58\uff0c\u6e05\u9192\u5f8c\uff0c\u5728\u6025\u8a3a\u4ea6\u7121\u795e\u7d93\u5b78\u7570\u5e38\u75c7\u72c0 \uff0c\u5efa\u8b70\u4f4f\u9662\u9032\u4e00\u6b65\u8ffd\u67e5\u539f\u56e0 \u3002\u5728\u75c5\u623f\u4f4f\u9662\u6642 \uff0c\u7a7a\u81798\u5c0f\n\u6642\uff0c\u7121\u8f38\u6db2\u4e0b \uff0c\u6e05\u66688\u9ede\u7a7a\u8179\u8840\u7cd6\u70ba 82mg /dL\uff0c\u540c\u6642\u4e4b\u5167\u5206\u6ccc\u6aa2\u67e5\u986f\u793a \uff0cACTH 38 .6 pg/mL, Cortisol 19 .6 \nug/dL, Insulin 2.2 mIU/mL, C-peptide 2.0 ng/mL, TSH 3.82 mIU/mL\u3002\u8acb\u554f\u4e0b\u4e00\u6b65\u61c9\u8a72\u5efa\u8b70\u90a3\u4e00\u9805\u6aa2\u67e5 ?   \nA.\u53e3\u670d75\u516c\u514b\u8461\u8404\u7cd6\u8010\u53d7\u8a66\u9a57\u3002\nB.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71 (Pituitary MRI)\u3002\nC.\u8179\u90e8\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002\nD.Overnight 1mg Dexamathasone suppression\u6e2c\u8a66\u3002\nE.72 \u5c0f\u6642\u4e4b Prolonged fasting test\u3002   \n": "[E]", "110-110.\u6709\u95dc\u65bc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5 \uff0c\u7814\u7a76\u986f\u793a35 -60%\u7684\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973 \uff0c\u572810\u81f320\u5e74\u671f\u9593\u4ecd\u6703\u9032\u5c55\u70ba\u771f\u6b63\u4e4b\u7cd6\u5c3f\u75c5\n\u60a3\u3002\u4ee5\u4e0b\u6709\u95dc\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u4e4b\u76f8\u95dc\u6558\u8ff0 \uff0c\u90a3\u4e00\u9805\u662f\u932f\u8aa4\u7684 \uff1f   \nA.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u7684\u8868\u73fe\uff0c\u4e3b\u8981\u8207\u6b64\u985e\u60a3\u8005\u61f7\u5b55\u6642\u7684\u80f0\u5cf6\u7d20\u5206\u6ccc\u4e0d\u8db3\u76f8\u95dc\u3002\nB.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u589e\u52a0\u7684\u8da8\u52e2\uff0c\u8207\u5a66\u5973\u80a5\u80d6\u7387\u7684\u589e\u52a0\u76f8\u95dc\u3002\nC.\u5982\u679c\u61f7\u5b55\u7b2c\u4e00\u671f\u5b55\u7a0b (first trimester )\u6642\uff0c\u5373\u51fa\u73fe\u8840\u7cd6\u7570\u5e38\u4e4b\u7cd6\u5c3f\u75c5\u8a3a\u65b7 \uff0c\u4ee3\u8868\u6b64\u75c5\u60a3\u65bc\u61f7\u5b55\u524d \uff0c\u5df2\u662f\n\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005 \u3002\nD.\u76ee\u524d\u81e8\u5e8a\u5efa\u8b70\uff0c\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\u7522\u5f8c\uff0c\u4ecd\u61c9\u6bcf\u4e09\u5e74\u9032\u884c\u8840\u7cd6\u7be9\u6aa2\u3002\nE.\u598a\u5a20\u6027\u7cd6\u5c3f\u75c5\u5a66\u5973\u7522\u4e0b\u4e4b\u65b0\u751f\u5152 \uff0c\u6bd4\u8d77\u6b63\u5e38\u598a\u5a20\u5a66\u5973\u4e4b\u4e0b\u4e00\u4ee3 \uff0c\u9577\u5927\u5f8c\u6709\u66f4\u9ad8\u7684\u98a8\u96aa \uff0c\u6210\u70ba\u7cd6\u5c3f\u75c5\u7684\n\u75c5\u60a3\u3002\n": "[A]", "110-111.\u6709\u95dc\u7cd6\u5c3f\u75c5\u80f0\u5cf6\u7d20\u7684\u751f\u7406\u6a5f\u8f49\u53ca\u85e5\u7269\u6cbb\u7642\uff0c\u4e0b\u5217\u4e4b\u6558\u8ff0\u4f55\u8005\u662f\u932f\u8aa4\u7684?    \nA.\u4eba\u9ad4\u80f0\u81df\u5206\u6ccc\u4e4b\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\uff0c\u5206\u6ccc\u5f8c\u76f4\u63a5\u9032\u5165\u9580\u975c\u8108\u7cfb\u7d71\u3002\nB.\u6ce8\u5c04\u578b\u4e4b\u5916\u6e90\u6027\u80f0\u5cf6\u7d20 \uff0c\u65bc\u6ce8\u5c04\u5f8c\u9032\u5165\u5168\u8eab\u7cfb\u7d71\u5faa\u74b0 \uff0c\u76f8\u8f03\u65bc\u4eba\u9ad4\u5167\u6e90\u6027\u80f0\u5cf6\u7d20\u9032\u5165\u809d\u81df\u7684\u6fc3\u5ea6\u70ba\n\u4f4e\uff0c\u5c6c\u65bcsubphysiologic insulin level \u3002\nC.\u5728\u75c5\u60a3\u6b63\u5e38\u4f5c\u606f\u4e0b\uff0c\u6bcf\u65e5\u6ce8\u5c04\u9577\u6548\u578b\u57fa\u790e\u80f0\u5cf6\u7d20\u7684\u6642\u6a5f\u70ba\u508d\u665a (evening)\u6216\u7761\u524d (before bedtime)\u3002\nD.\u5c31\u7cd6\u5c3f\u75c5\u63a7\u5236\u8840\u7cd6\u800c\u8a00 \uff0c\u6700\u7b26\u5408\u4eba\u9ad4\u751f\u7406\u6027\u9700\u6c42\u7684\u80f0\u5cf6\u7d20\u6ce8\u5c04\u65b9\u5f0f\u662f\u4e00\u5929\u4e00\u6b21\u7684\u9577\u6548\u578b\u57fa\u790e\u80f0\u5cf6\n\u7d20(basal insulin )\u3002\nE.\u75c5\u60a3\u4f4f\u9662\u6642 \uff0c\u5982\u679c\u9700\u8981\u6bcf\u65e5\u591a\u6b21\u6ce8\u5c04\u80f0\u5cf6\u7d20 \uff0c\u7d93\u9ad4\u91cd\u8a08\u7b97\u4e4b\u80f0\u5cf6\u7d20\u7e3d\u5291\u91cf\u768450 %\uff0c\u61c9\u4ee5\u57fa\u790e\u80f0\u5cf6\n\u7d20(basal insulin) \u7684\u65b9\u5f0f\u7d66\u85e5 \u3002\n": "[D]", "110-112.\u4ee5\u4e0b\u6709\u95dc\u8840\u8102\u7570\u5e38\u7684\u75be\u75c5\u72c0\u614b\u6558\u8ff0\uff0c\u4f55\u8005\u70ba\u932f\u8aa4\u7684?    \nA.\u4f4e\u5bc6\u5ea6\u53ca\u6975\u4f4e\u5bc6\u5ea6\u8102\u86cb\u767d(LDL & VLDL)\u7684\u589e\u52a0\u662f\u91cd\u8981\u7684\u81f4\u75c5\u56e0\u5b50\uff0c\u4e26\u4e14\u8207\u80a5\u80d6\u3001\u80f0\u5cf6\u7d20\u963b\u6297\u76f8\u95dc\u3002\nB.\u9577\u671f\u651d\u53d6\u5927\u91cf\u7684\u91a3\u985e\u98df\u7269\u53ca\u6301\u7e8c\u7684\u98f2\u9152 \uff0c\u5176\u8840\u8102\u7570\u5e38\u8868\u73fe\u70baVLDL \u53caTG\u589e\u52a0\uff0c\u4ee5\u53ca\u8840\u4e2d\u4e4bHDL\u6fc3\u5ea6\u964d\n\u4f4e\u3002\nC.\u80a5\u80d6\u53ca\u80f0\u5cf6\u7d20\u963b\u6297\u6027\u589e\u52a0\u6642\uff0c\u8840\u8102\u7570\u5e38\u7684\u8868\u73fe\u4e3b\u8981\u662fTG\u589e\u52a0\u3002\nD.\u7532\u72c0\u817a\u6a5f\u80fd\u4e0d\u8db3 (Hypothyroidism) \u6642\uff0c\u8840\u4e2d\u4e4bLDL\u6fc3\u5ea6\u6703\u660e\u986f\u5347\u9ad8\uff0c\u9020\u6210\u5fc3\u8840\u7ba1\u75be\u75c5\u3002\nE.\u8840\u8102\u7570\u5e38\u75be\u75c5 \uff0c\u540c\u6642\u53d7\u5230\u907a\u50b3\u56e0\u5b50 (genetic predisposition )\u53ca\u74b0\u5883\u56e0\u7d20 (environmental contribution )\u7684\n\u5f71\u97ff\u3002\n": "[B]", "111-97.\u4ee5\u4e0b\u6709\u95dc\u61f7\u5b55\u8207\u7532\u72c0\u817a\u75be\u75c5\u7684\u63cf\u8ff0 \uff0c\u54ea\u5e7e\u9805\u6700\u6b63\u78ba ?\n(1) \u61f7\u5b55\u5a66\u5973\u9ad4\u5167\u7684\u7532\u72c0\u817a\u523a\u6fc0\u7403\u86cb\u767d (thyroid stimulating immunoglobulins )\u53ef\u4ee5\u904e\u80ce\u76e4\u9020\u6210\u80ce\u5152\u7684\u7532\u72c0\u817a\n\u6bd2\u75c7\u3002\n(2) \u7f8e\u570b\u98df\u54c1\u85e5\u7269\u7ba1\u7406\u5c40 (Food and Drug Administration) \u5efa\u8b70\u4e0d\u8ad6\u61f7\u5b55\u9031\u671f \uff0c\u61f7\u5b55\u5a66\u5973\u7684\u9996\u9078\u6297\u7532\u72c0\u817a\u85e5\n\u7269\u5747\u70bapropylthiouracil \u3002\n(3) \u4e00\u822c\u800c\u8a00 \uff0c\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u516d\u500b\u6708\u4ee5\u5f8c\u53ef\u4ee5\u5b89\u5168\u53d7\u5b55 \uff0c\u4f46\u5728\u61f7\u5b55\u53ca\u54fa\u4e73\u671f\u4f7f\u7528\u653e\u5c04\u6027\u7898\u6cbb\u7642\u662f\u7d55\u5c0d\n\u7981\u5fcc\u3002\n(4) \u80ce\u5152\u7532\u72c0\u817a\u6bd2\u75c7\u7684\u5fb5\u5019\u5305\u62ec\u5b50\u5bae\u5167\u751f\u9577\u9072\u7de9 (poor intrauterine  growth) \u3001\u5fc3\u8df3\u8d85\u904e\u6bcf\u5206\u9418160 \u4e0b\u3001\u9aa8\u9f61\n\u8d85\u904e(advanced bone age )\u3001\u7532\u72c0\u817a\u816b\u7b49 \u3002\n(5) \u7522\u5f8c\u5f88\u5bb9\u6613\u6709\u7532\u72c0\u817a\u529f\u80fd\u4ea2\u9032\u7684\u5fa9\u767c \uff0c\u4f46\u82e5\u54fa\u4e73 \uff0c\u5247\u4e0d\u61c9\u8a72\u4f7f\u7528\u6297\u7532\u72c0\u817a\u85e5\u7269 \u3002   \nA.(1)+(2)\u3002\nB.(3)+(4)\u3002\nC.(4)+(5)\u3002\nD.(1)+(3)+(4)\u3002\nE.(2)+(3)+(5)\u3002   \n": "[D]", "111-98.\u4e0b\u5217\u56e0\u7d20\u53ef\u80fd\u9020\u6210\u9ad8\u8840\u9223\u75c7 \uff0c\u54ea\u5e7e\u9805\u63cf\u8ff0\u6700\u6b63\u78ba ?\n(1) \u8207\u526f\u7532\u72c0\u817a\u8377\u723e\u8499 (parathyroid hormone, PTH )\u76f8\u95dc\uff0c\u5305\u62ec\u526f\u7532\u72c0\u817a\u764c \u3001\u4f7f\u7528\u92f0\u9e7d\u6cbb\u7642 \u3001\u5bb6\u65cf\u6027\u4f4e\u5c3f\u9223\n\u9ad8\u8840\u9223\u7b49 \u3002\n(2) 24-hydroxylase\u7f3a\u4e4f\u4f7f 1,25(OH)\u2082D\u4ee3\u8b1d\u8b8a\u6162\u53ef\u80fd\u5c0e\u81f4\u9ad8\u8840\u9223 \u3002\n(3) \u7dad\u751f\u7d20A\u7f3a\u4e4f\u3001\u4f7f\u7528Thiazides \u3001\u8102\u80aa\u6d88\u89e3 (fat necrosis )\u7b49\u53ef\u80fd\u52a0\u5feb\u9aa8\u4ee3\u8b1d\u800c\u9020\u6210\u9ad8\u8840\u9223 \u3002\n(4) \u7532\u72c0\u817a\u529f\u80fd\u4f4e\u4e0b \u3001\u4e0d\u52d5(immobilization) \u4f7f\u4ee3\u8b1d\u8b8a\u6162 \uff0c\u9223\u4e0d\u6613\u6392\u51fa \uff0c\u56e0\u6b64\u53ef\u80fd\u9020\u6210\u9ad8\u8840\u9223 \u3002\n(5) \u60e1\u6027\u816b\u7624\u53ef\u80fd\u56e0\u70ba\u8f49\u79fb (metastasis )\u6216\u5206\u6ccc\u67d0\u4e9b\u56e0\u5b50 (humoral mediation )\u800c\u9020\u6210\u9ad8\u8840\u9223 \u3002   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(5)\u3002\nD.(2)+(3)+(5)\u3002\nE.(1)+(2)+(5)\u3002\n": "[E]", "111-99.\u4e0b\u5217\u6709\u95dc\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4(Cushing's syndrome)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u75c5\u56e0\u4e0d\u540c \uff0c\u7537\u5973\u597d\u767c\u6bd4\u4f8b\u5404\u7570 \u3002\u5176\u4e2d\uff0c\u6613\u4f4d\u6027\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 (ectopic ACTH \nsyndrome )\u4ee5\u5973\u6027\u5c45\u591a \uff1b\u4f46\u814e\u4e0a\u817a\u76ae\u8cea\u816b\u7624\u7684 \uff0c\u5247\u4ee5\u7537\u6027\u5c45\u591a \u3002\nB.\u5728\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u8a3a\u65b7\u6d41\u7a0b\u4e2d \uff0c\u4f4e\u5291\u91cfdexamethasone \u58d3\u6291\u6e2c\u8a66 (low dose dexamethasone \nsuppression test )\uff0c\u7d66\u4e880.5 mg dexamethasone q 6h \u5169\u5929\u5f8c \uff0c\u5982\u679c\u8840\u6e05\u4e2d\u7684cortisol \u6fc3\u5ea6\u4f4e\u65bc 50 \nnmol/L\uff0c\u61c9\u8a72\u53ef\u4ee5\u5148\u6392\u9664\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4 \u3002\nC.40%\u5eab\u6b23\u6c0f\u75c7 (Cushing's disease)\u75c5\u4eba\u7684\u8166\u5782\u9ad4\u816b\u7624\u5927\u65bc1\u516c\u5206\u3002\nD.\u5eab\u6b23\u6c0f\u75c7\u5019\u7fa4\u7684\u75c5\u4eba\u901a\u5e38\u767d\u8840\u7403\u6578\u4e0b\u964d\uff0c\u4e14\u55dc\u9e7c\u6027\u7d30\u80de(basophil)\u589e\u52a0\u3002\nE.\u5eab\u6b23\u6c0f\u75c7\u7684\u75c5\u4eba\u6709\u9ad8\u51dd\u8840 (hypercoagulation )\uff0c\u80ba\u6813\u585e(pulmonary embolism )\u7684\u98a8\u96aa\u589e\u52a0 \uff0c\u4f46\u6df1\u90e8\u975c\n\u8108\u6813\u585e(deep vein thromobosis )\u7684\u98a8\u96aa\u4e26\u672a\u589e\u52a0 \u3002\n": "[B]", "111-100.\u4e0b\u5217\u6709\u95dc\u65bc\u539f\u767c\u6027\u919b\u56fa\u916e\u75c7(primary aldosteronism, PA)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.PA\u7684\u75c5\u4eba\u53ef\u80fd\u589e\u52a0\u9aa8\u8cea\u758f\u9b06\u3001\u7cd6\u5c3f\u75c5\u3001\u8a8d\u77e5\u969c\u7919\u7b49\u75be\u75c5\u98a8\u96aa\uff0c\u4e5f\u53ef\u80fd\u4f7fcortisol\u7684\u5206\u6ccc\u6e1b\u5c11\u3002\nB.PA\u7684\u9451\u5225\u8a3a\u65b7\u904e\u7a0b\u4e2d \uff0c\u6aa2\u6e2c\u919b\u56fa\u916e /\u814e\u7d20\u6bd4\u503c (aldosterone /renin ratio, ARR )\u6642, \u9664\u4e86\u9700\u8981\u505c\n\u7528spironolactone 4\u9031\u5916\uff0c\u53ef\u4ee5\u6301\u7e8c\u539f\u6709\u7684\u8840\u58d3\u85e5 \u3002\u4f46\u56e0\u70ba\u03b2-blocker\u53ef\u80fd\u4f7fARR\u4e0b\u964d \uff0c\u56e0\u6b64\u82e5\u6aa2\u6e2c\u7d50\n\u679c\u4e0d\u78ba\u5b9a (equivocal )\u6642\uff0c\u6700\u597d\u505c\u7528 \u03b2-blocker\u5169\u9031\u5f8c\u518d\u91cd\u8907\u6e2c\u91cf\u4e00\u6b21 \u3002\nC.\u751f\u7406\u98df\u9e7d\u6c34\u975c\u6ce8\u6e2c\u8a66 (saline infusion test )\uff0c\u57284\u5c0f\u6642\u5167\u975c\u8108\u8f38\u6ce8 2\u516c\u5347\u751f\u7406\u98df\u9e7d\u6c34\u5f8c \uff0caldosterone \u6fc3\n\u5ea6\u70ba280 pmol /L (10 ng/dL)\u53ef\u6392\u9664PA \u3002\nD.\u814e\u4e0a\u817a\u975c\u8108\u53d6\u6a23 (adrenal vein sampling )\u6642\uff0c\u5982\u679c\u53f3\u3001\u5de6\u814e\u4e0a\u817a\u975c\u8108\u4e2d\u7684aldosterone /cortisone\u6fc3\u5ea6\u6bd4\n\u5dee\u8ddd\u70ba1.8\uff0c\u53ef\u63a1\u4fe1\u662f\u53f3\u814e\u4e0a\u817a\u9020\u6210PA \u3002\nE.\u7cd6\u76ae\u8cea\u985e\u56fa\u9187\u53ef\u6291\u5236\u6027\u919b\u56fa\u916e\u589e\u591a\u75c7 \uff08glucocorticoid remediable aldosteronism, GRA \uff09\u61c9\u5148\u4ee5\u4f4e\u5291\n\u91cfdexamethasone\u63a7\u5236\u8840\u58d3 \u3002\u82e5\u9700\u8981\uff0c\u53ef\u52a0\u4e0a\u919b\u56fa\u916e\u53d7\u9ad4\u62ee\u6297\u5291 \u3002\n": "[E]", "111-101.\u55dc\u927b\u7d30\u80de\u7624 (pheochromocytoma) \u88ab\u8996\u70ba \u201c\u5049\u5927\u7684\u507d\u88dd\u8005 (the great masquerader )\u201d\uff0c\u4ee5\u4e0b\u54ea\u4e00\u9805\u63cf\u8ff0\u6700\u6b63\n\u78ba?   \nA.\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u5305\u62ec\u9ad8\u8840\u58d3\u53ca\u9663\u767c\u6027\u7684\u5fc3\u60b8 \u3001\u5192\u6c57\u3001\u982d\u75db\u7b49\u3002\u901a\u5e38\u5176\u75c7\u72c0\u660e\u986f \uff0c\u4f46\u4e5f\u6709\u67d0\u4e9b\u75c5\u4eba\u53ef\n\u4ee5\u7121\u75c7\u72c0\u9054\u6578\u5e74\u4e4b\u4e45 \u3002\nB.\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u767c\u4f5c\u983b\u7387\u4e0d\u5b9a\uff0c\u4f46\u6bcf\u6b21\u767c\u4f5c\u6642\u9593\u901a\u5e38\u5927\u65bc\u5169\u5c0f\u6642\u3002\nC.\u4e09\u74b0\u6297\u6182\u9b31\u85e5 (tricyclic antidepressants )\u3001opiates\u3001metoclopramide\u7b49\u85e5\u6703\u6e1b\u5c11\u55dc\u927b\u7d30\u80de\u7624\u7684\u75c7\u72c0\u8868\n\u73fe\uff0c\u5ef6\u7de9\u8a3a\u65b7 \u3002\nD.\u75c5\u4eba\u61f7\u7591\u6709\u55dc\u927b\u7d30\u80de\u7624\u9700\u8981\u505a\u96fb\u8166\u65b7\u5c64\u6216\u6838\u78c1\u5171\u632f\u7b49\u5f71\u50cf\u5b78\u6aa2\u67e5\u6642 \uff0c\u70ba\u6e1b\u5c11\u523a\u6fc0 \uff0c\u6700\u597d\u4e0d\u8981\u65bd\u6253\u986f\u5f71\n\u5291\u3002   \nE.\u8207\u5176\u4ed6\u6aa2\u9a57\u65b9\u5f0f\u6bd4\u8f03 \uff0c\u6aa2\u6e2c\u8840\u4e2d\u7684metanephrine \u5177\u6709\u9ad8\u654f\u611f\u5ea6 \uff0c\u4f46\u56e0\u5f88\u5bb9\u6613\u53d7\u5230\u975c\u8108\u7a7f\n\u523a(venipuncture )\u7b49\u58d3\u529b\u5f71\u97ff \uff0c\u800c\u6709\u8f03\u9ad8\u7684\u507d\u967d\u6027 \u3002\n": "[A]", "111-102.\u8166\u5782\u9ad4\u816b\u7624 (pituitary adenomas) \u53ef\u80fd\u4f34\u96a8\u8166\u5782\u9ad4\u8377\u723e\u8499\u5206\u6ccc\u7570\u5e38\u3002\u4e0b\u5217\u54ea\u4e00\u9805\u63cf\u8ff0\u4e0d\u6b63\u78ba?    \nA.\u8166\u5782\u9ad4\u816b\u7624\u901a\u5e38\u6e90\u81ea\u55ae\u4e00\u578b\u614b\u7d30\u80de\uff0c\u4f46\u53ef\u80fd\u6709\u5169\u7a2e\u4ee5\u4e0a\u8377\u723e\u8499\u7684\u904e\u591a\u5206\u6ccc\u3002\nB.\u6ccc\u4e73\u6fc0\u7d20\u7624 (prolactinoma )\u7684\u5927\u5c0f\u8207\u6ccc\u4e73\u6fc0\u7d20 (prolactin, PRL )\u6fc3\u5ea6\u76f8\u95dc \u3002PRL\u6fc3\u5ea6\u5927\u65bc150 \u03bcg/L\uff0c\u5176\n\u816b\u7624\u7686\u5927\u65bc1 \u516c\u5206 \u3002\nC.\u751f\u9577\u6fc0\u7d20 (growth hormone, GH )\u6709\u8108\u52d5\u6027 (pulsatile)\u5206\u6ccc\uff0c\u55ae\u4e00\u96a8\u610f (single, random )\u6aa2\u6e2c\u7684GH\u6fc3\u5ea6\u7121\n\u6cd5\u7528\u4ee5\u78ba\u5b9a (\u6216\u6392\u9664)\u80a2\u7aef\u80a5\u5927\u75c7 (acromegaly )\u7684\u8a3a\u65b7\uff0c\u4e5f\u7121\u6cd5\u4ee3\u8868\u75be\u75c5\u7684\u56b4\u91cd\u5ea6 \u3002\nD.\u985e\u80f0\u5cf6\u7d20\u751f\u9577\u56e0\u5b501 (insulin-like growth factor 1\uff0cIGF-1)\u7684\u6fc3\u5ea6\u6703\u56e0\u5e74\u7d00\u4e0d\u540c\u800c\u7570 \u3002GH\u53ef\u4ee5\n\u4f7fIGF-1\u7684\u6fc3\u5ea6\u589e\u52a0 \uff0c\u9650\u5236\u71b1\u91cf\u651d\u53d6 (caloric restriction )\u6703\u4f7f IGF -1\u6fc3\u5ea6\u4e0b\u964d \u3002\nE.\u5927\u591a\u6578\u5eab\u6b23\u6c0f\u75c7(Cushing's disease)\u7684\u8166\u5782\u9ad4\u816b\u7624\u662f\u5c0f\u65bc0.5 \u516c\u5206\u7684 microadenoma\u3002\n": "[B]", "111-103.\u6709\u95dc\u6027\u817a\u529f\u80fd\u7570\u5e38\u7684\u63cf\u8ff0\uff0c\u4e0b\u5217\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.Turner's syndrome \u6703\u8868\u73fe hypogonadotropic hypogonadism\u3002\nB.\u9871\u54bd\u7624(Craniopharygioma)\u53ef\u5c0e\u81f4hypergonadotropic hypogonadism\u3002\nC.\u8840\u6db2\u4e2d\u7684\u776a\u56fa\u916e (testosterone )\u7d0480%\u8207\u767d\u86cb\u767d\u6216\u6027\u8377\u723e\u8499\u7d50\u5408\u7403\u86cb\u767d (sex hormone -binding globulin, \nSHBG)\u7d50\u5408\uff0c\u7d0420%\u5c6c\u6e38\u96e2\u578b \u3002\nD.Klinefelter syndrome\u75c5\u4eba\u7f79\u60a3\u4e73\u764c \u3001\u7cd6\u5c3f\u75c5\u3001\u9aa8\u8cea\u758f\u9b06 \u3001\u5168\u8eab\u6027\u7d05\u6591\u6027\u72fc\u7621 (systemic lupus \nerythematosus, SLE )\u7b49\u75be\u75c5\u7684\u98a8\u96aa\u589e\u52a0 \uff0c\u4f46\u7f79\u60a3\u651d\u8b77\u817a\u764c\u7684\u98a8\u96aa\u964d\u4f4e \u3002\nE.Ketoconazole\u53ef\u4ee5\u523a\u6fc0\u6291\u5236\u776a\u56fa\u916e (testosterone )\u7684\u751f\u6210\uff0c\u800cspironolactone\u53ef\u4ee5\u963b\u65b7\u96c4\u6fc0\n\u7d20(androgen )\u7684\u4f5c\u7528\u3002\n": "[D]", "111-104.\u4e0b\u5217\u6709\u95dc\u5c3f\u5d29\u75c7(diabetes insipidus, DI)\u7684\u63cf\u8ff0\uff0c\u54ea\u4e00\u9805\u6700\u6b63\u78ba?    \nA.\u5c3f\u5d29\u75c7\u7684\u5b9a\u7fa9\u70ba24 \u5c0f\u6642\u5c3f\u91cf\u8d85\u904e30 ml/\u516c\u65a4\u9ad4\u91cd\uff0c\u4e14\u5c3f\u6ef2\u900f\u58d3 <250 mosmol/L\u3002\nB.\u6b63\u5e38\u4eba\u7684\u8166\u5782\u9ad4\u6838\u78c1\u5171\u632f\u6aa2\u67e5 \uff0c\u5f8c\u8449\u5728T1-weighted midsagittal images \u6703\u5448\u73fe\u4eae\u9ede \u3002\u6b64\u4eae\u9ede\u5728\u539f\u767c\n\u6027\u591a\u98f2\u75c7 \uff08primary polydipsia \uff09\u6216\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI )\u6703\u6d88\u5931\u3002\nC.\u67d0\u4e9b\u85e5\u7269 \uff0c\u4f8b\u5982lithium \u3001amphotericin B \u3001aminoglycosides\u7b49\u53ef\u80fd\u5c0e\u81f4\u814e\u6027\u5c3f\u5d29\u75c7 (nephrogenic \nDI)\u3002\nD.\u61f7\u5b55\u671f\u5c3f\u5d29\u75c7(gestational DI) \u5e38\u8868\u73fe\u65bc\u61f7\u5b55\u7684\u982d\u4e09\u500b\u6708\uff0c\u96a8\u5b55\u671f\u4e4b\u589e\u52a0\u800c\u9010\u6f38\u6539\u5584\u3002\nE.Desmopressin (DDAVP)\u53ef\u6cbb\u7642\u539f\u767c\u6027\u591a\u98f2\u75c7 (primary polydipsia )\u6216\u4e2d\u6a1e\u6027\u5c3f\u5d29\u75c7 (central DI )\u3002\u814e\u6027\n\u5c3f\u5d29\u75c7 (nephrogenic DI )\u61c9\u4ee5thiazide\u5229\u5c3f\u5291\u3001 amiloride \u3001indomethacin \u7b49\u85e5\u7269\u6cbb\u7642 \u3002\n": "[C]", "111-105.\u7cd6\u5c3f\u75c5\u8207\u80a5\u80d6\u7d44\u6210\u7cd6\u80d6\u75c7 (Diabesity )\uff0c\u5728\u65b0\u9673\u4ee3\u8b1d\u75be\u75c5\u7684\u7bc4\u7587\u5167 \uff0c\u80a5\u80d6\u5df2\u7d93\u6210\u70ba\u63a7\u5236\u7cd6\u5c3f\u75c5\u8840\u7cd6\u4e4b\u91cd\u8981\u969c\n\u7919\uff0c\u4e0b\u5217\u4e4b\u6709\u95dc\u7cd6\u80d6\u75c7\u4e4b\u63cf\u8ff0 \uff0c\u4f55\u8005\u6709\u8aa4 ?   \nA.\u904b\u52d5\u5c0d\u65bc\u9ad4\u91cd\u63a7\u5236\u975e\u5e38\u91cd\u8981 \uff0c\u5be6\u8b49\u7814\u7a76\u986f\u793a\u904b\u52d5\u5f37\u5ea6\u6108\u5f37\u6642 \uff0c\u53ef\u4ee5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u767c\u75c5\u7387 \uff0c\u4e5f\u53ef\u4ee5\u964d\u4f4e\u5fc3\n\u81df\u8840\u7ba1\u75be\u75c5\u4e4b\u6b7b\u4ea1\u7387 \u3002\nB.\u7f8e\u570b\u570b\u885b\u9662\u9032\u884c\u4e4b\u751f\u6d3b\u578b\u614b\u7814\u7a76LOOKAHEAD \uff0c\u91dd\u5c0d\u7cd6\u5c3f\u75c5\u7684\u60a3\u8005\u5b89\u6392\u71df\u990a\u8aee\u8a62\u53ca\u9ad4\u91cd\u7ba1\u7406 \uff0c\u96d6\u7136\n\u53ef\u4ee5\u6539\u5584\u8840\u7cd6\u53caHbA 1c\u4e4b\u63a7\u5236\uff0c\u4f46\u662f\u6700\u7d42\u7814\u7a76\u7d50\u679c \uff0c\u537b\u986f\u793a\u7121\u6cd5\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u8005\u5fc3\u81df\u8840\u7ba1\u75be\u75c5\u6b7b\u4ea1\n\u7387\u3002\nC.\u751f\u6d3b\u578b\u614b\u4e4b\u65bc\u7cd6\u5c3f\u75c5\u98f2\u98df\u63a7\u5236\u539f\u5247 \uff0c\u8a08\u756b\u6027\u98f2\u98df\u53ca\u904b\u52d5\u964d\u4f4e\u7684\u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54 \uff0c\u53ef\u4ee5\u9810\u9632\u75be\u75c5\u4e4b\u9032\n\u5c55\u3002\nD.\u76ee\u524d\u5be6\u8b49\u91ab\u5b78\u4e0a \uff0c\u91dd\u5c0d\u7cd6\u80d6\u75c7\u4e4b\u8840\u7cd6\u63a7\u5236 \uff0c\u4ee5\u53ca\u6709\u6548\u964d\u4f4e\u9ad4\u91cd \uff0c\u4f7f\u7528Glucagon -like peptide -1 \nreceptor agonist (GLP-1 RA)\u662f\u6cbb\u7642\u4e0a\u5e38\u898b\u7684\u8003\u91cf\u4e4b\u4e00 \u3002   \nE.\u904e\u53bb\u4e8c\u5341\u5e74\u4e4b\u6e1b\u91cd\u624b\u8853\u7814\u7a76 \uff0c\u986f\u793a\u9ad4\u91cd\u6e1b\u8f15\u4e4b\u904e\u7a0b\u4e2d \uff0c\u7cd6\u5c3f\u75c5\u9032\u5c55\u53ca\u5fc3\u81df\u8840\u7ba1\u6b7b\u4ea1\u7387\u5747\u5f97\u5230\u7d71\u8a08\u5b78\n\u4e0a\uff0c\u6709\u610f\u7fa9\u4e4b\u6539\u5584 \u3002\n": "[A]", "111-106.\u694a\u5148\u751f\uff0c56\u6b72\uff0c\u8eab\u9ad8164\u516c\u5206 \uff0c\u9ad4\u91cd 77 \u516c\u65a4 \uff0c\u4e26\u7121\u7cd6\u5c3f\u75c5\u4e4b\u5bb6\u65cf\u53ca\u500b\u4eba\u75c5\u53f2 \uff0c\u6700\u8fd1\u534a\u5e74 \uff0c\u9ad4\u91cd\u589e\u52a0\u4e86 4\u516c\n\u65a4\u3002\u8fd1\u4e00\u5e74\u4ee5\u4f86 \uff0c\u6578\u6b21\u56e0\u4e0d\u660e\u539f\u56e0\u660f\u5012 \uff0c\u9001\u81f3\u6025\u8a3a\u5c31\u91ab \u3002\u75c5\u53f2\u6709\u9ad8\u8840\u58d3 \uff0c\u6bcf\u65e5\u898f\u5247\u670d\u7528Losartan \n50mg\u53caAmlodipine 5mg\uff0c\u904e\u53bb\u9580\u8a3a\u7121\u7570\u5e38\u795e\u7d93\u8840\u7ba1\u4e4b\u7570\u5e38\u72c0\u6cc1 \u3002\u672c\u6b21\u5c45\u5bb6\u6642 \uff0c\u518d\u5ea6\u660f\u5012 \uff0c\u4e26\u4e14\u610f\u8b58\u6301\u7e8c\n\u4e0d\u6e05\uff0c\u56e0\u6b64\u9001\u5230\u6025\u8a3a \u3002\u672c\u6b21\u6025\u8a3a\u4e4b\u8840\u58d3\u70ba98 /60 mmHg \uff0c\u8108\u640f\u70ba\u898f\u5f8b\u768484 bpm \uff0c\u6025\u8a3a\u4e4b\u8840\u7cd6\u986f\u793a\u70ba22 \nmg/dL\uff0c\u7d66\u4e8850%\u4e4b\u8461\u8404\u7cd6\u8f38\u6db2\u5f8c \uff0c\u6062\u5fa9\u610f\u8b58 \u3002\u56e0\u6b64\u5efa\u8b70\u4f4f\u9662\u8a3a\u5bdf \uff0c\u5728\u75c5\u623f\u7121\u9ede\u6ef4\u8f38\u6db2\u7684\u524d\u63d0\u4e0b \uff0c\u7a7a\u81798 \n\u5c0f\u6642\u5f8c\uff0c\u62bd\u8840\u5831\u544a\u70ba: \u7a7a\u8179\u8840\u7cd6 76 mg /dL \uff0cInsulin 3.6 mIU/mL \uff0cC-peptide 2.6 ng/mL\uff0cACTH 62 .2 \npg/mL\uff0cCortisol 16 .3 ug/dL\uff0cIGF-1 106 ng /mL\uff0cTSH 4.32 mIU/mL\uff0c\u65bc\u6b64\u6642\u61c9\u8003\u616e\u4e4b\u512a\u5148\u6aa2\u67e5\u9805\u76ee\u70ba\n\u4f55?   \nA.\u8179\u90e8\u809d\u80f0\u78c1\u632f\u651d\u5f71 (Magnetic resonance image, MRI)\u3002\nB.72\u5c0f\u6642\u5ef6\u9577\u7981\u98df\u6e2c\u8a66 ( Prolonged fasting test)\u3002\nC.24\u5c0f\u6642\u5fc3\u96fb\u5716 (Holter ECG monitor)\u3002\nD.\u8166\u4e0b\u5782\u9ad4\u78c1\u632f\u651d\u5f71(MRI)\u3002\nE.\u7d93\u98df\u9053\u5167\u8996\u93e1\u8d85\u97f3\u6ce2 (Endoscopic ultrasound, EUS)\u3002\n": "[B]", "111-107.\u7cd6\u5c3f\u75c5\u964d\u8840\u7cd6\u85e5\u7269\u773e\u591a \uff0c\u4e0b\u5217\u4e4b\u964d\u8840\u7cd6\u85e5\u7269\u4e2d \uff0c\u5be6\u8b49\u7814\u7a76\u986f\u793a\u90a3\u4e9b\u85e5\u7269 \uff0c\u6709\u660e\u78ba\u53ef\u964d\u4f4e Major adverse \ncardiovascular events (cardiovascular death, non -fatal myocardial infarctiomn, non -fatal stroke) \u4e4b\u7d50\u679c ?\n(1) Alpha-glucosidase inhibitors\n(2) Glucagon -like peptide 1 receptor agonists\n(3) Sulfonylurea\n(4) Dipepetidyl peptidase inhibitor\n(5) Sodium -glucose co -transporter -2 inhibitors   \nA.(1)+(3)\u3002\nB.(2)+(4)\u3002\nC.(1)+(4)\u3002\nD.(3)+(5)\u3002\nE.(2)+(5)\u3002\n": "[E]", "111-108.Thiazolidinedione (TZD)\u985e\u4e4b\u80f0\u5cf6\u7d20\u589e\u654f\u5291 \uff0c\u53ef\u4ee5\u6539\u5584\u80f0\u5cf6\u7d20\u5728\u4eba\u9ad4\u5167\u4e4b\u654f\u611f\u5ea6 \uff0c\u6587\u737b\u5831\u544a\u986f\u793a\u4e5f\u53ef\u4ee5\u6539\n\u5584\u86cb\u767d\u5c3f \uff0c\u4f46\u662f\u672c\u985e\u85e5\u7269\u4e5f\u6709\u4e9b\u526f\u4f5c\u7528 \u3002\u4ee5Pioglitazone\u70ba\u4f8b \uff0c\u4f7f\u7528\u76f8\u95dc\u85e5\u7269\u526f\u4f5c\u7528\u5305\u62ec\u4e0b\u5217\u4f55\u8005? \n(1) \u6c34\u816b (edema)\n(2) \u8a8d\u77e5\u969c\u7919 (cognitive dysfunction) \n(3 )\u8106\u5f31\u6027\u9aa8\u6298 (fragility frcuture )\n(4) \u8166\u4e2d\u98a8 (Storke) \n(5) \u9ad4\u91cd\u53ca\u8102\u80aa\u7d44\u7e54\u589e\u52a0   \nA.(1)+(2)+(4)\u3002\nB.(1)+(2)+(3)\u3002\nC.(1)+(3)+(5)\u3002\nD.(2)+(3)+(5)\u3002\nE.(3)+(4)+(5)\u3002   \n": "[C]", "111-109.\u674e\u5148\u751f\uff0c64\u6b72\uff0c\u7cd6\u5c3f\u75c5\u75c5\u53f2\u70ba 8\u5e74\uff0c\u4e00\u5e74\u524d\u56e0\u51a0\u72c0\u52d5\u8108\u75be\u75c5 (three vessles disease )\u9032\u884c\u5fc3\u5c0e\u7ba1 \uff0c\u4e26\u7f6e\u653e\n\u652f\u67b6\uff0c\u76ee\u524d\u4f7f\u7528\u4e4b\u8840\u7cd6\u63a7\u85e5\u7269\u70ba\u80f0\u5cf6\u7d20 insulin degludec (70%)/aspart (30%)\u3002\u9ad8\u8840\u58d3\u85e5\u7269\u70ba\u6bcf\n\u65e5Valsatan 160mg \u53caAmlodipine 5mg \uff0c\u81bd\u56fa\u9187\u85e5\u7269\u70ba Atorvastatin \u6bcf\u65e540mg \u3002\u76ee\u524d\u4e4b\u7a7a\u8179\u8840\u7cd6\u70ba 132 \nmg/dL\uff0cHbA1c \u70ba 7.0 %\uff0cLDL cholesterol \u70ba 55 mg /dL\uff0cHDL cholesterol 48 mg /dL\uff0cTriglyceride \u70ba \n628 mg/dL\uff0c\u5c3f\u6db2\u986f\u793a\u6709\u5de8\u91cf\u767d\u86cb\u767d\u5c3f (macroalbuminuria )\uff0c\u4e14\u6709\u975e\u589e\u6b96\u578b\u8996\u7db2\u819c\u75c5\u8b8a (Non-proliferative \nretinopathy )\uff0c\u76ee\u524d\u61c9\u8a72\u589e\u52a0\u4f7f\u7528\u4e0b\u5217\u54ea\u4e00\u9805\u85e5\u7269 ?   \nA.Ezetimibe\u3002\nB.Cholestyramine\u3002\nC.PCSK9 (Proprotein convertase subtilisin/kexin type9) inhibitor\u3002\nD.Fenofibrate\u3002\nE.Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors\u3002\n": "[D]", "111-110.GLP-1 receptor agonist \u8207DPP-4 inhibitors\u5c6c\u65bcIncretin \u8178\u6ccc\u7d20\u985e\u985e\u85e5\u7269 \u3002\u4ee5\u4e0b\u6709\u95dc \u8178\u6ccc\u7d20\u4e4b\u6558\u8ff0 \uff0c\u4f55\u8005\n\u70ba\u6b63\u78ba? \n(1) GLP-1 (Glucagon like peptide -1) \u7531\u8178\u9053\u4e4bL cell\u5206\u6ccc\n(2) GLP-1 \u53ef\u523a\u6fc0\u80f0\u5cf6\u7d20\u5206\u6ccc \uff0c\u4f46\u4e5f\u523a\u6fc0\u6607\u7cd6\u6fc0\u7d20 (Glucagon )\u5206\u6ccc\n(3) \u4f7f\u7528GLP -1 receptor agonist\u6cbb\u7642\u7cd6\u5c3f\u75c5\u60a3\u8005\u6642 \uff0c\u4e5f\u6709\u660e\u986f\u6e1b\u8f15\u9ad4\u91cd\u4e4b\u6548\u679c\n(4) \u7b2c\u4e00\u578b\u7cd6\u5c3f\u75c5\u60a3\u8005\u4e5f\u9069\u7528GLP -1 receptor agonist\n(5) \u4f7f\u7528GLP -1 receptor agonist\u53ef\u964d\u4f4e\u7cd6\u5c3f\u75c5\u60a3\u4e4b\u98df\u617e\u53ca\u5ef6\u7de9\u80c3\u6392\u7a7a\u6642\u9593   \nA.(1)+(2)+(3)\u3002\nB.(2)+(3)+(4)\u3002\nC.(2)+(3)+(5)\u3002\nD.(1)+(4)+(5)\u3002\nE.(1)+(3)+(5)\u3002\n": "[E]", "111-111.Biguanides \u985e\u7684\u85e5\u7269 \uff0c\u662f\u76ee\u524d\u5168\u4e16\u754c\u5927\u591a\u6578\u7cd6\u5c3f\u75c5\u6cbb\u7642\u6307\u5f15\u7684\u5efa\u8b70\u9996\u9078\u7528\u85e5 \uff0c\u4ee5\u4e0b\u6709\u95dcMetformin\u4e4b\u6558\u8ff0\n\u4f55\u8005\u70ba\u932f\u8aa4\u7684 ?   \nA.\u814e\u529f\u80fd\u4e0d\u4f73\u7684\u7cd6\u5c3f\u75c5\u60a3\u8005\uff0ceGFR\u5c0f\u65bc30 ml/min/1.73 \u33a1\u6642\uff0c\u4e0d\u61c9\u4f7f\u7528Metformin\u3002\nB.Metformin\u53ef\u80fd\u9020\u6210\u7dad\u4ed6\u547dB12 (Vitamin B12) \u4e4bmalabsorption\u3002\nC.\u96d6\u7136Metfmornin\u4e4b\u4f7f\u7528\u53ef\u4ee5\u964d\u4f4e\u8840\u7cd6 \uff0c\u4f46\u662f\u6839\u64daDiabetes Prevention Program\u4e4b\u7814\u7a76 \uff0cMetformin \u4e26\n\u7121\u6cd5\u5ef6\u7de9\u7cd6\u5c3f\u75c5\u4e4b\u767c\u75c5\u75c5\u7a0b \u3002\nD.\u4e73\u9178\u4e2d\u6bd2\u662f\u7f55\u898b\u7684Metformin\u85e5\u7269\u526f\u4f5c\u7528\uff0c\u7d71\u8a08\u4e0a\uff0c\u5ef6\u9072\u8a3a\u65b7\u4e4b\u6b7b\u4ea1\u7387\u53ef\u905450%\u3002\nE.\u76ee\u524d\u7cd6\u5c3f\u75c5\u4e4b\u5b55\u5a66\u61f7\u5b55\u6642\uff0c\u4f9d\u64da\u7f8e\u570b\u53ca\u53f0\u7063\u4e4b\u6cbb\u7642\u6307\u5f15\uff0cMetformin\u662f\u5b89\u5168\u7684\u7cd6\u5c3f\u75c5\u7528\u85e5\u9078\u64c7\u4e4b\u4e00\u3002\n": "[C]", "111-112.\u7cd6\u5c3f\u75c5\u65b0\u578b\u7528\u85e5\u4e2d \uff0cSGLT-2\u6291\u5236\u5291 (Sodium-glucose Cotransporter 2 inhibitor )\uff0c\u6700\u8fd1\u6578\u5e74\u5ee3\u6cdb\u4f7f\u7528\u7684\u65bc\n\u7cd6\u5c3f\u75c5\u4e4b\u65b0\u8208\u6cbb\u7642\u85e5\u7269 \u3002\u4e0b\u5217\u6709\u95dcSGLT -2\u6291\u5236\u5291\u7684\u6558\u8ff0 \uff0c\u4f55\u8005\u662f\u932f\u8aa4\u7684 ?   \nA.SGLT-2\u6291\u5236\u5291\u7684\u4f5c\u7528\u6a5f\u8f49\uff0c\u4e3b\u8981\u662f\u6291\u5236\u5c3f\u7cd6\u4e4b\u518d\u5438\u6536\uff0c\u56e0\u6b64\u8461\u8404\u7cd6\u5927\u91cf\u7684\u5f9e\u5c3f\u4e2d\u6392\u51fa\u3002\nB.\u76ee\u524d\u5927\u591a\u6578\u7684SGLT-2\u6291\u5236\u5291\uff0c\u4f7f\u7528\u4e4b\u814e\u529f\u80fd\u4e4b\u9650\u5236\u70ba eGFR > 45 ml/min/1.73 \u33a1\u4ee5\u4e0a\u3002\nC.\u6b64\u985e\u85e5\u7269\u5728\u964d\u8840\u7cd6\u7684\u904e\u7a0b\u4e2d\uff0c\u7cd6\u5c3f\u75c5\u60a3\u8005\u9ad4\u91cd\u591a\u534a\u4e5f\u6703\u96a8\u4e4b\u6e1b\u8f15\u3002\nD.\u5be6\u8b49\u91ab\u5b78\u7814\u7a76\u986f\u793a\uff0cSGLT-2\u6291\u5236\u5291\u4e5f\u53ef\u4ee5\u4f7f\u7528\u65bc\u975e\u7cd6\u5c3f\u75c5\u4e4b\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u3002\nE.\u7531\u65bc\u6b64\u985e\u85e5\u7269\u589e\u52a0\u5c3f\u7cd6\u6392\u51fa\uff0c\u56e0\u6b64\u5bb9\u6613\u767c\u751f\u6ccc\u5c3f\u9053\u611f\u67d3\uff0c\u800c\u4e14\u53ef\u80fd\u767c\u751f\u56b4\u91cd\u4e4b\u751f\u6b96\u5668\u611f\u67d3\u3002\n": "[B]"}